# ::snt Production and characterization of murine models of classic and intermediate maple syrup urine disease .
# ::tok Production and characterization of murine models of classic and intermediate maple syrup urine disease .
# ::alignments 13-14|0.1.0.0.1 12-13|0.1.0.0.1.0 11-12|0.1.0.0.1.1.0 10-11|0.1.0.0.1.1 9-10|0.1.0.0.1.1.0.0 8-9|0 7-8|0.0 5-6|0.1.0.0 4-5|0.1.0.0.0 2-3|0.1.1 1-2|0.1 0-1|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:09.756
(a / and 
      :op1 (c / classic) 
      :op3-of (a2 / and 
            :op1 (p / production 
                  :mod (m2 / model 
                        :mod (m3 / murine) 
                        :poss (d / disease 
                              :mod (u / urine) 
                              :mod (m / maple 
                                    :mod-of (s / syrup 
                                          :mod (i / intermediate)))))) 
            :op2 (c2 / characterization)))

# ::snt Maple Syrup Urine Disease ( MSUD ) is an inborn error of metabolism caused by a deficiency of branched-chain keto acid dehydrogenase .
# ::tok Maple Syrup Urine Disease ( MSUD ) is an inborn error of metabolism caused by a deficiency of branched-chain keto acid dehydrogenase .
# ::alignments 21-22|0.0.0 20-21|0.0.0.0 16-17|0.0 13-14|0 12-13|0.1.0 10-11|0.1 9-10|0.1.2 5-6|0.0.0.1.0.0+0.0.0.1.0+0.0.0.1 0-4|0.1.1.0.3+0.1.1.0.2+0.1.1.0.1+0.1.1.0.0+0.1.1.0+0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:10.953
(c / cause-01 
      :ARG0 (d2 / deficiency 
            :mod (d / dehydrogenase 
                  :mod (a / acid) 
                  :mod-of (t / thing 
                        :name (n / name 
                              :op1 "MSUD")))) 
      :ARG1 (e / error 
            :domain (m / metabolism) 
            :domain (t2 / thing 
                  :name (n2 / name 
                        :op1 "Maple" 
                        :op2 "Syrup" 
                        :op3 "Urine" 
                        :op4 "Disease")) 
            :mod (i / inborn)))

# ::snt MSUD has several clinical phenotypes depending on the degree of enzyme deficiency .
# ::tok MSUD has several clinical phenotypes depending on the degree of enzyme deficiency .
# ::alignments 11-12|0.0 10-11|0 8-9|0.0.1 5-6|0.0.0 4-5|0.0.0.0 3-4|0.0.0.0.0 2-3|0.0.0.0.1 0-1|0.0.0.1.0.0+0.0.0.1.0+0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:11.184
(e / enzyme 
      :mod-of (d / deficiency 
            :ARG1-of (d3 / depend-01 
                  :ARG0 (p / phenotyp 
                        :mod (c / clinical) 
                        :quant (s / several)) 
                  :domain-of (t / thing 
                        :name (n / name 
                              :op1 "MSUD"))) 
            :mod-of (d2 / degree)))

# ::snt Current treatments are not satisfactory and require new approaches to combat this disease .
# ::tok Current treatments are not satisfactory and require new approaches to combat this disease .
# ::alignments 12-13|0.0.1.0.0 11-12|0.0.1.0.0.0 10-11|0.0.1.0 8-9|0.0.1 7-8|0.0.1.1 6-7|0.0 5-6|0 4-5|0.0.0.0 3-4|0.0.1.0.1 1-2|0.0.0 0-1|0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:11.520
(a2 / and 
      :op1 (r / require-01 
            :ARG0 (t2 / treat-03 
                  :domain-of (s / satisfactory) 
                  :time (c2 / current)) 
            :ARG1 (a / approach-02 
                  :ARG1 (c / combat-01 
                        :ARG1 (d / disease 
                              :mod (t / this)) 
                        :polarity -) 
                  :mod (n / new))))

# ::snt A major hurdle in developing new treatments has been the lack of a suitable animal model .
# ::tok A major hurdle in developing new treatments has been the lack of a suitable animal model .
# ::alignments 15-16|0.0.0.0.0 14-15|0.0.0.0.0.1 13-14|0.0.0.0.0.0 10-11|0.0.0.0 6-7|0 5-6|0.1 4-5|0.0 2-3|0.0.0 1-2|0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:11.649
(t / treat-03 
      :ARG1-of (d / develop-02 
            :ARG0 (h / hurdle 
                  :ARG0-of (l / lack-01 
                        :ARG1 (m / model 
                              :ARG1-of (s / suitable-04) 
                              :mod (a / animal))) 
                  :ARG1-of (m2 / major-02))) 
      :mod (n / new))

# ::snt To create a murine model of classic MSUD , we used gene targeting and embryonic stem cell technologies to create a mouse line that lacked a functional E2 subunit gene of branched-chain keto acid dehydrogenase .
# ::tok To create a murine model of classic MSUD , we used gene targeting and embryonic stem cell technologies to create a mouse line that lacked a functional E2 subunit gene of branched-chain keto acid dehydrogenase .
# ::alignments 34-35|0.0.0 33-34|0.0 32-33|0 29-30|0.0.0.0 28-29|0.0.0.0.1 27-28|0.0.0.0.3.0.0+0.0.0.0.3.0+0.0.0.0.3 26-27|0.0.0.0.2 24-25|0.0.0.0.0 22-23|0.0.0.0.0.0 21-22|0.0.0.0.0.0.1 19-20|0.0.0.0.0.0.0 17-18|0.0.0.0.0.0.0.0.1.0 16-17|0.0.0.0.0.0.0.0.1.0.0 15-16|0.0.0.0.0.0.0.0.1.0.0.0 14-15|0.0.0.0.0.0.0.0.1.0.1 13-14|0.0.0.0.0.0.0.0.1 12-13|0.0.0.0.0.0.0.1.0 11-12|0.0.0.0.0.0.0.1 10-11|0.0.0.0.0.0.0.0 9-10|0.0.0.0.0.0.0.0.0 7-8|0.0.0.0.0.0.0.0.0.0.0.1.1.0+0.0.0.0.0.0.0.0.0.0.0.1.1+0.0.0.0.0.0.0.0.0.0.0.1 6-7|0.0.0.0.0.0.0.0.0.0.0.1.0 4-5|0.0.0.0.0.0.0.0.0.0.0 3-4|0.0.0.0.0.0.0.0.0.0.0.0 1-2|0.0.0.0.0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:14.424
(k / keto 
      :mod-of (a / acid 
            :mod-of (d / dehydrogenase 
                  :mod-of (g / gene 
                        :ARG1-of (l / lack-01 
                              :ARG0 (l2 / line 
                                    :ARG1-of (c / create-01 
                                          :ARG2-of (u / use-01 
                                                :ARG0 (w / we 
                                                      :ARG0-of (c4 / create-01 
                                                            :ARG1 (m2 / model 
                                                                  :mod (m3 / murine) 
                                                                  :poss (t4 / thing 
                                                                        :mod (c3 / classic) 
                                                                        :name (n2 / name 
                                                                              :op1 "MSUD"))))) 
                                                :ARG1 (a2 / and 
                                                      :op1 (t2 / technology 
                                                            :mod (c2 / cell 
                                                                  :mod (s2 / stem)) 
                                                            :mod (e / embryonic)))) 
                                          :purpose-of (g2 / gene 
                                                :ARG1-of (t3 / target-01))) 
                                    :mod (m / mouse))) 
                        :mod (s / subunit) 
                        :mod (f / functional) 
                        :mod (t / thing 
                              :name (n / name 
                                    :op1 "E2"))))))

# ::snt To create a murine model of intermediate MSUD , we used transgenic technology to express a human E2 cDNA on the knockout background .
# ::tok To create a murine model of intermediate MSUD , we used transgenic technology to express a human E2 cDNA on the knockout background .
# ::alignments 22-23|0.0 21-22|0 18-19|0.0.0 17-18|0.0.0.1.1.0+0.0.0.1.1+0.0.0.1 16-17|0.0.0.1.0 14-15|0.0.0.0 12-13|0.0.0.0.0.1 10-11|0.0.0.0.0 9-10|0.0.0.0.0.0 7-8|0.0.0.0.0.0.0.0.1.1.0+0.0.0.0.0.0.0.0.1.1+0.0.0.0.0.0.0.0.1 6-7|0.0.0.0.0.0.0.0.1.0 4-5|0.0.0.0.0.0.0.0 3-4|0.0.0.0.0.0.0.0.0 1-2|0.0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:15.531
(k / knockout 
      :mod-of (b / background 
            :topic-of (c / cdna 
                  :ARG1-of (e / express-01 
                        :ARG2-of (u / use-01 
                              :ARG0 (w / we 
                                    :ARG0-of (c2 / create-01 
                                          :ARG1 (m / model 
                                                :mod (m2 / murine) 
                                                :poss (t3 / thing 
                                                      :mod (i / intermediate) 
                                                      :name (n2 / name 
                                                            :op1 "MSUD"))))) 
                              :ARG1 (t2 / technology))) 
                  :mod (t / thing 
                        :mod (h / human) 
                        :name (n / name 
                              :op1 "E2")))))

# ::snt Mice of both models were characterized at the molecular , biochemical , and whole animal levels .
# ::tok Mice of both models were characterized at the molecular , biochemical , and whole animal levels .
# ::alignments 15-16|0.3 14-15|0.3.0 13-14|0.3.1 12-13|0 10-11|0.2 8-9|0.1 5-6|0.0 3-4|0.0.0.0 2-3|0.0.0.0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:15.638
(a2 / and 
      :ARG0-of (c / characterize-01 
            :ARG1 (m3 / mouse 
                  :poss (m2 / model 
                        :mod (b2 / both)))) 
      :op1 (m / molecule) 
      :op2 (b / biochemical) 
      :op3 (l / level 
            :mod (a / animal) 
            :mod (w / whole)))

# ::snt By disrupting the E2 subunit gene of branched-chain keto acid dehydrogenase , we created a gene knockout mouse model of classic MSUD .
# ::tok By disrupting the E2 subunit gene of branched-chain keto acid dehydrogenase , we created a gene knockout mouse model of classic MSUD .
# ::alignments 21-22|0.1.3.1.0+0.1.3.1+0.1.3 20-21|0.1.3.0 18-19|0.1 17-18|0.1.0 16-17|0.1.2 15-16|0.1.1 13-14|0 12-13|0.0 10-11|0.0.0.1.1 9-10|0.0.0.1.1.0 8-9|0.0.0.1.1.0.0 5-6|0.0.0.1 4-5|0.0.0.1.0 3-4|0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:16.755
(c2 / create-01 
      :ARG0 (w / we 
            :ARG0-of (d2 / disrupt-01 
                  :ARG1 (t2 / thing 
                        :name (n2 / name 
                              :op1 "E2")) 
                  :ARG2 (g2 / gene 
                        :mod (s / subunit) 
                        :mod (d / dehydrogenase 
                              :mod (a / acid 
                                    :mod (k2 / keto)))))) 
      :ARG1 (m / model 
            :mod (m2 / mouse) 
            :mod (g / gene) 
            :mod (k / knockout) 
            :poss (t / thing 
                  :mod (c / classic) 
                  :name (n / name 
                        :op1 "MSUD"))))

# ::snt The homozygous knockout mice lacked branched-chain keto acid dehydrogenase activity , E2 immunoreactivity , and had a 3-fold increase in circulating branched-chain amino acids .
# ::tok The homozygous knockout mice lacked branched-chain keto acid dehydrogenase activity , E2 immunoreactivity , and had a 3-fold increase in circulating branched-chain amino acids .
# ::alignments 23-24|0.1.1.0 22-23|0.1.1.0.0 20-21|0.1.1 18-19|0.1 14-15|0 12-13|0.1.0.0 11-12|0.1.0.1.0+0.1.0.1+0.1.0 9-10|0.0.1 8-9|0.0.1.1 7-8|0.0.1.0 6-7|0.0.1.0.0 4-5|0.0 3-4|0.0.0 2-3|0.0.0.0 1-2|0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:17.717
(a3 / and 
      :op1 (l / lack-01 
            :ARG0 (m / mouse 
                  :mod (k2 / knockout 
                        :mod (h / homozygou))) 
            :ARG1 (a4 / activity-06 
                  :ARG0 (a5 / acid 
                        :mod (k / keto)) 
                  :ARG1 (d / dehydrogenase))) 
      :op2 (i / increase-01 
            :ARG1 (t / thing 
                  :mod-of (i2 / immunoreactivity) 
                  :name (n / name 
                        :op1 "E2")) 
            :ARG2 (c / circulate-01 
                  :ARG1 (a / acid 
                        :mod (a2 / amino)))))

# ::snt These metabolic derangements resulted in neonatal lethality .
# ::tok These metabolic derangements resulted in neonatal lethality .
# ::alignments 6-7|0.1 5-6|0.1.0 3-4|0 2-3|0.0 1-2|0.0.1 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:17.761
(r / result-01 
      :ARG1 (d / derangement 
            :mod (t / this) 
            :mod (m / metabolic)) 
      :ARG2 (l / lethality 
            :mod (n / neonatal)))

# ::snt Transgenic expression of a human E2 cDNA in the liver of the E2 knockout animals produced a model of intermediate MSUD .
# ::tok Transgenic expression of a human E2 cDNA in the liver of the E2 knockout animals produced a model of intermediate MSUD .
# ::alignments 20-21|0.0.0.0.0.1.0+0.0.0.0.0.1+0.0.0.0.0 19-20|0.0.0.0.0.0 17-18|0.0.0.0 15-16|0.0.0 14-15|0.1 13-14|0 9-10|0.0.0.1 6-7|0.0.1 5-6|0.0.1.0.1.0+0.0.1.0.1+0.0.1.0 4-5|0.0.1.0.0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:18.243
(k / knockout 
      :ARG0-of (e / express-01 
            :ARG0-of (p / produce-01 
                  :ARG1 (m / model 
                        :poss (t / thing 
                              :mod (i / intermediate) 
                              :name (n / name 
                                    :op1 "MSUD"))) 
                  :manner (l / liver)) 
            :ARG1 (c / cdna 
                  :mod (t2 / thing 
                        :mod (h / human) 
                        :name (n2 / name 
                              :op1 "E2")))) 
      :mod-of (a / animal))

# ::snt Branched-chain keto acid dehydrogenase activity was 5 -- 6 % of normal and was sufficient to allow survival , but was insufficient to normalize circulating branched-chain amino acids levels , which were intermediate between wildtype and the classic MSUD mouse model .
# ::tok Branched-chain keto acid dehydrogenase activity was 5 -- 6 % of normal and was sufficient to allow survival , but was insufficient to normalize circulating branched-chain amino acids levels , which were intermediate between wildtype and the classic MSUD mouse model .
# ::alignments 40-41|0.0.1.0.0.0.1.0.0 39-40|0.0.1.0.0.0.1.0.0.1 38-39|0.0.1.0.0.0.1.0.1.0+0.0.1.0.0.0.1.0.1+0.0.1.0.0.0.1.0 37-38|0.0.1.0.0.0.1.0.0.0 35-36|0.0.1.0.0 34-35|0.0.1.0.0.3 32-33|0.0.1.0.0.2 28-29|0.0.1.0.1 27-28|0.0.1.0.1.0 26-27|0.0.1.0.0.1.0 24-25|0.0.1.0 23-24|0.0.1 21-22|0.0.2+0.0 19-20|0 17-18|0.0.1.0.0.0.0 16-17|0.0.1.0.0.0 14-15|0.0.1.0.0.0.1 12-13|0.1 11-12|0.0.1.0.0.1 9-10|0.0.1.0.1.1 8-9|0.0.1.0.0.0.0.0 6-7|0.0.1.0.0.1.1 4-5|0.0.0.0 3-4|0.0.0.0.0 2-3|0.0.0.1 0-2|0.0.0.2.1+0.0.0.2.0+0.0.0.2+0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:21.209
(c3 / contrast-01 
      :ARG1 (s / suffice-01 
            :ARG0 (t2 / thing 
                  :ARG1-of (a6 / activity-06 
                        :ARG0 (d / dehydrogenase)) 
                  :mod-of (a7 / acid) 
                  :name (n4 / name 
                        :op1 (b / Branched-chain) 
                        :op2 (k / keto))) 
            :ARG1 (n2 / normalize-01 
                  :ARG1 (c2 / circulate-01 
                        :ARG0 (a / and 
                              :ARG0-of (a4 / allow-01 
                                    :ARG1 (s2 / survive-01 
                                          :ARG1 6) 
                                    :ARG1-of (s3 / suffice-01 
                                          :ARG0 (t / thing 
                                                :mod-of (m / model 
                                                      :mod (c / classic) 
                                                      :mod (m2 / mouse)) 
                                                :name (n / name 
                                                      :op1 "MSUD")))) 
                              :op1 (n3 / normal-02 
                                    :ARG0 (a3 / amino) 
                                    :ARG1 5) 
                              :op2 (i / intermediate) 
                              :op3 (w / wildtype)) 
                        :ARG1 (l / level 
                              :mod (a2 / acid) 
                              :mod (p / percentage-entity)))) 
            :polarity -) 
      :ARG2 (a5 / and))

# ::snt These mice represent important animal models that closely approximate the phenotype of humans with the classic and intermediate forms of MSUD .
# ::tok These mice represent important animal models that closely approximate the phenotype of humans with the classic and intermediate forms of MSUD .
# ::alignments 20-21|0.3.0.0.0+0.3.0.0+0.3.0 18-19|0.3 17-18|0.2 16-17|0 15-16|0.1 12-13|0.0.2.0 10-11|0.0.2 8-9|0.0 7-8|0.0.1 5-6|0.0.0 4-5|0.0.0.2 3-4|0.0.0.1 2-3|0.0.0.0 1-2|0.0.0.0.0 0-1|0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:21.657
(a / and 
      :op1 (a2 / approximately 
            :consist (m / model 
                  :ARG1-of (r / represent-01 
                        :ARG0 (m2 / mouse 
                              :mod (t2 / this))) 
                  :mod (i2 / important) 
                  :mod (a3 / animal)) 
            :manner (c2 / close) 
            :op1 (p / phenotype 
                  :poss (h / human))) 
      :op2 (c / classic) 
      :op3 (i / intermediate) 
      :op4 (f / form 
            :mod-of (t / thing 
                  :name (n / name 
                        :op1 "MSUD"))))

# ::snt These animals provide useful models to further characterize the pathogenesis of MSUD , as well as models to test novel therapeutic strategies , such as gene and cellular therapies , to treat this devastating metabolic disease .
# ::tok These animals provide useful models to further characterize the pathogenesis of MSUD , as well as models to test novel therapeutic strategies , such as gene and cellular therapies , to treat this devastating metabolic disease .
# ::alignments 35-36|0.3.0 34-35|0.3.0.1 33-34|0.3.0.0 32-33|0.3.0.2 31-32|0.3 28-29|0.2 27-28|0.2.0 26-27|0 25-26|0.1 23-24|0.0 21-22|0.3.1.1 20-21|0.3.0.0.0 19-20|0.3.1.2.0.0.0 18-19|0.3.1 16-17|0.3.1.0 11-12|0.3.1.2.1.0.0.0+0.3.1.2.1.0.0+0.3.1.2.1.0 9-10|0.3.1.2.1 7-8|0.3.1.2 6-7|0.3.1.2.2 4-5|0.3.1.2.0 3-4|0.3.1.2.0.0 2-3|0.3.1.2.0.1 1-2|0.3.1.2.0.1.0 0-1|0.3.1.2.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:23.183
(a / and 
      :op1 (s / such) 
      :op2 (g / gene) 
      :op3 (t3 / therapi 
            :mod (c / cell)) 
      :op4 (t2 / treat-01 
            :ARG1 (d / disease 
                  :ARG0-of (d2 / devastate-01 
                        :ARG1 (t4 / therapeutic)) 
                  :mod (m / metabolic) 
                  :mod (t / this)) 
            :ARG2-of (t5 / test-01 
                  :ARG0 (m2 / model) 
                  :ARG1 (s2 / strategy) 
                  :purpose-of (c2 / characterize-01 
                        :ARG0 (m3 / model 
                              :ARG1-of (u / useful-05 
                                    :ARG0 (n / novel)) 
                              :ARG1-of (p2 / provide-01 
                                    :ARG0 (a2 / animal 
                                          :mod (t7 / this)))) 
                        :ARG1 (p / pathogenesi 
                              :poss (t6 / thing 
                                    :name (n2 / name 
                                          :op1 "MSUD"))) 
                        :degree (f / further)))))

# ::snt Maple Syrup Urine Disease ( MSUD ) is a genetic disorder caused by a deficiency of branched-chain keto acid dehydrogenase ( BCKDH ) , a mitochondrial multienzyme complex responsible for the oxidative decarboxylation of branched-chain keto acids derived from branched-chain amino acids ( BCAA ) , leucine , isoleucine and valine ( for review , see : [ 1 ] ) .
# ::tok Maple Syrup Urine Disease ( MSUD ) is a genetic disorder caused by a deficiency of branched-chain keto acid dehydrogenase ( BCKDH ) , a mitochondrial multienzyme complex responsible for the oxidative decarboxylation of branched-chain keto acids derived from branched-chain amino acids ( BCAA ) , leucine , isoleucine and valine ( for review , see : [ 1 ] ) .
# ::alignments 58-59|0.2.2.0.1.0 55-56|0.2.0 53-54|0.2.2.0.1.2 50-51|0.2.5 49-50|0.2 48-49|0.2.4 46-47|0.2.3 43-44|0.2.2.0.1.2.0.0.0+0.2.2.0.1.2.0.0+0.2.2.0.1.2.0 41-42|0.2.2.0.1.3 40-41|0.2.2.0.1.3.0 37-38|0.2.2.0.1 36-37|0.2.2.0.1.1 32-33|0.2.2.0.1.1.0 31-32|0.2.2.0.1.1.0.0 28-29|0.2.2.0 27-28|0.2.0.0 26-27|0.2.2 19-20|0.0.0 18-19|0.0.0.0 17-18|0.0.0.0.0 14-15|0.0 11-12|0 10-11|0.1 9-10|0.2.1 5-6|0.2.2.0.0.0.0+0.2.2.0.0.0+0.2.2.0.0 0-4|0.1.0.0.3+0.1.0.0.2+0.1.0.0.1+0.1.0.0.0+0.1.0.0+0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:24.765
(c2 / cause-01 
      :ARG0 (d4 / deficiency 
            :mod (d3 / dehydrogenase 
                  :mod (a5 / acid 
                        :mod (k / keto)))) 
      :ARG1 (d5 / disord 
            :domain (t2 / thing 
                  :name (n3 / name 
                        :op1 "Maple" 
                        :op2 "Syrup" 
                        :op3 "Urine" 
                        :op4 "Disease"))) 
      :op1-of (a / and 
            :ARG1-of (s / see-01 
                  :ARG0 (c / complex)) 
            :mod (g / gene) 
            :op2 (m / multienzyme 
                  :ARG1-of (r2 / responsible-01 
                        :ARG0 (t / thing 
                              :name (n2 / name 
                                    :op1 "MSUD")) 
                        :purpose (d / derive-01 
                              :ARG0 1 
                              :ARG1 (a4 / acid 
                                    :mod-of (d2 / decarboxylation 
                                          :mod (o2 / oxidative))) 
                              :ARG1-of (r / review-01 
                                    :ARG0 (o / organization 
                                          :name (n / name 
                                                :op1 "BCAA"))) 
                              :ARG2 (a2 / acid 
                                    :mod (a3 / amino))))) 
            :op3 (l / leucine) 
            :op4 (i / isoleucine) 
            :op5 (v / valine)))

# ::snt Patients with MSUD , depending on the mutation , show variable degrees of enzyme deficiency leading to several different clinical phenotypes [ 1 ] .
# ::tok Patients with MSUD , depending on the mutation , show variable degrees of enzyme deficiency leading to several different clinical phenotypes [ 1 ] .
# ::alignments 22-23|0.1.0 20-21|0.2.0.0.0 19-20|0.2.0.0.0.1 18-19|0.2.0.0.0.0 17-18|0.2.0.0.0.2 15-16|0.2.0.0 14-15|0.2.0 13-14|0.2.0.1 11-12|0.2 10-11|0.2.1 9-10|0 7-8|0.1.1 4-5|0.1 2-3|0.0.0.0+0.0.0+0.0 0-1|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:25.265
(s2 / show-01 
      :ARG0 (t / thing 
            :name (n / name 
                  :op1 "MSUD") 
            :prep-with-of (p2 / patient)) 
      :ARG0-of (d4 / depend-01 
            :ARG1 1 
            :ARG2 (m / mutation)) 
      :ARG1 (d3 / degree 
            :mod (d2 / deficiency 
                  :ARG1-of (l / lead-01 
                        :ARG4 (p / phenotyp 
                              :ARG1-of (d / differ-02) 
                              :mod (c / clinical) 
                              :quant (s / several))) 
                  :mod (e / enzyme)) 
            :mod (v / variable)))

# ::snt Approximately 75 % of MSUD patients have the classic form of the disease with BCKDH activity in the range of 0 -- 2 % of normal [ 1 ] .
# ::tok Approximately 75 % of MSUD patients have the classic form of the disease with BCKDH activity in the range of 0 -- 2 % of normal [ 1 ] .
# ::alignments 27-28|0.1.0.0.0.0.0.0 25-26|0.1.0.0.0.0.0.2 23-24|0.1.0.0.0.0.0.1 22-23|0.1.0.0.0.0.0.1.0 20-21|0.1.0.0.0.0.0.2.0 18-19|0.1.0.0.0.0.0 15-16|0.1.0.0 12-13|0.1.0.0.0 9-10|0.1.0.0.0.0 8-9|0.1.0.0.0.0.1 5-6|0.1.0.1.0+0.1.0.1+0.1.0 4-5|0.1.0.2.0.0+0.1.0.2.0+0.1.0.2 2-3|0.1 1-2|0.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:26.124
(a2 / approximately 
      :op1 75 
      :op2 (p4 / percentage-entity 
            :quant-of (p2 / person 
                  :ARG0-of (a / activity-06 
                        :accompanier-of (d / disease 
                              :poss-of (f / form 
                                    :ARG1-of (r / range-01 
                                          :ARG0 1 
                                          :ARG2 (p / percentage-entity 
                                                :value 2) 
                                          :ARG2-of (n / normal-02 
                                                :ARG0 0)) 
                                    :mod (c / classic)))) 
                  :ARG0-of (h / have-rel-role-91 
                        :ARG2 (p3 / patient)) 
                  :mod (t / thing 
                        :name (n2 / name 
                              :op1 "MSUD")))))

# ::snt These patients show markedly elevated levels of BCAA in blood and other body fluids [ 1 ] .
# ::tok These patients show markedly elevated levels of BCAA in blood and other body fluids [ 1 ] .
# ::alignments 15-16|0.1.0.0 13-14|0.1.1.0.0 12-13|0.1.1.0 11-12|0.1.1.0.0.0 10-11|0.2 9-10|0.3 7-8|0.1.1.1.0+0.1.1.1+0.1.1 5-6|0.1 4-5|0.1.0 3-4|0.1.0.1 2-3|0 1-2|0.0.0.0+0.0.0+0.0 0-1|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:26.676
(s / show-01 
      :ARG0 (p / person 
            :ARG0-of (h / have-rel-role-91 
                  :ARG2 (p2 / patient)) 
            :mod (t / this)) 
      :ARG1 (l / level 
            :ARG1-of (e / elevate-01 
                  :ARG0 1 
                  :degree (m / markedly)) 
            :mod (o2 / organization 
                  :mod (b / body 
                        :mod-of (f / fluid 
                              :mod (o / other))) 
                  :name (n / name 
                        :op1 "BCAA"))) 
      :op1-of (a / and) 
      :time (b2 / blood))

# ::snt Besides the classic form , there are other variants of the disease .
# ::tok Besides the classic form , there are other variants of the disease .
# ::alignments 11-12|0.1 8-9|0 7-8|0.0 3-4|0.1.0.0 2-3|0.1.0 0-1|0.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:26.711
(v / variant 
      :mod (o / other) 
      :poss (d / disease 
            :mod-of (c / classic 
                  :mod-of (f / form 
                        :op1-of (b / besides)))))

# ::snt Patients with the intermediate form of the disease show BCKDH activity in the range of 3 -- 30 % of normal .
# ::tok Patients with the intermediate form of the disease show BCKDH activity in the range of 3 -- 30 % of normal .
# ::alignments 20-21|0.0.0.0.1.1 18-19|0.0.0.0.1.0 17-18|0.0.0.0.1.0.0 15-16|0.0.0.0.1.1.0 13-14|0.0.0.0.1 10-11|0.0.0.0 9-10|0.0.0.0.0 8-9|0.0 7-8|0.0.0 4-5|0.0.0.0.2 3-4|0.0.0.0.2.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:26.906
(p2 / patient 
      :ARG0-of (s / show-01 
            :ARG1 (d / disease 
                  :ARG1-of (a / activity-06 
                        :ARG0 (b / BCKDH) 
                        :manner (r / range-01 
                              :ARG1 (p / percentage-entity 
                                    :value 30) 
                              :ARG2-of (n / normal-02 
                                    :ARG1 3)) 
                        :mod-of (f / form 
                              :mod (i / intermediate))))))

# ::snt In such patients the onset of the disease is delayed , but there are persistently elevated levels of BCAA [ 1 ] .
# ::tok In such patients the onset of the disease is delayed , but there are persistently elevated levels of BCAA [ 1 ] .
# ::alignments 20-21|0.0.0.0.0 18-19|0.1.2.0.0+0.1.2.0+0.1.2 16-17|0.1 15-16|0.1.0 14-15|0.1.1 11-12|0 9-10|0.0 7-8|0.0.1.0 4-5|0.0.1 2-3|0.0.0.0.1+0.0.0.0+0.0.0 1-2|0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:27.097
(c / contrast-01 
      :ARG1 (d / delay-01 
            :ARG0 (p2 / person 
                  :ARG0-of (h / have-rel-role-91 
                        :ARG1 1 
                        :ARG2 (p3 / patient)) 
                  :mod (s / such)) 
            :ARG1 (o2 / onset 
                  :poss (d2 / disease))) 
      :ARG2 (l / level 
            :ARG1-of (e / elevate-01) 
            :mod (p / persistently) 
            :poss (o / organization 
                  :name (n / name 
                        :op1 "BCAA"))))

# ::snt Patients with the intermittent form of MSUD show BCKDH activity in the range of 5 -- 20 % and during the asymptomatic phase the blood BCAA levels are normal [ 1 ] .
# ::tok Patients with the intermittent form of MSUD show BCKDH activity in the range of 5 -- 20 % and during the asymptomatic phase the blood BCAA levels are normal [ 1 ] .
# ::alignments 30-31|0.1.0 28-29|0.4.0.0 26-27|0.4.0 25-26|0.4.0.1.0.0+0.4.0.1.0+0.4.0.1 24-25|0.4.0.2 22-23|0.2.0 21-22|0.2.0.0 18-19|0.4 17-18|0.4.0.0.0.0 16-17|0.4.0.0.0 14-15|0.4.0.0.1 12-13|0.2 9-10|0.1 7-8|0 6-7|0.3.0.0+0.3.0+0.3 4-5|0.3.1 3-4|0.3.1.0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:28.216
(s / show-01 
      :ARG0 (p3 / patient) 
      :ARG1 (a3 / activity-06 
            :ARG0 1) 
      :ARG2 (r / range-01 
            :ARG0 (p / phase 
                  :mod (a / asymptomatic))) 
      :manner (t / thing 
            :name (n3 / name 
                  :op1 "MSUD") 
            :poss-of (f / form 
                  :mod (i / intermittent))) 
      :op1-of (a2 / and 
            :op2 (l / level 
                  :ARG1-of (n / normal-02 
                        :ARG0 (2 / 20 
                              :value-of (p2 / percentage-entity)) 
                        :op1-of 5) 
                  :mod (o / organization 
                        :name (n2 / name 
                              :op1 "BCAA")) 
                  :mod (b / blood))))

# ::snt The overall incidence of MSUD in the general population is 1:185,000 [ 1 ] , and in certain population groups , such as Mennonites of Pennsylvania , the incidence is estimated to be as high as 1:176 [ 2 ] .
# ::tok The overall incidence of MSUD in the general population is 1:185,000 [ 1 ] , and in certain population groups , such as Mennonites of Pennsylvania , the incidence is estimated to be as high as 1:176 [ 2 ] .
# ::alignments 38-39|0.0.0.0 34-35|0.1.1.0 30-31|0.1 28-29|0.1.1 25-26|0.1.2.0.0.0.0+0.1.2.0.0.0+0.1.2.0.0 23-24|0.1.2.0 21-22|0.0.0.1 19-20|0.1.2 18-19|0.1.2.2 17-18|0.1.2.1 15-16|0 12-13|0.1.1.0.0 8-9|0.0 7-8|0.0.0 4-5|0.1.0.1.0.0+0.1.0.1.0+0.1.0.1 2-3|0.1.0 1-2|0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:28.533
(a / and 
      :op1 (p2 / population 
            :mod (g2 / general-02 
                  :ARG0 2 
                  :ARG1 (s / such))) 
      :op2 (e / estimate-01 
            :ARG0 (i2 / incidence 
                  :mod (o / overall) 
                  :poss (t / thing 
                        :name (n2 / name 
                              :op1 "MSUD"))) 
            :ARG1 (i / incidence 
                  :ARG1-of (h / high-02 
                        :ARG0 1)) 
            :prep-in (g / group 
                  :example (m / mennonit 
                        :poss (c / country 
                              :name (n / name 
                                    :op1 "Pennsylvania"))) 
                  :mod (c2 / certain) 
                  :mod (p / population))))

# ::snt The BCKDH complex , the deficient enzyme in MSUD , consists of three catalytic proteins , a decarboxylase ( E1 ) , a dihydrolipoyl transacylase ( E2 ) , and a dihydrolipoyl dehydrogenase ( E3 ) .
# ::tok The BCKDH complex , the deficient enzyme in MSUD , consists of three catalytic proteins , a decarboxylase ( E1 ) , a dihydrolipoyl transacylase ( E2 ) , and a dihydrolipoyl dehydrogenase ( E3 ) .
# ::alignments 32-33|0.2.4 29-30|0.2 26-27|0.2.3.0.0+0.2.3.0+0.2.3 24-25|0.2.2 17-18|0.0.0.0 14-15|0.2.1 13-14|0.2.1.0 12-13|0.0.0.1 10-11|0 8-9|0.2.0.0.0+0.2.0.0+0.2.0 6-7|0.0 5-6|0.0.0 2-3|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:29.308
(c2 / consist-01 
      :ARG0 (e / enzyme 
            :mod (d3 / deficient 
                  :poss (d2 / decarboxylase) 
                  :quant 3)) 
      :ARG1 (c3 / complex) 
      :ARG2 (a / and 
            :op1 (t3 / thing 
                  :name (n2 / name 
                        :op1 "MSUD")) 
            :op2 (p / protein 
                  :mod (c / catalytic)) 
            :op3 (t2 / transacylase) 
            :op4 (t / thing 
                  :name (n / name 
                        :op1 "E2")) 
            :op5 (d / dehydrogenase)))

# ::snt The E1 component is a heterotetramer composed of two  and two  subunits [ 3 ] .
# ::tok The E1 component is a heterotetramer composed of two  and two  subunits [ 3 ] .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:29.310
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt The E1 and E2 components are specific to BCKDH , whereas E3 is also used by pyruvate and -ketoglutarate dehydrogenase complexes [ 3 ] and the glycine cleavage system [ 4 ] .
# ::tok The E1 and E2 components are specific to BCKDH , whereas E3 is also used by pyruvate and -ketoglutarate dehydrogenase complexes [ 3 ] and the glycine cleavage system [ 4 ] .
# ::alignments 30-31|0.0.1.0.1 28-29|0.1 27-28|0.1.0 26-27|0.1.1 24-25|0 22-23|0.0.1.0.3 20-21|0.0.1.0.2 19-20|0.0.1.0.2.0 17-18|0.0.1.0.0.0 16-17|0.0.1.0.0.0.0 14-15|0.0.1.0.0 13-14|0.0.1.0.0.1 10-11|0.0.1.0.0.2 6-7|0.0.1.0 4-5|0.0.1 3-4|0.0.0.0.0+0.0.0.0+0.0.0 2-3|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:30.221
(a / and 
      :op1 (a4 / and 
            :op1 (t / thing 
                  :name (n / name 
                        :op1 "E2")) 
            :op2 (c3 / component 
                  :ARG1-of (s2 / specific-02 
                        :ARG0 (u / use-01 
                              :ARG0 (a2 / and 
                                    :op1 (p / pyruvate)) 
                              :mod (a3 / also) 
                              :op1-of (w / whereas)) 
                        :op1-of 4 
                        :op1-of (c2 / complex 
                              :mod (d / dehydrogenase)) 
                        :op1-of 3))) 
      :op2 (s / system 
            :mod (c / cleavage) 
            :mod (g / glycine)))

# ::snt BCKDH is also associated with two regulatory proteins , a specific kinase and a phosphatase which regulate the activity of this enzyme through a phosphorylation ( inactivation ) and dephosphorylation ( activation ) cycle of the E1  subunit [ 5,6 ] .
# ::tok BCKDH is also associated with two regulatory proteins , a specific kinase and a phosphatase which regulate the activity of this enzyme through a phosphorylation ( inactivation ) and dephosphorylation ( activation ) cycle of the E1  subunit [ 5,6 ] .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:30.227
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt Mutations in the genes of the E1 and E2 subunits of BCKDH have been described , however , the majority of MSUD mutations identified thus far are in the E2 subunit [ 1,7 ] .
# ::tok Mutations in the genes of the E1 and E2 subunits of BCKDH have been described , however , the majority of MSUD mutations identified thus far are in the E2 subunit [ 1,7 ] .
# ::alignments 30-31|0.0.0.0.0 25-26|0.0.0.0.2.0 24-25|0.0.2 23-24|0.0.0.0.2 22-23|0.0.0.0 21-22|0.0.0.0.1.0.0+0.0.0.0.1.0+0.0.0.0.1 19-20|0.0.0 14-15|0.0 9-10|0.2 8-9|0.1.0.0+0.1.0+0.1 7-8|0 3-4|0.0.1.0 0-1|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:30.643
(a / and 
      :ARG1-of (d / describe-01 
            :ARG0 (m2 / majority 
                  :quant-of (m / mutate-01 
                        :ARG0 (s / subunit) 
                        :ARG1 (t2 / thing 
                              :name (n / name 
                                    :op1 "MSUD")) 
                        :ARG1-of (i / identify-01 
                              :ARG2 (f / far)))) 
            :ARG2 (m3 / mutation 
                  :location (g / gene)) 
            :op1-of (t / thus-far)) 
      :op1 (t3 / thing 
            :name (n2 / name 
                  :op1 "E2")) 
      :op2 (s2 / subunit))

# ::snt To date , cases of MSUD have not been associated with defects in the regulatory kinase and phosphatase [ 1 ] .
# ::tok To date , cases of MSUD have not been associated with defects in the regulatory kinase and phosphatase [ 1 ] .
# ::alignments 19-20|0.0 17-18|0.1.0 16-17|0.2.0 15-16|0.2.0.0 14-15|0.2.0.0.0 11-12|0.2 9-10|0 7-8|0.4 5-6|0.1.1.0.0+0.1.1.0+0.1.1 3-4|0.1 1-2|0.3 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:30.841
(a2 / associate-01 
      :ARG0 1 
      :ARG1 (c / case-03 
            :ARG0 (p / phosphatase) 
            :ARG1 (t / thing 
                  :name (n / name 
                        :op1 "MSUD"))) 
      :ARG2 (d / defect-01 
            :ARG1 (a / and 
                  :op1 (k / kinase 
                        :ARG0-of (r / regulate-01)))) 
      :ARG3 (d2 / date) 
      :polarity -)

# ::snt Current management of MSUD patients relies on a strict lifelong dietary restriction of protein or BCAA [ 1,8 ] .
# ::tok Current management of MSUD patients relies on a strict lifelong dietary restriction of protein or BCAA [ 1,8 ] .
# ::alignments 15-16|0.1.0.2.0.0+0.1.0.2.0+0.1.0.2 14-15|0.1.0 13-14|0.1.0.1 11-12|0.1 10-11|0.1.2 9-10|0.1.3 8-9|0.1.1 5-6|0 4-5|0.0.0.0+0.0.0+0.0 3-4|0.1.0.0.0.0+0.1.0.0.0+0.1.0.0 1-2|0.0.1 0-1|0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:31.937
(r2 / rely-01 
      :ARG0 (p2 / person 
            :ARG0-of (h / have-rel-role-91 
                  :ARG2 (p3 / patient)) 
            :ARG1-of (m / manage-01 
                  :time (c / current))) 
      :ARG1 (r / restrict-01 
            :ARG1 (o2 / or 
                  :op1 (t / thing 
                        :name (n2 / name 
                              :op1 "MSUD")) 
                  :op2 (p / protein) 
                  :op3 (o / organization 
                        :name (n / name 
                              :op1 "BCAA"))) 
            :mod (s / strict) 
            :mod (d / dietary) 
            :mod (l / lifelong)))

# ::snt Such a dietary management of the disease , however , is not entirely satisfactory especially in times of metabolic decompensation due to infection , injuries and other stressors .
# ::tok Such a dietary management of the disease , however , is not entirely satisfactory especially in times of metabolic decompensation due to infection , injuries and other stressors .
# ::alignments 27-28|0.3 26-27|0.3.0 25-26|0 24-25|0.2 22-23|0.1 19-20|0.2.1.0 18-19|0.2.1 14-15|0.1.0 13-14|0.0.2 12-13|0.2.0 11-12|0.0.2.0 6-7|0.0.1 3-4|0.0 2-3|0.0.0 0-1|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:32.314
(a / and 
      :op1 (m2 / manage-01 
            :ARG0 (d3 / dietary 
                  :manner (s3 / such)) 
            :ARG1 (d2 / disease) 
            :domain-of (s2 / satisfactory 
                  :polarity -)) 
      :op2 (i2 / infect-01 
            :ARG1 (e / especially)) 
      :op3 (i / injure-01 
            :ARG0 (e2 / entire) 
            :ARG1 (m / metabolic 
                  :mod-of (d / decompensation))) 
      :op4 (s / stressor 
            :mod (o / other)))

# ::snt In spite of dietary intervention , there is significant mortality associated with MSUD and there is a high incidence of mental retardation in survivors [ 9 ] .
# ::tok In spite of dietary intervention , there is significant mortality associated with MSUD and there is a high incidence of mental retardation in survivors [ 9 ] .
# ::alignments 25-26|0.0.0 23-24|0.3.0+0.3 21-22|0.2.1 20-21|0.2.1.0 18-19|0.2 17-18|0.2.0 13-14|0 12-13|0.1.1.0.0.0+0.1.1.0.0+0.1.1.0 10-11|0.1.1 9-10|0.1 8-9|0.1.0 4-5|0.0 3-4|0.0.1 1-2|0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:32.608
(a / and 
      :op1 (i2 / intervene-01 
            :ARG1 9 
            :manner (d / dietary) 
            :quant (s3 / spite)) 
      :op2 (m2 / mortality 
            :ARG1-of (s2 / significant-02) 
            :ARG1-of (a2 / associate-01 
                  :ARG2 (t / thing 
                        :name (n / name 
                              :op1 "MSUD")))) 
      :op3 (i / incidence 
            :ARG1-of (h / high-02) 
            :mod (r / retardation 
                  :mod (m / mental))) 
      :op4 (p / person 
            :ARG0-of (s / survive-01)))

# ::snt Because of the central role of the liver in amino acid metabolism and moderate/high levels of BCKDH activity in human liver [ 10-12 ] , a few cases of MSUD have recently been treated by liver transplantation [ 13-16 ] .
# ::tok Because of the central role of the liver in amino acid metabolism and moderate/high levels of BCKDH activity in human liver [ 10-12 ] , a few cases of MSUD have recently been treated by liver transplantation [ 13-16 ] .
# ::alignments 36-37|0.0.0.0 35-36|0.0.0 33-34|0.0.1.1.0.0.0.0 31-32|0.0.1.1.0.0.0.0.1 29-30|0.0.1.1.0.0.0.0.0.0.0.0+0.0.1.1.0.0.0.0.0.0.0+0.0.1.1.0.0.0.0.0.0 27-28|0.0.1.1.0.0.0.0.0 26-27|0.0.1.1.0.0.0.0.0.1 20-21|0 19-20|0.1 17-18|0.0 14-15|0.0.1.1.1 12-13|0.0.1.1 11-12|0.0.1 10-11|0.0.1.1.1.0 9-10|0.0.1.0 7-8|0.0.1.1.0 4-5|0.0.1.1.0.0 3-4|0.0.1.1.0.0.1 0-1|0.0.1.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:33.009
(l2 / liver 
      :ARG2-of (a / activity-06 
            :ARG1 (l / liver 
                  :mod-of (t / transplantation)) 
            :mod-of (m / metabolism 
                  :mod (a4 / amino) 
                  :op1-of (a2 / and 
                        :consist (l4 / liver 
                              :poss-of (r2 / role 
                                    :ARG0-of (c3 / cause-01 
                                          :ARG1 (t2 / treat-01 
                                                :ARG1 (c / case-03 
                                                      :ARG1 (t3 / thing 
                                                            :name (n / name 
                                                                  :op1 "MSUD")) 
                                                      :quant (f / few)) 
                                                :time (r / recent))) 
                                    :mod (c2 / central))) 
                        :op2 (l3 / level 
                              :mod (a3 / acid))))) 
      :mod (h / human))

# ::snt While the short-term outcome of liver transplantation is encouraging , long-term effects of this approach are not known .
# ::tok While the short-term outcome of liver transplantation is encouraging , long-term effects of this approach are not known .
# ::alignments 17-18|0.0.0.0.0 16-17|0.0.0.0.0.2 14-15|0.0.0.0.0.0.1 13-14|0.0.0.0.0.0.1.0 11-12|0.0.0.0.0.0 10-11|0.0.0.0.0.0.0 8-9|0.0.0.0 6-7|0.0 5-6|0 3-4|0.0.0 2-3|0.0.0.1 0-1|0.0.0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:33.247
(l2 / liver 
      :mod-of (t2 / transplantation 
            :poss-of (o / outcome 
                  :ARG0-of (e2 / encourage-01 
                        :condition-of (k / know-02 
                              :ARG1 (e / effect 
                                    :mod (l / long-term) 
                                    :poss (a / approach-02 
                                          :mod (t / this))) 
                              :ARG1-of (w / while-01) 
                              :polarity -)) 
                  :mod (s / short-term))))

# ::snt However , these patients are now required to take immunosuppressant drugs for the rest of their lives , often with undesirable side effects .
# ::tok However , these patients are now required to take immunosuppressant drugs for the rest of their lives , often with undesirable side effects .
# ::alignments 22-23|0.1.2.0.0 21-22|0.1.2.0.0.0 20-21|0.1.2.0.1+0.1.2.0 18-19|0.0 16-17|0.1.3.0 13-14|0.1.3 10-11|0.1.1 9-10|0.1.2 8-9|0.1 6-7|0 5-6|0.2 3-4|0.1.0.0.0+0.1.0.0+0.1.0 2-3|0.1.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:33.774
(r2 / require-01 
      :ARG0 (o / often) 
      :ARG1 (t / take-01 
            :ARG0 (p / person 
                  :ARG0-of (h / have-rel-role-91 
                        :ARG2 (p2 / patient)) 
                  :mod (t2 / this)) 
            :ARG1 (d2 / drug) 
            :ARG2 (i / immunosuppressant 
                  :ARG1-of (d / desire-01 
                        :mod-of (e / effect 
                              :mod (s / side)) 
                        :polarity -)) 
            :beneficiary (r / rest 
                  :part-of (l / life))) 
      :time (n / now))

# ::snt Moreover , the cost associated with liver transplantation and the availability of donor livers are additional limiting factors for the practicality of treatment of this disease .
# ::tok Moreover , the cost associated with liver transplantation and the availability of donor livers are additional limiting factors for the practicality of treatment of this disease .
# ::alignments 25-26|0.1.0.0 24-25|0.1.0 22-23|0.1.0.0.0 20-21|0.1.0.0.0.1 17-18|0 16-17|0.0 15-16|0.2 13-14|0.1.1.0.1.0 12-13|0.1.1.0.1.0.0 10-11|0.1.1.0.1 8-9|0.1.1.0 7-8|0.1.1.0.0 6-7|0.1.1.0.0.0 4-5|0.1.1 3-4|0.1 0-1|0.1.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:34.041
(f / factor 
      :ARG1-of (l / limit-01) 
      :domain (c / cost-01 
            :ARG1 (t / this 
                  :mod-of (d / disease 
                        :ARG1-of (t2 / treat-03 
                              :ARG0 (m / moreover) 
                              :poss-of (p / practicality)))) 
            :ARG1-of (a4 / associate-01 
                  :ARG2 (a3 / and 
                        :op1 (t3 / transplantation 
                              :mod (l3 / liver)) 
                        :op2 (a2 / available-02 
                              :ARG2 (l2 / liver 
                                    :mod (d2 / donor)))))) 
      :mod (a / additional))

# ::snt Because of the current unsatisfactory options for the treatment of MSUD , there is a need for improved therapies to combat this disease .
# ::tok Because of the current unsatisfactory options for the treatment of MSUD , there is a need for improved therapies to combat this disease .
# ::alignments 22-23|0.1.0.1 21-22|0.1.0.1.1 20-21|0.1.0 18-19|0.1.0.0 17-18|0.1.0.0.0 15-16|0.1 10-11|0.1.0.1.0.0.0.0+0.1.0.1.0.0.0+0.1.0.1.0.0 8-9|0.1.0.1.0 5-6|0.0 4-5|0.0.0 3-4|0.0.1 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:34.294
(c3 / cause-01 
      :ARG0 (o / option 
            :mod (u / unsatisfactory) 
            :time (c2 / current)) 
      :ARG1 (n / need-01 
            :ARG1 (c / combat-01 
                  :ARG0 (t2 / therapi 
                        :ARG1-of (i / improve-01)) 
                  :ARG1 (d / disease 
                        :ARG2-of (t4 / treat-03 
                              :ARG1 (t3 / thing 
                                    :name (n2 / name 
                                          :op1 "MSUD"))) 
                        :mod (t / this)))))

# ::snt An obstacle to developing novel treatments for MSUD has been the lack of a suitable animal model to perform necessary preclinical studies .
# ::tok An obstacle to developing novel treatments for MSUD has been the lack of a suitable animal model to perform necessary preclinical studies .
# ::alignments 21-22|0.0 20-21|0 18-19|0.0.0 16-17|0.0.0.0 15-16|0.0.0.0.2 14-15|0.0.0.0.1 11-12|0.0.0.0.0 7-8|0.0.0.0.0.0.2.0.0+0.0.0.0.0.0.2.0+0.0.0.0.0.0.2 5-6|0.0.0.0.0.0 4-5|0.0.0.0.0.0.1 3-4|0.0.0.0.0.0.0 1-2|0.0.0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:34.927
(p / preclinical 
      :ARG1-of (s / study-01 
            :ARG1-of (p2 / perform-02 
                  :ARG0 (m / model 
                        :ARG1-of (l / lack-01 
                              :ARG1-of (t2 / treat-03 
                                    :ARG0-of (d / develop-02 
                                          :ARG1 (o / obstacle)) 
                                    :ARG2 (n2 / novel) 
                                    :ARG3 (t / thing 
                                          :name (n / name 
                                                :op1 "MSUD")))) 
                        :ARG1-of (s2 / suitable-04) 
                        :mod (a / animal)))))

# ::snt Although a Hereford calf model with MSUD has been described [ 17-19 ] , this model is neither readily available nor practical to perform preclinical studies .
# ::tok Although a Hereford calf model with MSUD has been described [ 17-19 ] , this model is neither readily available nor practical to perform preclinical studies .
# ::alignments 25-26|0.1.0.0.0.0 24-25|0.1.0.0.0.0.0 23-24|0.1.0.0.0 21-22|0.1.0.0.2 19-20|0.1.0.0.1 18-19|0.1.0.0.1.0 15-16|0.1.0.0 14-15|0.1.0.0.3 9-10|0.1.0 6-7|0.0.0+0.0+0 4-5|0.1 3-4|0.1.1 2-3|0.1.2.0.0+0.1.2.0+0.1.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:35.311
(t2 / thing 
      :name (n / name 
            :op1 "MSUD") 
      :prep-with-of (m2 / model 
            :ARG1-of (d / describe-01 
                  :ARG0 (m / model 
                        :ARG0-of (p2 / perform-02 
                              :ARG1 (s / study-01 
                                    :ARG1 (p / preclinical))) 
                        :ARG2-of (a / available-02 
                              :ARG1-of (r / ready-02)) 
                        :domain-of (p3 / practical) 
                        :mod (t / this))) 
            :mod (c / calf) 
            :mod (c2 / country 
                  :name (n2 / name 
                        :op1 "Hereford"))))

# ::snt Furthermore , comparison of this animal model with human MSUD has shown some differences in the pathology of the disease [ 1 ] , making this animal a less desirable model for the human disease .
# ::tok Furthermore , comparison of this animal model with human MSUD has shown some differences in the pathology of the disease [ 1 ] , making this animal a less desirable model for the human disease .
# ::alignments 34-35|0.2.1.0 33-34|0.2.1.0.0 30-31|0.2.1 29-30|0.2 28-29|0.2.2 26-27|0.1.0.0 25-26|0.1.0 21-22|0.0.0 19-20|0.1.1.0 16-17|0.1.1 13-14|0.1 12-13|0.1.2 11-12|0 9-10|0.0.1.2.1.0+0.0.1.2.1+0.0.1.2 8-9|0.0.1.2.0 6-7|0.0.1 5-6|0.0.1.1 4-5|0.0.1.0 2-3|0.0 0-1|0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:35.811
(s2 / show-01 
      :ARG0 (c / compare-01 
            :ARG0 1 
            :ARG1 (m2 / model 
                  :mod (t3 / this) 
                  :mod (a2 / animal) 
                  :prep-with (t2 / thing 
                        :mod (h2 / human) 
                        :name (n / name 
                              :op1 "MSUD")))) 
      :ARG1 (d4 / differ-01 
            :ARG0 (t / this 
                  :mod-of (a / animal)) 
            :ARG2 (p / pathology 
                  :poss (d3 / disease)) 
            :mod (s / some)) 
      :purpose-of (d2 / desirable-02 
            :ARG0 (f / furthermore) 
            :ARG1 (m / model 
                  :beneficiary (d / disease 
                        :mod (h / human))) 
            :degree (l / less)))

# ::snt Recently , a N-ethyl-N-nitrosourea ( ENU ) - induced mutant mouse that phenotypically resembles human MSUD has been described [ 20 ] .
# ::tok Recently , a N-ethyl-N-nitrosourea ( ENU ) - induced mutant mouse that phenotypically resembles human MSUD has been described [ 20 ] .
# ::alignments 20-21|0.0.0.0 18-19|0.0.1 15-16|0.1.1.0+0.1.1+0.1 14-15|0.1.0 13-14|0 10-11|0.0 9-10|0.0.2 8-9|0.0.0 5-6|0.2.0.0+0.2.0+0.2 3-4|0.0.1.0.0.0+0.0.1.0.0+0.0.1.0 0-1|0.0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:36.322
(r / resemble-01 
      :ARG0 (m / mouse 
            :ARG1-of (i / induce-01 
                  :ARG0 20) 
            :ARG1-of (d / describe-01 
                  :ARG2 (t3 / thing 
                        :name (n3 / name 
                              :op1 "N-ethyl-N-nitrosourea")) 
                  :time (r2 / recent)) 
            :mod (m2 / mutant)) 
      :ARG1 (t / thing 
            :mod (h / human) 
            :name (n / name 
                  :op1 "MSUD")) 
      :ARG2 (t2 / thing 
            :name (n2 / name 
                  :op1 "ENU")))

# ::snt However , the mutation in this model disrupts a splice site in the mitochondrial branched-chain aminotransferase ( BCAT ) gene , not in BCKDH , the deficient enzyme in MSUD .
# ::tok However , the mutation in this model disrupts a splice site in the mitochondrial branched-chain aminotransferase ( BCAT ) gene , not in BCKDH , the deficient enzyme in MSUD .
# ::alignments 29-30|0.0.0.1.0+0.0.0.1+0.0.0 27-28|0.0 26-27|0 21-22|0.0.0.0.1.0.0 19-20|0.0.0.0.2 15-16|0.0.0.0.2.0 10-11|0.0.0.0.1 9-10|0.0.0.0.1.0 7-8|0.0.0.0 6-7|0.0.0.0.0.0 5-6|0.0.0.0.0.0.0 3-4|0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:36.531
(d / deficient 
      :mod-of (e / enzyme 
            :location (t / thing 
                  :ARG2-of (d2 / disrupt-01 
                        :ARG0 (m2 / mutation 
                              :location (m / model 
                                    :mod (t2 / this))) 
                        :ARG1 (s / site 
                              :mod (s2 / splice-01 
                                    :ARG0 -)) 
                        :location (g / gene 
                              :mod (a / aminotransferase))) 
                  :name (n / name 
                        :op1 "MSUD"))))

# ::snt Because the mutation is not in BCKDH , the validity of this mutant mouse line for modeling human MSUD is questionable .
# ::tok Because the mutation is not in BCKDH , the validity of this mutant mouse line for modeling human MSUD is questionable .
# ::alignments 20-21|0 18-19|0.1.1.1.0+0.1.1.1+0.1.1 17-18|0.1.1.0 16-17|0.1.1.0.0 14-15|0.1.0 13-14|0.1.0.1 12-13|0.1.0.2 11-12|0.1.0.0 9-10|0.1 4-5|0.1.1.0.0.0 2-3|0.0.0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:36.885
(q / questionable 
      :ARG1-of (c / cause-01 
            :ARG0 (m4 / mutation)) 
      :domain (v / valid-02 
            :ARG0 (l / line 
                  :mod (t2 / this) 
                  :mod (m2 / mouse) 
                  :mod (m3 / mutant)) 
            :ARG1 (t / thing 
                  :mod (h / human 
                        :ARG1-of (m / model-01 
                              :ARG0 -)) 
                  :name (n / name 
                        :op1 "MSUD"))))

# ::snt The objective of the present study was to create genetically engineered murine models of MSUD that mimic the pathology of the classic and intermediate variant forms of the human disease .
# ::tok The objective of the present study was to create genetically engineered murine models of MSUD that mimic the pathology of the classic and intermediate variant forms of the human disease .
# ::alignments 29-30|0.0.0.0.0.0.0 28-29|0.0.0.0.0.0 25-26|0.2 24-25|0.2.0 23-24|0.2.0.0 22-23|0 21-22|0.1 18-19|0.0.1 16-17|0.0 14-15|0.0.0.3.0.0+0.0.0.3.0+0.0.0.3 12-13|0.0.0 11-12|0.0.0.2 10-11|0.0.0.1 9-10|0.0.0.1.0 8-9|0.0.0.0 5-6|0.0.0.0.0 4-5|0.0.0.0.0.1 1-2|0.0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:37.707
(a / and 
      :manner-of (m / mimic-01 
            :ARG0 (m2 / model 
                  :ARG1-of (c2 / create-01 
                        :ARG0 (s / study-01 
                              :ARG1 (h / human 
                                    :mod-of (d / disease)) 
                              :time (p2 / present)) 
                        :domain-of (o / objective)) 
                  :ARG1-of (e / engineer-01 
                        :ARG2 (g / genetics)) 
                  :mod (m3 / murine) 
                  :poss (t / thing 
                        :name (n / name 
                              :op1 "MSUD"))) 
            :ARG1 (p / pathology)) 
      :op1 (c / classic) 
      :op2 (f / form 
            :mod (v / variant 
                  :mod (i / intermediate))))

# ::snt The classic model was created by targeted inactivation of the E2 subunit of BCKDH by homologous recombination in embryonic stem ( ES ) cells .
# ::tok The classic model was created by targeted inactivation of the E2 subunit of BCKDH by homologous recombination in embryonic stem ( ES ) cells .
# ::alignments 23-24|0.2 21-22|0.4 19-20|0.0.0.0 18-19|0.3 16-17|0.2.0 15-16|0.2.0.0 11-12|0.0.1 10-11|0.0.1.0.0.0+0.0.1.0.0+0.0.1.0 7-8|0.0 6-7|0.0.0 4-5|0 2-3|0.1 1-2|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:37.932
(c2 / create-01 
      :ARG0 (i / inactivation 
            :ARG1-of (t2 / target-01 
                  :ARG2 (s / stem)) 
            :poss (s2 / subunit 
                  :mod (t / thing 
                        :name (n / name 
                              :op1 "E2")))) 
      :ARG1 (m / model 
            :mod (c3 / classic)) 
      :location (c / cell 
            :location-of (r / recombination 
                  :mod (h / homologou))) 
      :op1-of (e2 / embryonic) 
      :op1-of (e / e))

# ::snt The model of intermediate MSUD was created by partial transgenic rescue of the E2 gene knockout .
# ::tok The model of intermediate MSUD was created by partial transgenic rescue of the E2 gene knockout .
# ::alignments 15-16|0.0.0 14-15|0.0.0.0 13-14|0.0.0.1.0.0+0.0.0.1.0+0.0.0.1 10-11|0.0 8-9|0.0.1 6-7|0 4-5|0.1.1.0+0.1.1+0.1 3-4|0.1.0 1-2|0.1.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:38.249
(c / create-01 
      :ARG0 (r / rescue-01 
            :ARG1 (k / knockout 
                  :mod (g / gene) 
                  :mod (t / thing 
                        :name (n / name 
                              :op1 "E2"))) 
            :quant (p / partial)) 
      :ARG1 (t2 / thing 
            :mod (i / intermediate) 
            :name (n2 / name 
                  :op1 "MSUD") 
            :poss-of (m / model)))

# ::snt This report describes the generation and characterization of these murine models of MSUD .
# ::tok This report describes the generation and characterization of these murine models of MSUD .
# ::alignments 12-13|0.2.0.2.0.0+0.2.0.2.0+0.2.0.2 10-11|0.2.0 9-10|0.2.0.1 8-9|0.2.0.0 6-7|0.1.0 5-6|0.1 4-5|0.2 2-3|0 1-2|0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:38.748
(d / describe-01 
      :ARG0 (r / report 
            :mod (t3 / this)) 
      :ARG1 (a / and 
            :op1 (c / characterization)) 
      :ARG2 (g / generation 
            :consist-of (m / model 
                  :mod (t2 / this) 
                  :mod (m2 / murine) 
                  :poss (t / thing 
                        :name (n / name 
                              :op1 "MSUD")))))

# ::snt These models will allow for the development of novel treatment approaches , such as gene or stem cell therapies , to ultimately cure MSUD .
# ::tok These models will allow for the development of novel treatment approaches , such as gene or stem cell therapies , to ultimately cure MSUD .
# ::alignments 23-24|0.0.1.0.1.0.0.0+0.0.1.0.1.0.0+0.0.1.0.1.0 22-23|0.0.1.0.1 21-22|0.0.1.0.1.1 18-19|0.3.0.0 17-18|0.3.0 16-17|0.3 15-16|0 14-15|0.2 12-13|0.1 10-11|0.0 9-10|0.0.0 8-9|0.0.0.0 6-7|0.0.1 3-4|0.0.1.0 1-2|0.0.1.0.0 0-1|0.0.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:39.074
(o / or 
      :ARG0-of (a / approach-02 
            :ARG1 (t3 / treat-03 
                  :ARG1 (n2 / novel)) 
            :ARG1-of (d / develop-02 
                  :ARG2-of (a2 / allow-01 
                        :ARG0 (m / model 
                              :mod (t4 / this)) 
                        :ARG1 (c / cure-01 
                              :ARG1 (t / thing 
                                    :name (n / name 
                                          :op1 "MSUD")) 
                              :time (u / ultimate))))) 
      :op1 (s2 / such) 
      :op2 (g / gene) 
      :op3 (s / stem 
            :mod-of (c2 / cell 
                  :mod-of (t2 / therapi))))

# ::snt All studies involving animals were reviewed and approved by the University of Pittsburgh 's Institutional Animal Care and Use Committee .
# ::tok All studies involving animals were reviewed and approved by the University of Pittsburgh 's Institutional Animal Care and Use Committee .
# ::alignments 18-20|0.1.1.0.1+0.1.1.0.0+0.1.1.0+0.1.1 17-18|0.1 14-17|0.1.0.0.2+0.1.0.0.1+0.1.0.0.0+0.1.0.0+0.1.0 12-13|0.1.0.1.1+0.1.0.1.0.0+0.1.0.1.0+0.1.0.1 7-8|0.0 6-7|0 5-6|0.0.0.0 3-4|0.0.0.1.0 2-3|0.0.0.1 1-2|0.0.0 0-1|0.0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:39.635
(a3 / and 
      :ARG0-of (a2 / approve-01 
            :ARG1 (s / study-01 
                  :ARG1-of (r / review-01) 
                  :ARG2-of (i / involve-01 
                        :ARG1 (a4 / animal)) 
                  :mod (a5 / all))) 
      :op1-of (a / and 
            :op2 (c / country 
                  :name (n2 / name 
                        :op1 "Institutional" 
                        :op2 "Animal" 
                        :op3 "Care") 
                  :poss (c2 / city 
                        :name (n3 / name 
                              :op1 "Pittsburgh") 
                        :wiki "Pittsburgh")) 
            :op3 (o / organization 
                  :name (n / name 
                        :op1 "Use" 
                        :op2 "Committee"))))

# ::snt A genomic DNA subclone of Strain 129/SvJ DNA that contained a portion of Exons 4 and 5 of the E2 gene and flanking DNA was obtained from a P1 phage library from Genome Systems , Inc. , ( St. Louis , MO ; ' 3-Hit Mouse ES Library ' ) .
# ::tok A genomic DNA subclone of Strain 129/SvJ DNA that contained a portion of Exons 4 and 5 of the E2 gene and flanking DNA was obtained from a P1 phage library from Genome Systems , Inc. , ( St. Louis , MO ; ' 3-Hit Mouse ES Library ' ) .
# ::alignments 45-48|0.2.0.2+0.2.0.1+0.2.0.0+0.2.0+0.2 42-43|0 41-42|0.1.0.0+0.1.0+0.1 38-40|0.0.1.0.1.1.0.1+0.0.1.0.1.1.0.0+0.0.1.0.1.1.0+0.0.1.0.1.1 35-36|0.0.3.0.0.0+0.0.3.0.0+0.0.3.0 32-34|0.0.3.2.0.1+0.0.3.2.0.0+0.0.3.2.0+0.0.3.2 30-31|0.0.3.1 29-30|0.0.3.1.0 25-26|0.0.3 23-24|0.0.2 22-23|0.0.2.0 21-22|0.0 20-21|0.0.1 19-20|0.0.1.0.0.0+0.0.1.0.0+0.0.1.0 16-17|0.0.2.0.0 15-16|0.0.1.0.1 14-15|0.0.3.3 13-14|0.0.1.0.1.0.1.0.0.0+0.0.1.0.1.0.1.0.0+0.0.1.0.1.0.1.0 11-12|0.0.1.0.1.0.1 9-10|0.0.1.0.1.0 7-8|0.0.1.0.1.0.0 5-6|0.0.0.0.0+0.0.0.0+0.0.0 3-4|0.0.1.0.1.0.0.0 2-3|0.0.1.0.1.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:42.497
(a / and 
      :op1 (a2 / and 
            :op1 (p3 / person 
                  :name (n8 / name 
                        :op1 "Strain")) 
            :op2 (g / gene 
                  :mod (t / thing 
                        :name (n6 / name 
                              :op1 "E2") 
                        :op2-of (a3 / and 
                              :op1 (c3 / contain-01 
                                    :ARG0 (d2 / DNA 
                                          :beneficiary-of (s / subclone 
                                                :mod (d3 / DNA))) 
                                    :ARG1 (p2 / portion 
                                          :quant-of (o5 / organization 
                                                :name (n7 / name 
                                                      :op1 "Exons")))) 
                              :op3 (c2 / country 
                                    :name (n3 / name 
                                          :op1 "St." 
                                          :op2 "Louis"))))) 
            :op3 (d / DNA 
                  :ARG1-of (f / flank-01 
                        :ARG0 5)) 
            :op4 (o4 / obtain-01 
                  :ARG0 (o2 / organization 
                        :name (n4 / name 
                              :op1 "Inc.")) 
                  :ARG1 (l / library 
                        :mod (p / phage)) 
                  :ARG2 (o3 / organization 
                        :name (n5 / name 
                              :op1 "Genome" 
                              :op2 "Systems")) 
                  :op1-of 4)) 
      :op2 (c / country 
            :name (n2 / name 
                  :op1 "MO")) 
      :op3 (o / organization 
            :name (n / name 
                  :op1 "Mouse" 
                  :op2 "ES" 
                  :op3 "Library")))

# ::snt A positive/negative replacement type gene targeting vector [ 21 ] was created by replacing a 1.67 kb EcoRV-Smal fragment that included a portion of Exon 4 and all of Exon 5 with the PGKneo marker gene ( See Fig. 1A ) from the pPNT vector [ 22 ] .
# ::tok A positive/negative replacement type gene targeting vector [ 21 ] was created by replacing a 1.67 kb EcoRV-Smal fragment that included a portion of Exon 4 and all of Exon 5 with the PGKneo marker gene ( See Fig. 1A ) from the pPNT vector [ 22 ] .
# ::alignments 46-47|0.1.0.1.1.1 44-45|0.1.1 37-38|0.1.0.1.1.0.0 35-36|0.2 34-35|0 33-34|0.0.0.0+0.0.0+0.0 30-31|0.1.0.1.1.0.0.1 27-28|0.1.0.0.0.0 26-27|0.1.0.1.1.0 25-26|0.1.0.0.1.0.0 24-25|0.1.0.1.1.0.1.0.0.0+0.1.0.1.1.0.1.0.0+0.1.0.1.1.0.1.0 22-23|0.1.0.1.1.0.1 20-21|0.1.0.1.1 18-19|0.1.0.1 17-18|0.1.0.1.0.0.0+0.1.0.1.0.0+0.1.0.1.0 13-14|0.1.0 11-12|0.1 8-9|0.1.0.1.1.0.0.0 6-7|0.1.0.0.1.0.1 5-6|0.1.0.0.0 4-5|0.1.0.0 3-4|0.1.0.0.1 2-3|0.1.0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:43.756
(m / mark-01 
      :ARG1 (c / country 
            :name (n / name 
                  :op1 "PGKneo")) 
      :ARG2-of (c3 / create-01 
            :ARG1 (r / replace-01 
                  :ARG0 (g2 / gene 
                        :ARG0-of (t / target-01 
                              :op1-of (a / all)) 
                        :mod (t2 / type 
                              :mod (r2 / replace-01 
                                    :ARG1 4 
                                    :ARG2 (v2 / vector)))) 
                  :ARG1 (f / fragment-01 
                        :ARG1 (c2 / country 
                              :name (n3 / name 
                                    :op1 "EcoRV-Smal")) 
                        :ARG2-of (i / include-01 
                              :ARG1 (a2 / and 
                                    :ARG1-of (s / see-01 
                                          :ARG0 21 
                                          :ARG2 5) 
                                    :op1 (p / portion 
                                          :quant-of (o / organization 
                                                :name (n2 / name 
                                                      :op1 "Exon")))) 
                              :op1-of 22))) 
            :op1-of (v / vector)) 
      :mod-of (g / gene))

# ::snt The targeting construct was linearized with NotI and electroporated into R1 ES cells [ 23 ] under conditions described previously [ 24 ] .
# ::tok The targeting construct was linearized with NotI and electroporated into R1 ES cells [ 23 ] under conditions described previously [ 24 ] .
# ::alignments 21-22|0.0.1.0 19-20|0.0.1.1.1 18-19|0.0.1.1 17-18|0.0.1.1.0 14-15|0.0.0 12-13|0.2.0 10-12|0.2.1.1+0.2.1.0+0.2.1+0.2 7-8|0 6-7|0.1.0.0+0.1.0+0.1 2-3|0.0 1-2|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:43.991
(a / and 
      :ARG1-of (c3 / construct-01 
            :ARG0 23 
            :ARG1-of (t3 / target-01 
                  :ARG0 24 
                  :ARG2 (d / describe-01 
                        :ARG0 (c / condition) 
                        :manner (p / previous)))) 
      :op1 (t2 / thing 
            :name (n2 / name 
                  :op1 "NotI")) 
      :op2 (t / thing 
            :mod-of (c2 / cell) 
            :name (n / name 
                  :op1 (r / R1) 
                  :op2 (e / ES))))

# ::snt ES cells were selected with G418 ( 300 g/ml ; Life Technologies Inc. , Gaithersburg , MD ) and gancyclovir ( 2 M ; gift of Syntex , Palo Alto , CA ) .
# ::tok ES cells were selected with G418 ( 300 g/ml ; Life Technologies Inc. , Gaithersburg , MD ) and gancyclovir ( 2 M ; gift of Syntex , Palo Alto , CA ) .
# ::alignments 31-32|0.3.1.0.1+0.3.1.0.0.0+0.3.1.0.0+0.3.1.0 28-30|0.3.1.1.1.0.1+0.3.1.1.1.0.0+0.3.1.1.1.0+0.3.1.1.1 26-27|0.3.2.0+0.3.2+0.3 24-25|0.3.0+0.3.0.0 22-23|0.3.1.2.1.1.2+0.3.1.2.1.1.0.0+0.3.1.2.1.1.0+0.3.1.2.1.1 21-22|0.3.1.2.1.1.1 19-20|0.3.1.2.1.0 18-19|0.3.1.2.1 16-17|0.2.0.0+0.2.0+0.2 14-15|0.1.0.0+0.1.0+0.1 10-13|0.0.0.2+0.0.0.1+0.0.0.0+0.0.0+0.0 9-10|0 7-8|0.3.3 5-6|0.3.1.2.0.0+0.3.1.2.0+0.3.1.2 3-4|0.3.1 1-2|0.3.1.1 0-1|0.3.1.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:44.902
(a2 / and 
      :op1 (o2 / organization 
            :name (n7 / name 
                  :op1 "Life" 
                  :op2 "Technologies" 
                  :op3 "Inc.")) 
      :op2 (c3 / country 
            :name (n6 / name 
                  :op1 "Gaithersburg")) 
      :op3 (c2 / country 
            :name (n5 / name 
                  :op1 "MD")) 
      :op4 (o / organization 
            :ARG0-of (g / gift-01 
                  :ARG1 (t / thing)) 
            :ARG2-of (s2 / select-01 
                  :ARG0 (s / state 
                        :name (n / name 
                              :op1 "CA") 
                        :wiki "California") 
                  :ARG1 (c4 / cell 
                        :mod (e / e) 
                        :mod (c / country 
                              :name (n2 / name 
                                    :op1 "Palo" 
                                    :op2 "Alto"))) 
                  :ARG3 (p / person 
                        :name (n8 / name 
                              :op1 "G418") 
                        :op1-of (a / and 
                              :op2 (g2 / gancyclovir) 
                              :op3 (v / vehicle 
                                    :name (n4 / name 
                                          :op1 "M1") 
                                    :quant 2 
                                    :wiki "M1_Abrams")))) 
            :name (n3 / name 
                  :op1 "Syntex") 
            :poss-of 300))

# ::snt Doubly resistant clones were screened for gene targeting by Southern blot analysis of BglI digested genomic DNA .
# ::tok Doubly resistant clones were screened for gene targeting by Southern blot analysis of BglI digested genomic DNA .
# ::alignments 16-17|0.0.0.0 14-15|0.0.0 13-14|0.1.0.1.0.0+0.1.0.1.0+0.1.0.1 11-12|0.1.0 10-11|0.1.0.2 9-10|0.1.0.0.0.0+0.1.0.0.0+0.1.0.0 7-8|0.1 6-7|0.1.1 4-5|0 2-3|0.0 1-2|0.0.1 0-1|0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:45.426
(s / screen-01 
      :ARG1 (c / clone-01 
            :ARG1 (d2 / digest-01 
                  :ARG1 (d / DNA)) 
            :ARG1-of (r / resist-01 
                  :degree (d3 / doubly-so))) 
      :ARG2 (t3 / target-01 
            :ARG0 (a / analyze-01 
                  :ARG0 (t2 / thing 
                        :name (n2 / name 
                              :op1 "Southern")) 
                  :ARG1 (t / thing 
                        :name (n / name 
                              :op1 "BglI")) 
                  :ARG2 (b / blot-01)) 
            :ARG1 (g / gene)))

# ::snt Blots were hybridized with an Exon 6 specific probe that was external to the gene targeting construct .
# ::tok Blots were hybridized with an Exon 6 specific probe that was external to the gene targeting construct .
# ::alignments 16-17|0.1 15-16|0 14-15|0.0 11-12|0.1.1.0.0.1 8-9|0.1.1.0.0 7-8|0.1.1.0.0.2 6-7|0.1.0 5-6|0.1.1.0.0.0.0.0+0.1.1.0.0.0.0+0.1.1.0.0.0 2-3|0.1.1.0 0-1|0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:45.535
(t / target-01 
      :ARG0 (g / gene) 
      :ARG1 (c / construct-01 
            :ARG1 6 
            :ARG1-of (b / blot-01 
                  :ARG1-of (h / hybridize-01 
                        :ARG2 (p / probe-01 
                              :ARG0 (o / organization 
                                    :name (n / name 
                                          :op1 "Exon")) 
                              :ARG1 (e / external) 
                              :ARG1-of (s / specific-02))))))

# ::snt Correctly targeted ES cells were injected into C57BL/6J blastocysts to produce chimeric mice using standard procedures .
# ::tok Correctly targeted ES cells were injected into C57BL/6J blastocysts to produce chimeric mice using standard procedures .
# ::alignments 15-16|0.0.0.0.0.0.0 14-15|0.0.0.0.0.0.0.0 13-14|0.0.0.0.0.0 12-13|0.0.0.0.0 11-12|0.0.0.0.0.1 10-11|0.0.0.0 8-9|0.0.0.1.0 7-8|0.0.0.1.0.0.0.0+0.0.0.1.0.0.0+0.0.0.1.0.0 5-6|0.0.0.1 3-4|0.0.0 2-3|0.0.0.2 1-2|0.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:45.753
(c3 / correctly 
      :mod-of (t2 / target-01 
            :ARG1 (c2 / cell 
                  :ARG0-of (p2 / produce-01 
                        :ARG1 (m / mouse 
                              :ARG0-of (u / use-01 
                                    :ARG1 (p / procedure 
                                          :ARG1-of (s / standard-02))) 
                              :mod (c / chimeric))) 
                  :ARG1-of (i / inject-01 
                        :ARG2 (b / blastocyst 
                              :mod (t / thing 
                                    :name (n / name 
                                          :op1 "C57BL/6J")))) 
                  :mod (e / e))))

# ::snt Heterozygous offspring from germline competent chimeras were intercrossed to produce wild type ( + / + ) , heterozygous ( + / - ) and homozygous knockout ( - / - ) mice .
# ::tok Heterozygous offspring from germline competent chimeras were intercrossed to produce wild type ( + / + ) , heterozygous ( + / - ) and homozygous knockout ( - / - ) mice .
# ::alignments 32-33|0.3 29-30|0.0.0.1.0.1 26-27|0.0.0.1.0.4 25-26|0.0.0.1.0.0 24-25|0 21-22|0.0.0.1.0.3 18-19|0.2 14-15|0.0.0.1.0.2 11-12|0.1 10-11|0.1.0 9-10|0.0 5-6|0.0.0.1 4-5|0.0.0.1.0 1-2|0.0.0 0-1|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:46.039
(a / and 
      :ARG1-of (p / produce-01 
            :ARG0 (o / offspr 
                  :mod (h3 / heterozygou) 
                  :source (c / chimera 
                        :ARG1-of (c2 / competent-01 
                              :op1-of (h / homozygou) 
                              :op1-of (s / slash) 
                              :op1-of (s3 / slash) 
                              :op1-of (s2 / slash) 
                              :op1-of (k / knockout))))) 
      :op1 (t / type 
            :mod (w / wild)) 
      :op2 (h2 / heterozygou) 
      :op3 (m / mouse))

# ::snt At all generations , + / - breeding pairs were used .
# ::tok At all generations , + / - breeding pairs were used .
# ::alignments 10-11|0 8-9|0.2 7-8|0.2.0 5-6|0.1 2-3|0.0 1-2|0.2.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:46.147
(u / use-01 
      :ARG0 (g / generation) 
      :ARG1 (s / slash) 
      :ARG2 (p / pair-01 
            :ARG1 (b / breed-01 
                  :ARG1 (a / all))))

# ::snt Results presented here are from mice derived from the F2 + generations .
# ::tok Results presented here are from mice derived from the F2 + generations .
# ::alignments 11-12|0.0.1 9-10|0.0.1.0.0.0+0.0.1.0.0+0.0.1.0 6-7|0.0 5-6|0.0.0 2-3|0.1.0 1-2|0.1 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:46.228
(r / result-01 
      :ARG0-of (d / derive-01 
            :ARG1 (m / mouse) 
            :ARG2 (g / generation 
                  :mod (c / country 
                        :name (n / name 
                              :op1 "F2")))) 
      :ARG1-of (p / present-01 
            :location (h / here)))

# ::snt All animals were of a mixed C57BL/6J  Strain 129Sv/SvJ genetic background .
# ::tok All animals were of a mixed C57BL/6J  Strain 129Sv/SvJ genetic background .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:46.230
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt E2 gene knockout mouse production .
# ::tok E2 gene knockout mouse production .
# ::alignments 4-5|0 3-4|0.0 2-3|0.0.0 1-2|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:46.283
(p / produce-01 
      :ARG1 (m / mouse 
            :mod (k / knockout 
                  :mod (g / gene))))

# ::snt A , Gene targeting strategy used for targeting the E2 locus in mouse ES cells .
# ::tok A , Gene targeting strategy used for targeting the E2 locus in mouse ES cells .
# ::alignments 14-15|0.0.1.0.0.0.0 13-14|0.0.1.0.0.0.0.0 12-13|0 10-11|0.0.1.0.0.0 9-10|0.0.1.0.0.0.1.0.0+0.0.1.0.0.0.1.0+0.0.1.0.0.0.1 7-8|0.0.1.0.0 5-6|0.0.1.0 4-5|0.0.1 3-4|0.0 2-3|0.0.0.0.0+0.0.0.0+0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:46.692
(m / mouse 
      :ARG2-of (t3 / target-01 
            :ARG0 (p / person 
                  :name (n2 / name 
                        :op1 "Gene")) 
            :ARG1 (s / strategy 
                  :ARG1-of (u / use-01 
                        :ARG2 (t2 / target-01 
                              :ARG1 (l / locu 
                                    :location (c / cell 
                                          :mod (e / e)) 
                                    :mod (t / thing 
                                          :name (n / name 
                                                :op1 "E2"))))))))

# ::snt The targeting construct was designed to delete 1.67 kb of sequence between an EcoRV site in Exon 4 and a Smal site in intron 5 .
# ::tok The targeting construct was designed to delete 1.67 kb of sequence between an EcoRV site in Exon 4 and a Smal site in intron 5 .
# ::alignments 24-25|0.0.1.0.0 23-24|0.0.1.0.2.0 21-22|0.2 18-19|0 17-18|0.0.1.0.1 16-17|0.1.0.0.0+0.1.0.0+0.1.0 14-15|0.1 10-11|0.0.0.0 8-9|0.0.0 6-7|0.0 4-5|0.0.1 2-3|0.0.1.0 1-2|0.0.1.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:47.311
(a / and 
      :ARG0-of (d / delete-01 
            :ARG1 (k / kb 
                  :mod (s3 / sequence)) 
            :ARG3-of (d2 / design-01 
                  :ARG1 (c / construct-01 
                        :ARG0 5 
                        :ARG1 4 
                        :ARG1-of (t / target-01 
                              :ARG0 (i / intron))))) 
      :op1 (s2 / site 
            :mod (o / organization 
                  :name (n / name 
                        :op1 "Exon"))) 
      :op2 (s / site))

# ::snt The wild type E2 gene contains an ~ 16 kb BglI restriction fragment that hybridizes to the Exon 6 specific probe .
# ::tok The wild type E2 gene contains an ~ 16 kb BglI restriction fragment that hybridizes to the Exon 6 specific probe .
# ::alignments 20-21|0.1.1.0.0 19-20|0.1.1.0.0.0 18-19|0.1.2.0 17-18|0.1.1.0.1.0+0.1.1.0.1+0.1.1.0 14-15|0.1.1 12-13|0.1 11-12|0.1.2 9-11|0.1.0.0.1+0.1.0.0.0+0.1.0.0+0.1.0 8-9|0.1.1.0.0.0.0 5-6|0 4-5|0.0 3-4|0.0.1.0.0+0.0.1.0+0.0.1 2-3|0.0.0.0 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:48.182
(c / contain-01 
      :ARG0 (g / gene 
            :mod (w / wild 
                  :mod-of (t3 / type)) 
            :mod (t2 / thing 
                  :name (n3 / name 
                        :op1 "E2"))) 
      :ARG1 (f / fragment-01 
            :ARG0 (t / thing 
                  :name (n2 / name 
                        :op1 (k / kb) 
                        :op2 (b / BglI))) 
            :ARG0-of (h / hybridize-01 
                  :ARG1 (o / organization 
                        :ARG0-of (p / probe-01 
                              :ARG1-of (s / specific-02 
                                    :ARG0 16)) 
                        :name (n / name 
                              :op1 "Exon"))) 
            :ARG1 (r / restrict-01 
                  :ARG1 6)))

# ::snt A correctly targeted E2 locus harbors an ~ 11 kb BglI restriction fragment that hybridizes to the same probe .
# ::tok A correctly targeted E2 locus harbors an ~ 11 kb BglI restriction fragment that hybridizes to the same probe .
# ::alignments 18-19|0.1.1.0 17-18|0.1.1.0.0 14-15|0.1.1 12-13|0.1 11-12|0.1.2 9-11|0.1.0.0.1+0.1.0.0.0+0.1.0.0+0.1.0 8-9|0.0.0.0.0 5-6|0 4-5|0.0 3-4|0.0.1.0.0+0.0.1.0+0.0.1 2-3|0.0.0 1-2|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:48.855
(h2 / harbor-01 
      :ARG0 (l / locu 
            :ARG1-of (t3 / target-01 
                  :ARG1-of (c / correct-02 
                        :ARG0 11)) 
            :mod (t2 / thing 
                  :name (n2 / name 
                        :op1 "E2"))) 
      :ARG1 (f / fragment-01 
            :ARG0 (t / thing 
                  :name (n / name 
                        :op1 (k / kb) 
                        :op2 (b / BglI))) 
            :ARG0-of (h / hybridize-01 
                  :ARG2 (p / probe-01 
                        :ARG1-of (s / same-01))) 
            :ARG1 (r / restrict-01)))

# ::snt Note that the probe will not detect random integration of the targeting vector because it is external to the targeting vector .
# ::tok Note that the probe will not detect random integration of the targeting vector because it is external to the targeting vector .
# ::alignments 20-21|0.0.0.0.1 19-20|0.0.0.0 16-17|0.0.2.0 13-14|0.0.2 12-13|0.0.1 11-12|0.0.1.1 8-9|0.0.1.0 7-8|0.0.0.0.0 6-7|0.0 5-6|0.0.3 3-4|0.0.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:49.036
(n / note-01 
      :ARG1 (d / detect-01 
            :ARG0 (p / probe-01 
                  :ARG1 (t / target-01 
                        :ARG0 (r / random) 
                        :ARG1 (v / vector))) 
            :ARG1 (v2 / vector 
                  :ARG1-of (i / integrate-01) 
                  :ARG1-of (t2 / target-01)) 
            :ARG1-of (c / cause-01 
                  :ARG0 (e / external)) 
            :polarity -))

# ::snt B , Southern blot analysis of Bgll digested genomic DNA derived from the parental wild type ES cell line ( R1 ) , a heterozygous targeted ES cell line ( 362 ) , and from wild type ( + / + ) , heterozygous ( + / - ) and homozygous knockout ( - / - ) mice .
# ::tok B , Southern blot analysis of Bgll digested genomic DNA derived from the parental wild type ES cell line ( R1 ) , a heterozygous targeted ES cell line ( 362 ) , and from wild type ( + / + ) , heterozygous ( + / - ) and homozygous knockout ( - / - ) mice .
# ::alignments 57-58|0.2.2 54-55|0.3 51-52|0.0.0.0.0.0.0.2.0 49-50|0.2 46-47|0.2.1 39-40|0.0.0.0.0.0.0.0 36-37|0.1 35-36|0.1.0 33-34|0 28-29|0.0.0.0.0.0.0.2.1 27-28|0.0.0.0.0.0.0.2.1.0 25-26|0.0.0.0.0.0.0.2 24-25|0.0.0.0.0.0.0.1.0 18-19|0.0 17-18|0.0.1 16-17|0.0.2.0.0 15-16|0.0.2 14-15|0.0.2.0 13-14|0.0.0.0.0.0.0.1.1 10-11|0.0.0 9-10|0.0.0.0 7-8|0.0.0.0.0 6-7|0.0.0.0.0.0.1.0+0.0.0.0.0.0.1+0.0.0.0.0.0 4-5|0.0.0.0.0.0.0 3-4|0.0.0.0.0.0.0.1 2-3|0.0.0.0.0.0.0.3.0.0+0.0.0.0.0.0.0.3.0+0.0.0.0.0.0.0.3 0-1|0.2.0.1+0.2.0.0.0+0.2.0.0+0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:51.358
(a2 / and 
      :op1 (l2 / line 
            :ARG2-of (d / derive-01 
                  :ARG1 (d2 / DNA 
                        :ARG1-of (d3 / digest-01 
                              :ARG0 (t4 / thing 
                                    :ARG1-of (a3 / analyze-01 
                                          :ARG0 (s3 / slash) 
                                          :ARG2 (b / blot-01 
                                                :ARG0 (h / heterozygou) 
                                                :ARG1 (p / parental)) 
                                          :ARG2-of (t2 / target-01 
                                                :ARG0 (k / knockout) 
                                                :ARG1 (l / line 
                                                      :mod (c / cell))) 
                                          :manner (t5 / thing 
                                                :name (n2 / name 
                                                      :op1 "Southern"))) 
                                    :name (n / name 
                                          :op1 "Bgll"))))) 
            :mod (c2 / cell) 
            :mod (t3 / type 
                  :mod (w2 / wild 
                        :mod-of (e / e)))) 
      :op2 (t / type 
            :mod (w / wild)) 
      :op2-of (a / and 
            :op1 (l3 / location 
                  :name (n3 / name 
                        :op1 "B") 
                  :wiki -) 
            :op3 (s2 / slash) 
            :op4 (m / mouse)) 
      :op3 (s / slash))

# ::snt The blot was hybridized with an Exon 6 specific probe .
# ::tok The blot was hybridized with an Exon 6 specific probe .
# ::alignments 9-10|0.1 8-9|0.1.1 7-8|0.1.2 6-7|0.1.0.0.0+0.1.0.0+0.1.0 3-4|0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:51.425
(h / hybridize-01 
      :ARG1 (b / blot-01) 
      :ARG2 (p / probe-01 
            :ARG0 (o / organization 
                  :name (n / name 
                        :op1 "Exon")) 
            :ARG1-of (s / specific-02) 
            :quant 6))

# ::snt C , Immunohistochemical analysis of fresh frozen liver sections from control ( + / + ) and E2 knockout ( - / - ) postnatal day 1 mouse pups .
# ::tok C , Immunohistochemical analysis of fresh frozen liver sections from control ( + / + ) and E2 knockout ( - / - ) postnatal day 1 mouse pups .
# ::alignments 28-29|0.1.1.1 27-28|0.1.1.1.1 26-27|0.1.0.0.0 25-26|0.1.1.1.0 24-25|0.1.1.1.0.0 21-22|0.1.1.0 18-19|0.2 16-17|0 13-14|0.1.0.1.0 10-11|0.1.1 8-9|0.1.0 7-8|0.1.0.2 6-7|0.1.0.1 5-6|0.1.0.0 3-4|0.1 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:52.065
(a / and 
      :op1 (c2 / C) 
      :op2 (a2 / analyze-01 
            :ARG1 (s3 / section 
                  :ARG1-of (f2 / fresh-04 
                        :ARG0 1) 
                  :ARG1-of (f / freeze-01 
                        :ARG0 (s2 / slash)) 
                  :mod (l / liver)) 
            :purpose (c / control-01 
                  :ARG0 (s / slash) 
                  :ARG1 (p / pup-01 
                        :ARG0 (d / day 
                              :mod (p2 / postnatal)) 
                        :ARG1 (m / mouse)))) 
      :op3 (k / knockout))

# ::snt Sections were stained for E2 using an E2 specific antibody ( green ) and a nuclear stain ( blue ) .
# ::tok Sections were stained for E2 using an E2 specific antibody ( green ) and a nuclear stain ( blue ) .
# ::alignments 18-19|0.0.3.0 16-17|0.0.1.0 15-16|0.0.1.0.0 13-14|0.0.1 11-12|0 9-10|0.0.2 8-9|0.0.2.0 5-6|0.0 4-5|0.0.0.0.0+0.0.0.0+0.0.0 2-3|0.0.3 0-1|0.0.3.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:52.857
(g / green-02 
      :ARG1 (u / use-01 
            :ARG0 (t / thing 
                  :name (n2 / name 
                        :op1 "E2")) 
            :ARG1 (a / and 
                  :op1 (s / stain-01 
                        :mod (n / nucleus))) 
            :ARG2 (a2 / antibody 
                  :ARG1-of (s2 / specific-02)) 
            :manner-of (s3 / stain-01 
                  :ARG0 (b / blue) 
                  :ARG1 (s4 / section-01))))

# ::snt Note the complete absence of E2 immunoreactivity in the section from the knockout mouse .
# ::tok Note the complete absence of E2 immunoreactivity in the section from the knockout mouse .
# ::alignments 13-14|0.0.0.1 12-13|0.0.0.1.0 9-10|0.0.2 6-7|0.0.0 5-6|0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 3-4|0.0 2-3|0.0.1 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:52.903
(n2 / note-01 
      :ARG1 (a / absent-01 
            :ARG1 (i / immunoreactivity 
                  :mod (t / thing 
                        :name (n / name 
                              :op1 "E2")) 
                  :mod-of (m / mouse 
                        :mod (k / knockout))) 
            :ARG1-of (c / complete-02) 
            :location (s / section)))

# ::snt D , Similar results were observed upon immunohistochemical analysis of primary mouse embryonic fibroblasts ( MEFs ) .
# ::tok D , Similar results were observed upon immunohistochemical analysis of primary mouse embryonic fibroblasts ( MEFs ) .
# ::alignments 15-16|0 13-14|0.0.0 12-13|0.0.0.0 11-12|0.0.0.1 10-11|0.0.0.1.0 8-9|0.0 5-6|0.0.1 3-4|0.0.1.0.1+0.0.1.0 2-3|0.0.1.0.0 0-1|0.0.1.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:53.021
(m / mef 
      :ARG0-of (a / analyze-01 
            :ARG1 (f / fibroblast 
                  :mod (e / embryonic) 
                  :mod (m2 / mouse 
                        :mod (p / primary))) 
            :ARG2-of (o / observe-01 
                  :ARG1 (t / thing 
                        :ARG1-of (r2 / resemble-01) 
                        :ARG2-of (r / result-01) 
                        :mod (d / D)))))

# ::snt Note that the readily detectable signal for E2 in the control cells was present in a pattern characteristic of mitochondria , the subcellular location of BCKDH .
# ::tok Note that the readily detectable signal for E2 in the control cells was present in a pattern characteristic of mitochondria , the subcellular location of BCKDH .
# ::alignments 25-26|0.1.1.1.0+0.1.1.1+0.1.1 23-24|0.1.1.0 22-23|0.1.1.0.0 19-20|0.1.0.0.0.0.1 17-18|0.1.0.0.0.0 16-17|0.1.0.0.0.0.0 13-14|0.0 11-12|0.1.2 10-11|0.1 7-8|0.1.2.0.0.0+0.1.2.0.0+0.1.2.0 5-6|0.1.0 4-5|0.1.0.0 3-4|0.1.0.0.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:53.274
(n3 / note-01 
      :ARG1 (p2 / present) 
      :ARG2 (c4 / control-01 
            :ARG0 (s2 / signal 
                  :mod (d / detectable 
                        :ARG1-of (r / ready-02 
                              :ARG0 (c2 / characteristic 
                                    :mod (p / pattern) 
                                    :mod (m / mitochondrion))))) 
            :op1-of (c / country 
                  :location (l / location 
                        :mod (s / subcellular)) 
                  :name (n / name 
                        :op1 "BCKDH")) 
            :topic-of (c3 / cell 
                  :location-of (t / thing 
                        :name (n2 / name 
                              :op1 "E2")))))

# ::snt Production of transgenic mice .
# ::tok Production of transgenic mice .
# ::alignments 3-4|0.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:53.281
(p / production 
      :mod (m / mouse))

# ::snt Standard molecular techniques were used to assemble the transgenic construct , pTRE-E2 .
# ::tok Standard molecular techniques were used to assemble the transgenic construct , pTRE-E2 .
# ::alignments 9-10|0.1.0 6-7|0.1 4-5|0 2-3|0.0 1-2|0.1.0.0 0-1|0.0.0.0.0+0.0.0.0+0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:53.313
(u / use-01 
      :ARG1 (t / technique 
            :mod (c2 / country 
                  :name (n / name 
                        :op1 "Standard"))) 
      :ARG2 (a / assemble-01 
            :ARG1 (c / construct-01 
                  :ARG1 (m / molecule))))

# ::snt This transgene contains the tetracycline responsive hCMV * -1 promoter [ consisting of the tetracycline responsive element ( TRE ) and a minimal hCMV promoter ] [ 25 ] from pTRE2 ( Clontech Inc. , Mt. View , CA ) , a chimeric intron from pCI ( Promega ) to increase message stability and expression [ 26,27 ] , a Kozak consensus sequence at the initiation codon to optimize translation [ 28 ] , the human E2 cDNA which has been modified to contain a 4  alanine linker followed by a c-myc epitope tag at the carboxy terminus to facilitate detection , and an SV40 late polyadenylation sequence from pCI for enhanced mRNA stability and translation .
# ::tok This transgene contains the tetracycline responsive hCMV * -1 promoter [ consisting of the tetracycline responsive element ( TRE ) and a minimal hCMV promoter ] [ 25 ] from pTRE2 ( Clontech Inc. , Mt. View , CA ) , a chimeric intron from pCI ( Promega ) to increase message stability and expression [ 26,27 ] , a Kozak consensus sequence at the initiation codon to optimize translation [ 28 ] , the human E2 cDNA which has been modified to contain a 4  alanine linker followed by a c-myc epitope tag at the carboxy terminus to facilitate detection , and an SV40 late polyadenylation sequence from pCI for enhanced mRNA stability and translation .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:53.327
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt The 2.48 kb TRE-E2 transgene was purified from vector sequences following digestion with XhoI and BamHI and injected into C57BL/6J or C57BL/6J  Strain 129SvEv mouse embryos at the transgenic core facilities of the University of Pittsburgh and the University of Cincinnati , respectively .
# ::tok The 2.48 kb TRE-E2 transgene was purified from vector sequences following digestion with XhoI and BamHI and injected into C57BL/6J or C57BL/6J  Strain 129SvEv mouse embryos at the transgenic core facilities of the University of Pittsburgh and the University of Cincinnati , respectively .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:53.332
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt Genomic DNA from the tail of mice was screened by Southern blot analysis following digestion with EcoRI and hybridization to an ~ 400 bp probe derived from the SV40 portion of the TRE-E2 transgene .
# ::tok Genomic DNA from the tail of mice was screened by Southern blot analysis following digestion with EcoRI and hybridization to an ~ 400 bp probe derived from the SV40 portion of the TRE-E2 transgene .
# ::alignments 33-34|0.3.0.0.1 29-30|0.3.0.0 28-29|0.3.0.0.0.0.0+0.3.0.0.0.0+0.3.0.0.0 25-26|0.3.0 24-25|0.3 22-23|0.2.0.0.0.0 18-19|0.2.0.0.2 17-18|0.2.0.0 16-17|0.2.0.0.1.0.0+0.2.0.0.1.0+0.2.0.0.1 14-15|0.2.0 13-14|0.2 12-13|0.0 11-12|0.0.0 10-11|0.0.1.0.0+0.0.1.0+0.0.1 8-9|0 6-7|0.2.0.0.0.1 4-5|0.2.0.0.0 1-2|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:54.301
(s / screen-01 
      :ARG0 (a2 / analyze-01 
            :ARG1 (b / blot-01) 
            :manner (t3 / thing 
                  :name (n3 / name 
                        :op1 "Southern"))) 
      :ARG1 (d3 / DNA) 
      :ARG1-of (f / follow-01 
            :ARG2 (d2 / digestion 
                  :prep-with (a / and 
                        :op1 (t4 / tail-01 
                              :ARG0 400 
                              :ARG1 (m / mouse)) 
                        :op2 (p3 / person 
                              :name (n2 / name 
                                    :op1 "EcoRI")) 
                        :op3 (h / hybridization)))) 
      :ARG2 (p2 / probe-01 
            :ARG1-of (d / derive-01 
                  :ARG2 (p / portion 
                        :mod (t2 / thing 
                              :name (n / name 
                                    :op1 "SV40")) 
                        :part-of (t / transgene)))))

# ::snt Production of intermediate MSUD murine model .
# ::tok Production of intermediate MSUD murine model .
# ::alignments 5-6|0.0 4-5|0.0.1 3-4|0.0.0.0.0+0.0.0.0+0.0.0 2-3|0.0.2 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:54.327
(p / production 
      :mod (m / model 
            :mod (t / thing 
                  :name (n / name 
                        :op1 "MSUD")) 
            :mod (m2 / murine) 
            :mod (i / intermediate)))

# ::snt The various TRE-E2 transgenic lines produced were mated independently to mice that were heterozygous for both the E2 knockout and the LAP-tTA transgene [ Tg ( tTALap ) Bjd/J ; Stock 3272 ; The Jackson Laboratory , Bar Harbor , ME ; NMRI  FVB  C57BL/6J background ] .
# ::tok The various TRE-E2 transgenic lines produced were mated independently to mice that were heterozygous for both the E2 knockout and the LAP-tTA transgene [ Tg ( tTALap ) Bjd/J ; Stock 3272 ; The Jackson Laboratory , Bar Harbor , ME ; NMRI  FVB  C57BL/6J background ] .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:54.332
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt Interbreeding of animals that were heterozygous for both transgenes and the knockout resulted in the production of mice with a variety of genotypes including some animals that were homozygous for the knockout and were positive for both transgenes ( we refer to this genotype as the `` rescue '' genotype ) .
# ::tok Interbreeding of animals that were heterozygous for both transgenes and the knockout resulted in the production of mice with a variety of genotypes including some animals that were homozygous for the knockout and were positive for both transgenes ( we refer to this genotype as the `` rescue '' genotype ) .
# ::alignments 49-50|0.0.0.3.2.1.0.1 47-48|0.0.0.3.2 43-44|0.0.0.3.2.1 42-43|0.0.0.3.2.1.1 40-41|0.0.0.3.2.1.0 39-40|0.0.0.3.2.1.0.0 37-38|0.0.0.3.1.0 36-37|0.0.0.3.1.0.0 34-35|0.0.0.3.1 32-33|0.0.0.3 31-32|0.0.0.3.0.0 28-29|0.0.0.3.0 25-26|0.0.0.3.0.1 24-25|0.0.0.3.0.1.0 22-23|0.0.0.3.2.0 20-21|0.0.0.3.2.0.0 17-18|0.1.0 15-16|0.1 12-13|0 11-12|0.0 9-10|0.0.0 8-9|0.0.0.2 7-8|0.0.0.0 5-6|0.0.0.1 2-3|0.0.0.1.0 0-1|0.0.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:55.453
(r3 / result-01 
      :ARG0 (k2 / knockout 
            :op3-of (a3 / and 
                  :mod (b2 / both) 
                  :op1 (h2 / heterozygou 
                        :domain (a4 / animal 
                              :mod-of (i / interbreed))) 
                  :op2 (t3 / transgen) 
                  :op4 (a / and 
                        :op1 (h / homozygou 
                              :beneficiary (k / knockout) 
                              :domain (a2 / animal 
                                    :quant (s / some))) 
                        :op2 (p / positive 
                              :time (t2 / transgen 
                                    :mod (b / both))) 
                        :op3 (r / rescue-01 
                              :ARG1 (g3 / genotyp 
                                    :mod (v / variety)) 
                              :source-of (g2 / genotype 
                                    :ARG2-of (r2 / refer-01 
                                          :ARG0 (w / we) 
                                          :prep-as (g / genotype)) 
                                    :mod (t / this)))))) 
      :ARG2 (p2 / produce-01 
            :ARG1 (m / mouse)))

# ::snt If our strategy for rescuing the neonatal lethal phenotype of the knockout were successful , then those homozygous knockout animals that had both transgenes would survive beyond the neonatal period .
# ::tok If our strategy for rescuing the neonatal lethal phenotype of the knockout were successful , then those homozygous knockout animals that had both transgenes would survive beyond the neonatal period .
# ::alignments 29-30|0.0.1.0.0.0.0 28-29|0.0.1.0.0.0.0.0 26-27|0.0.1.0.0.0.0.1 25-26|0.0.1.0.0.0 23-24|0.0.1.0.0.3 22-23|0.0.1.0.0.3.0 19-20|0.0.1.0.0 18-19|0.0.1.0.0.1 17-18|0.0.1.0.0.2 15-16|0.0.0 13-14|0.0.1.0 11-12|0.3 8-9|0 7-8|0.1 6-7|0.2 4-5|0.0 2-3|0.0.1 1-2|0.0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:55.723
(p2 / phenotype 
      :ARG1-of (r / rescue-01 
            :ARG0 (t2 / then) 
            :mod-of (s3 / strategy 
                  :ARG0-of (s2 / succeed-01 
                        :ARG1 (a / animal 
                              :ARG0-of (s / survive-01 
                                    :ARG1 (p / period 
                                          :mod (n / neonatal) 
                                          :op1-of (b / beyond))) 
                              :mod (k / knockout) 
                              :mod (h / homozygou) 
                              :poss-of (t / transgen 
                                    :mod (b2 / both)))) 
                  :poss (w / we))) 
      :mod (l / lethal) 
      :mod (n2 / neonatal) 
      :poss (k2 / knockout))

# ::snt All mice were genotyped by Southern blot analysis .
# ::tok All mice were genotyped by Southern blot analysis .
# ::alignments 7-8|0.0.0.0 6-7|0.0.0 5-6|0.0.0.0.0.0.0+0.0.0.0.0.0+0.0.0.0.0 1-2|0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:55.758
(m / mouse 
      :quant (a2 / all 
            :ARG0-of (b / blot-01 
                  :ARG1 (a / analyze-01 
                        :ARG1 (t / thing 
                              :name (n / name 
                                    :op1 "Southern"))))))

# ::snt Genomic DNAs prepared from tail snips were digested with an appropriate restriction enzyme , size fractionated by agarose gel electrophoresis , blotted to nylon , and probed using standard procedures .
# ::tok Genomic DNAs prepared from tail snips were digested with an appropriate restriction enzyme , size fractionated by agarose gel electrophoresis , blotted to nylon , and probed using standard procedures .
# ::alignments 29-30|0 28-29|0.0 27-28|0.1 26-27|0.1.0 25-26|0.1.0.0 23-24|0.1.0.0.0.2 21-22|0.1.0.0.0 19-20|0.1.0.0.0.0 18-19|0.1.0.0.0.0.1 14-15|0.1.0.0.0.1 12-13|0.1.0.0.0.0.0.1.0 11-12|0.1.0.0.0.0.0.1.2 10-11|0.1.0.0.0.1.0 7-8|0.1.0.0.0.0.0.0.0 5-6|0.1.0.0.0.0.0.1 4-5|0.1.0.0.0.0.0.1.1 2-3|0.1.0.0.0.0.0 1-2|0.1.0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:56.023
(p / procedure 
      :ARG1-of (s / standard-02) 
      :ARG1-of (u / use-01 
            :ARG1-of (p2 / probe-01 
                  :op2-of (a / and 
                        :op1 (b / blot-01 
                              :ARG0 (e / electrophoresi 
                                    :ARG0-of (p3 / prepare-02 
                                          :ARG1 (d2 / dna 
                                                :ARG1-of (d / digest-01)) 
                                          :ARG2 (s3 / snip-01 
                                                :ARG0 (e2 / enzyme) 
                                                :ARG1-of (t / tail-01) 
                                                :ARG2-of (r / restrict-01))) 
                                    :mod (g / gel)) 
                              :ARG1 (s2 / size 
                                    :ARG1-of (a2 / appropriate-02)) 
                              :ARG2 (n / nylon))))))

# ::snt Primary mouse embryonic fibroblasts were prepared from embryonic day ~ 16.5 -- 18.5 fetuses as described [ 29 ] .
# ::tok Primary mouse embryonic fibroblasts were prepared from embryonic day ~ 16.5 -- 18.5 fetuses as described [ 29 ] .
# ::alignments 17-18|0.0.0.0.0 15-16|0.0 13-14|0 8-9|0.0.0.0.1 7-8|0.0.0.0.1.0 5-6|0.0.0.0 3-4|0.0.0 2-3|0.0.0.1 1-2|0.0.0.2 0-1|0.0.0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:56.132
(f / fetus 
      :ARG0-of (d / describe-01 
            :ARG1 (f2 / fibroblast 
                  :ARG1-of (p / prepare-02 
                        :ARG0 29 
                        :time (d2 / day 
                              :mod (e / embryonic))) 
                  :mod (e2 / embryonic) 
                  :mod (m / mouse 
                        :mod (p2 / primary)))))

# ::snt Fibroblasts were passed onto glass , fixed in 2 % paraformaldehyde in PBS for 10 minutes , permeabilized in 2 % paraformaldehyde containing 0.1 % Triton X100 for 10 minutes and washed three times in PBS containing 0.5 % BSA and 0.15 % glycine , pH 7.4 ( Buffer A ) .
# ::tok Fibroblasts were passed onto glass , fixed in 2 % paraformaldehyde in PBS for 10 minutes , permeabilized in 2 % paraformaldehyde containing 0.1 % Triton X100 for 10 minutes and washed three times in PBS containing 0.5 % BSA and 0.15 % glycine , pH 7.4 ( Buffer A ) .
# ::alignments 48-50|0.0.0.2.0.1.0.1+0.0.0.2.0.1.0.0+0.0.0.2.0.1.0+0.0.0.2.0.1 46-47|0.0.0.2.0.2 45-46|0.0.0.2.0.3 43-44|0.0.0.1 42-43|0.0.0.2.2.1.1 41-42|0.0.0.2.2.1.1.0 40-41|0 39-40|0.0.1.0+0.0.1+0.0 38-39|0.0.0.2.2 37-38|0.0.0.2.2.0 36-37|0.0.0 32-33|0.0.0.2.1.0.0.1.0.0.1 31-32|0.0.0.2.1 30-31|0.0.0.2 29-30|0.0.0.2.2.2.0.0+0.0.0.2.2.2.0 28-29|0.0.0.2.2.2 25-27|0.0.0.0.0.1+0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 24-25|0.0.0.2.0.0 23-24|0.0.0.2.0.0.0 22-23|0.0.0.2.0 20-21|0.0.0.2.1.0.0.0.0 19-20|0.0.0.2.1.0.0.0 15-16|0.0.0.2.2.1.0.0+0.0.0.2.2.1.0 14-15|0.0.0.2.2.1 12-13|0.0.0.2.1.0.0.1.1 10-11|0.0.0.2.1.0.0.1.0 9-10|0.0.0.2.1.0.0.1.0.0 8-9|0.0.0.2.1.0.0.1.0.0.0 6-7|0.0.0.2.1.0.0.1 4-5|0.0.0.2.1.0.0.2.0 3-4|0.0.0.2.1.0.0.2 2-3|0.0.0.2.1.0.0 0-1|0.0.0.2.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:12:57.830
(a2 / and 
      :op1 (o / organization 
            :ARG1-of (c / contain-01 
                  :ARG0 (p4 / person 
                        :name (n3 / name 
                              :op1 "Triton" 
                              :op2 "X100")) 
                  :ARG2 (g / glycine) 
                  :op3-of (a3 / and 
                        :op1 (c2 / contain-01 
                              :ARG1 (p5 / percentage-entity 
                                    :value 0.1) 
                              :op1-of (t / thing 
                                    :name (n / name 
                                          :op1 (b / Buffer) 
                                          :op2 (a / A))) 
                              :op1-of 7.4 
                              :op1-of (p / ph)) 
                        :op2 (w / wash-01 
                              :ARG1 (f2 / fibroblast 
                                    :ARG1-of (p10 / pass-01 
                                          :ARG0 (2 / 2 
                                                :value-of (p6 / percentage-entity)) 
                                          :ARG1-of (f / fix-03 
                                                :ARG0 (p8 / paraformaldehyde 
                                                      :mod (p9 / percentage-entity 
                                                            :value 2 
                                                            :value 3)) 
                                                :ARG2 (p7 / pb)) 
                                          :time (o2 / onto 
                                                :op1 (g2 / glass))))) 
                        :op4 (p3 / percentage-entity 
                              :value 0.5 
                              :value (12 / 10 
                                    :quant-of (t3 / temporal-quantity 
                                          :unit (m2 / minute)) 
                                    :value-of (p2 / percentage-entity 
                                          :value 0.15)) 
                              :value (1 / 10 
                                    :quant-of (t2 / temporal-quantity 
                                          :unit (m / minute)))))) 
            :name (n2 / name 
                  :op1 "BSA")))

# ::snt Following a 30 min incubation with purified goat IgG ( 50 ( g/ml ) at 25 C and three additional washes with Buffer A , cells were incubated for 60 min with E2-specific antiserum [ 30 ] at 1 g/ml followed by three washes in Buffer A and 60 minute incubation in fluorescently labeled second antibody ( 1 -- 2 g/ml ) .
# ::tok Following a 30 min incubation with purified goat IgG ( 50 ( g/ml ) at 25 C and three additional washes with Buffer A , cells were incubated for 60 min with E2-specific antiserum [ 30 ] at 1 g/ml followed by three washes in Buffer A and 60 minute incubation in fluorescently labeled second antibody ( 1 -- 2 g/ml ) .
# ::alignments 59-60|0.2.2.2.0 57-58|0.2.2.0 55-56|0.2.0.1 53-54|0.2.0 52-53|0.2.0.0 50-51|0.2.1 49-50|0.2.1.0.1+0.2.1.0 48-49|0.2.1.0.0 47-48|0.2 45-47|0.2.2.3.0.1+0.2.2.3.0.0+0.2.2.3.0+0.2.2.3 43-44|0.2.2 42-43|0.2.2.4 40-41|0.2.2.2 38-39|0.1.1 35-36|0.2.2.1.0.1.1.0.0.0 33-34|0.1.2.1 32-33|0.1.2.1.0.0.0+0.1.2.1.0.0+0.1.2.1.0 30-31|0.2.2.1.0.2 29-30|0.1.2.0 27-28|0.2.2.1.0 25-26|0.2.2.1 22-24|0.1.0.0.1+0.1.0.0.0+0.1.0.0+0.1.0 20-21|0.1 19-20|0.1.2 18-19|0.1.3 17-18|0 16-17|0.0 15-16|0.2.2.1.0.1.0 10-11|0.2.2.1.0.0 7-9|0.2.2.1.0.1.1.0.1.1+0.2.2.1.0.1.1.0.1.0+0.2.2.1.0.1.1.0.1+0.2.2.1.0.1.1.0 6-7|0.2.2.1.0.1.1.0.0 4-5|0.2.2.1.0.1.1 3-4|0.2.2.1.0.1.1.1 2-3|0.2.2.1.0.1.1.2 0-1|0.2.2.1.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:00.321
(a5 / and 
      :op1 (c2 / C) 
      :op2 (w2 / wash-01 
            :ARG1 (t4 / thing 
                  :name (n3 / name 
                        :op1 "Buffer" 
                        :op2 "A")) 
            :ARG2 1 
            :mod (a4 / additional 
                  :quant 60 
                  :quant-of (a3 / antiserum 
                        :mod (t3 / thing 
                              :name (n2 / name 
                                    :op1 "E2-specific")))) 
            :quant 3) 
      :op3 (a2 / and 
            :ARG2-of (l / label-01 
                  :ARG0 (f / fluorescently) 
                  :ARG1 (a / antibody)) 
            :op1 (i / incubation 
                  :mod (t / temporal-quantity 
                        :quant 60 
                        :unit (m / minute))) 
            :purpose-of (w / wash-01 
                  :ARG0 1 
                  :ARG1 (c / cell 
                        :ARG1-of (i2 / incubate-01 
                              :ARG0 50 
                              :ARG1-of (f3 / follow-01 
                                    :ARG0 25 
                                    :ARG2 (i4 / incubation 
                                          :accompanier (t5 / thing 
                                                :ARG1-of (p / purify-01 
                                                      :ARG0 30) 
                                                :name (n4 / name 
                                                      :op1 (g / goat) 
                                                      :op2 (i3 / IgG))) 
                                          :mod (m3 / min) 
                                          :quant 30)) 
                              :ARG2 (m2 / min))) 
                  :ARG1-of (f2 / follow-01 
                        :ARG2 2) 
                  :ARG2 (t2 / thing 
                        :name (n / name 
                              :op1 "Buffer" 
                              :op2 "A")) 
                  :quant 3)))

# ::snt The cells were then washed six times ( 5 min/wash ) in Buffer A and then mounted in gelvatol ( Monsanto , St Louis ) .
# ::tok The cells were then washed six times ( 5 min/wash ) in Buffer A and then mounted in gelvatol ( Monsanto , St Louis ) .
# ::alignments 22-24|0.0.0.0.1+0.0.0.0.0+0.0.0.0+0.0.0 20-21|0.2.0.0+0.2.0+0.2 18-19|0.1.2 16-17|0.1 15-16|0.1.3 14-15|0 12-14|0.0.1.0.1+0.0.1.0.0+0.0.1.0+0.0.1 8-9|0.1.0 5-6|0.0.0.1 4-5|0.0 3-4|0.0.2 1-2|0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:00.585
(a / and 
      :ARG1-of (w / wash-01 
            :ARG2 (o / organization 
                  :name (n / name 
                        :op1 "St" 
                        :op2 "Louis") 
                  :poss 6) 
            :manner (t2 / thing 
                  :name (n3 / name 
                        :op1 "Buffer" 
                        :op2 "A")) 
            :time (t3 / then)) 
      :op1 (m / mount-01 
            :ARG0 5 
            :ARG1 (c / cell) 
            :location (g / gelvatol) 
            :time (t / then)) 
      :op2 (o2 / organization 
            :name (n2 / name 
                  :op1 "Monsanto")))

# ::snt When livers from newborn pups were examined , fixation was by immersion in 2 % paraformaldehyde followed by cryoprotection and shock freezing in liquid nitrogen cooled isopentane and sectioning ( 5 microns ) .
# ::tok When livers from newborn pups were examined , fixation was by immersion in 2 % paraformaldehyde followed by cryoprotection and shock freezing in liquid nitrogen cooled isopentane and sectioning ( 5 microns ) .
# ::alignments 31-32|0.3.0.0.0.0.0.0.0 30-31|0.3.0.0.0.1.0 28-29|0.3.0.0.0.1 27-28|0.3.0.0.0 25-26|0.3.0.0 24-25|0.3.0 23-24|0.3.0.1 21-22|0.3 20-21|0.2 19-20|0 18-19|0.1 16-17|0.0 15-16|0.0.0 14-15|0.2.0 13-14|0.2.0.0 11-12|0.0.1 8-9|0.3.0.0.0.0.0.0.2 6-7|0.3.0.0.0.0 4-5|0.3.0.0.0.0.0.0 3-4|0.3.0.0.0.0.0.0.1 1-2|0.3.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:01.437
(a2 / and 
      :ARG0-of (f2 / follow-01 
            :ARG1 (p / paraformaldehyde) 
            :location (i / immersion)) 
      :op1 (c2 / cryoprotection) 
      :op2 (s2 / shock-01 
            :ARG0 (p2 / percentage-entity 
                  :value 2)) 
      :op3 (f / freeze-02 
            :ARG1 (n / nitrogen 
                  :ARG1-of (c / cool-01 
                        :ARG2 (a / and 
                              :op1 (e / examine-01 
                                    :ARG1 (l2 / liver 
                                          :source (p3 / pup-01 
                                                :ARG0 (m / micron) 
                                                :mod (n2 / newborn) 
                                                :mod (f3 / fixation)))) 
                              :op2 (s / section-01 
                                    :ARG1 5))) 
                  :mod (l / liquid))))

# ::snt Otherwise processing was as for the cells above ( without the fixation and permabilization steps ) .
# ::tok Otherwise processing was as for the cells above ( without the fixation and permabilization steps ) .
# ::alignments 14-15|0.2 13-14|0.2.1 12-13|0 11-12|0.1 7-8|0.0.0 6-7|0.2.0 1-2|0.0 0-1|0.2.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:01.508
(a / and 
      :ARG1-of (p2 / process-01 
            :ARG0 (a2 / above)) 
      :op1 (f / fixation) 
      :op2 (s / step-01 
            :ARG0 (c / cell) 
            :ARG1 (p / permabilization) 
            :op1-of (o / otherwise)))

# ::snt Blood was collected from the retroorbital sinus or tail vein of mice and spotted on a filter paper routinely used for blood amino acid analysis for prenatal screening .
# ::tok Blood was collected from the retroorbital sinus or tail vein of mice and spotted on a filter paper routinely used for blood amino acid analysis for prenatal screening .
# ::alignments 27-28|0 26-27|0.2 24-25|0.1 23-24|0.1.2 22-23|0.0 21-22|0.1.0 19-20|0.1.1 18-19|0.1.1.1 17-18|0.1.1.0 16-17|0.1.1.0.0 13-14|0.1.1.0.1 12-13|0.1.1.0.1.1 11-12|0.1.1.0.1.0.0.0.0.1 9-10|0.1.1.0.1.0.0.0.0.0 8-9|0.1.1.0.1.0.0.0.0.0.0 7-8|0.1.1.0.1.0.0.0.0 6-7|0.1.1.0.1.0.0.0 2-3|0.1.1.0.1.0.0 0-1|0.1.1.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:02.270
(s / screen-01 
      :ARG0 (a3 / amino) 
      :ARG2-of (a / analyze-01 
            :ARG1 (b / blood) 
            :ARG2-of (u / use-01 
                  :ARG1 (p2 / paper 
                        :ARG0-of (f / filter-02) 
                        :medium-of (s2 / spot-01 
                              :ARG1 (b2 / blood-01 
                                    :ARG1-of (c / collect-01 
                                          :ARG2 (s3 / sinu 
                                                :op1-of (o / or 
                                                      :op2 (v / vein-01 
                                                            :ARG1 (t / tail-01)) 
                                                      :poss (m / mouse))))) 
                              :op1-of (a4 / and))) 
                  :manner (r / routine)) 
            :manner (a2 / acid)) 
      :mod (p / prenatal))

# ::snt Concentrations of BCAA and other amino acids in blood were determined by tandem mass spectrometry ( Pediatrix Screening , Bridgeville , PA ) .
# ::tok Concentrations of BCAA and other amino acids in blood were determined by tandem mass spectrometry ( Pediatrix Screening , Bridgeville , PA ) .
# ::alignments 21-22|0.1.6.0.0+0.1.6.0+0.1.6 19-20|0.1.5.0.0+0.1.5.0+0.1.5 16-18|0.1.4.0.1+0.1.4.0.0+0.1.4.0+0.1.4 14-15|0.0 13-14|0.0.0 12-13|0.1.3 10-11|0 8-9|0.1.2.0 6-7|0.1.2 5-6|0.1.2.2 4-5|0.1.2.1 3-4|0.1 2-3|0.1.1.0.0+0.1.1.0+0.1.1 0-1|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:02.825
(d / determined-02 
      :ARG0 (s / spectrometry 
            :mod (m / mass)) 
      :ARG1 (a3 / and 
            :op1 (c3 / concentration) 
            :op2 (t2 / thing 
                  :name (n4 / name 
                        :op1 "BCAA")) 
            :op3 (a / acid 
                  :location (b / blood) 
                  :mod (o / other) 
                  :mod (a2 / amino)) 
            :op4 (t / tandem) 
            :op5 (p / person 
                  :name (n3 / name 
                        :op1 "Pediatrix" 
                        :op2 "Screening")) 
            :op6 (c2 / country 
                  :name (n2 / name 
                        :op1 "Bridgeville")) 
            :op7 (c / country 
                  :name (n / name 
                        :op1 "PA"))))

# ::snt Assay of BCKDH activity .
# ::tok Assay of BCKDH activity .
# ::alignments 3-4|0.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:02.833
(a2 / assay 
      :topic (a / activity-06))

# ::snt Livers were removed , frozen in liquid nitrogen , and stored at -80 C .
# ::tok Livers were removed , frozen in liquid nitrogen , and stored at -80 C .
# ::alignments 13-14|0.1.1 10-11|0.1 9-10|0 7-8|0.0.0 6-7|0.0.0.0 4-5|0.0 2-3|0.1.0.0 0-1|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:02.875
(a / and 
      :op1 (f / freeze-02 
            :ARG1 (n / nitrogen 
                  :mod (l / liquid))) 
      :op2 (s / store-01 
            :ARG1 (l2 / liver 
                  :ARG1-of (r / remove-01)) 
            :ARG2 (c / C)))

# ::snt At the time of enzyme assay , livers were thawed , and homogenized ( 1:9 , w/v ) in 0.25 M sucrose , 10 mM Tris-HC1 , pH 7.4 .
# ::tok At the time of enzyme assay , livers were thawed , and homogenized ( 1:9 , w/v ) in 0.25 M sucrose , 10 mM Tris-HC1 , pH 7.4 .
# ::alignments 28-29|0.0.0 27-28|0.2.0.1 24-25|0.1 23-24|0.2.0.0.0 21-22|0.3 20-21|0.3.0.1+0.3.0.0.0+0.3.0.0+0.3.0 11-12|0 9-10|0.0 7-8|0.0.1 5-6|0.2.0 4-5|0.2.0.0 2-3|0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:02.986
(a / and 
      :op1 (t / thaw-01 
            :ARG0 7.4 
            :ARG1 (l / liver)) 
      :op2 (m / mm) 
      :time (t2 / time 
            :part-of (a2 / assay 
                  :mod (e / enzyme 
                        :poss-of 10) 
                  :mod-of (p / ph))) 
      :time (s / sucrose 
            :mod (v / vehicle 
                  :name (n / name 
                        :op1 "M1") 
                  :wiki "M1_Abrams")))

# ::snt Liver homogenates were centrifuged at 600  g for 10 min at 4 C and the supernatant fraction was saved to determine the BCKDH activity .
# ::tok Liver homogenates were centrifuged at 600  g for 10 min at 4 C and the supernatant fraction was saved to determine the BCKDH activity .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:02.987
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt The use of tissue homogenates was necessitated by the limited availability of liver tissue , particularly from newborn pups .
# ::tok The use of tissue homogenates was necessitated by the limited availability of liver tissue , particularly from newborn pups .
# ::alignments 18-19|0.0.2 17-18|0.0.2.0 15-16|0.1.0 13-14|0.0.0 12-13|0.0.0.0 10-11|0.0 9-10|0.0.1 6-7|0 4-5|0.1.1 3-4|0.1.1.0 1-2|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:03.112
(n2 / necessitate-01 
      :ARG0 (a / available-02 
            :ARG1 (t / tissue 
                  :mod (l / liver)) 
            :ARG1-of (l2 / limit-01) 
            :ARG2 (p / pup-01 
                  :mod (n / newborn))) 
      :ARG1 (u / use-01 
            :ARG0 (p2 / particular) 
            :ARG1 (h / homogenat 
                  :mod (t2 / tissue))))

# ::snt BCKDH activity was determined by measuring the release of 14CO2 from -keto [ 1-14C ] isocaproate as described previously [ 31 ] .
# ::tok BCKDH activity was determined by measuring the release of 14CO2 from -keto [ 1-14C ] isocaproate as described previously [ 31 ] .
# ::alignments 20-21|0.1.0.0 18-19|0.0.0.1 17-18|0.0.0 15-16|0.0.0.0 7-8|0.1.0 5-6|0.1 3-4|0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:03.169
(d2 / determined-02 
      :ARG0 (a / activity-06 
            :ARG1-of (d / describe-01 
                  :ARG0 (i / isocaproate) 
                  :time (p / previous))) 
      :ARG1 (m / measure-01 
            :ARG1 (r / release-01 
                  :ARG1 31)))

# ::snt The complete reaction mixture contained ( final volume 1 ml ) 30 mM potassium phosphate buffer , pH 7.4 , 0.20 mM -ketoisocaproate , 0.40 mM CoASH , 0.40 mM thiamin pyrophosphate , 2 mM NAD + , 2 mM dithiothreitol , 5 mM Mg2 + , approximately 250,000 DPM of -keto [ 1-14C ] isocaproate , and 0.10 ml of liver homogenate ( 2 -- 3 mg protein ) .
# ::tok The complete reaction mixture contained ( final volume 1 ml ) 30 mM potassium phosphate buffer , pH 7.4 , 0.20 mM -ketoisocaproate , 0.40 mM CoASH , 0.40 mM thiamin pyrophosphate , 2 mM NAD + , 2 mM dithiothreitol , 5 mM Mg2 + , approximately 250,000 DPM of -keto [ 1-14C ] isocaproate , and 0.10 ml of liver homogenate ( 2 -- 3 mg protein ) .
# ::alignments 68-69|0 67-68|0.0 66-67|0.1 64-65|0.1.0.2.1.5.1.0 62-63|0.1.0.2.1.4.0 61-62|0.1.0.2.1.4.0.0 57-58|0.1.0.2.1 55-56|0.1.0.2.1.6 49-50|0.1.0.2.1.5.0.0+0.1.0.2.1.5.0+0.1.0.2.1.5 47-48|0.1.0.2.1.5.1 42-43|0.1.0.3 40-41|0.1.0.2.1.4 38-39|0.1.0.2.1.4.1 34-36|0.1.0.2.1.3.1.1+0.1.0.2.1.3.1.0+0.1.0.2.1.3.1+0.1.0.2.1.3 33-34|0.1.0.2.1.3.2 31-32|0.1.0.2.1.2 30-31|0.1.0.2.1.2.0 26-27|0.1.0.2.0.0+0.1.0.2.0+0.1.0.2 18-19|0.1.0.1.0.0.0 17-18|0.1.0.2.1.1 15-16|0.1.0.2.1.0 14-15|0.1.0.2.1.0.1 13-14|0.1.0.2.1.0.1.0 12-13|0.1.0.2.1.0.0 11-12|0.1.0.2.1.0.0.0 9-10|0.1.0.2.1.3.0.0 8-9|0.1.0.1.0.0.1 7-8|0.1.0.0 6-7|0.1.0.2.1.3.0 4-5|0.1.0.1 3-4|0.1.0.1.0 2-3|0.1.0 1-2|0.1.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:04.610
(p / protein 
      :mod (m / mg) 
      :quant (3 / 3 
            :op1 (r / react-01 
                  :ARG1 (v / volume) 
                  :ARG1-of (c / contain-01 
                        :ARG0 (m5 / mixture 
                              :ARG1-of (c2 / complete-02 
                                    :ARG0 7.4 
                                    :ARG2 1))) 
                  :ARG2 (t3 / thing 
                        :name (n4 / name 
                              :op1 "CoASH") 
                        :op3-of (a / and 
                              :op1 (b / buffer-01 
                                    :ARG0 (m3 / mm 
                                          :quant 30) 
                                    :ARG1 (p4 / phosphate 
                                          :mod (p5 / potassium))) 
                              :op2 (p3 / ph) 
                              :op4 (p2 / pyrophosphate 
                                    :mod (t2 / thiamin)) 
                              :op5 (t / thing 
                                    :mod (f / final 
                                          :mod-of (m4 / ml)) 
                                    :name (n2 / name 
                                          :op1 (m2 / mM) 
                                          :op2 (n3 / NAD)) 
                                    :quant 2) 
                              :op6 (d / dithiothreitol 
                                    :poss (h / homogenate 
                                          :mod (l / liver)) 
                                    :quant 2) 
                              :op7 (o / organization 
                                    :name (n / name 
                                          :op1 "DPM") 
                                    :quant (a2 / approximately 
                                          :poss-of 2)) 
                              :op8 (i / isocaproate))) 
                  :op1-of 5)))

# ::snt Assays were carried out for 15 min at 37 C , 14CO2 was trapped in hydroxide of Hyamine , and radioactivity was determined by liquid scintillation spectrometry .
# ::tok Assays were carried out for 15 min at 37 C , 14CO2 was trapped in hydroxide of Hyamine , and radioactivity was determined by liquid scintillation spectrometry .
# ::alignments 26-27|0.2.0 25-26|0.2.0.1 24-25|0.2.0.0 22-23|0.2 20-21|0.2.1 19-20|0 15-16|0.1.1 13-14|0.1 9-10|0.1.0.0 8-9|0.1.0 6-7|0.0.0 5-6|0.0.0.0 2-3|0.0 0-1|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:04.780
(a / and 
      :op1 (c2 / carry-out-03 
            :ARG0 (m / min 
                  :quant 15) 
            :ARG1 (a2 / assay)) 
      :op2 (t / trap-01 
            :ARG1 (3 / 37 
                  :era (c / C)) 
            :ARG2 (h / hydroxide)) 
      :op3 (d / determined-02 
            :ARG0 (s / spectrometry 
                  :mod (l / liquid) 
                  :mod (s2 / scintillation)) 
            :ARG1 (r / radioactivity)))

# ::snt Protein extracts were isolated from homogenized liver ( freshly harvested and flash frozen ) of wildtype , Line 525A , and Line A transgenic mice .
# ::tok Protein extracts were isolated from homogenized liver ( freshly harvested and flash frozen ) of wildtype , Line 525A , and Line A transgenic mice .
# ::alignments 24-25|0.0.0.2.3 21-23|0.0.0.2.2.0.1+0.0.0.2.2.0.0+0.0.0.2.2.0+0.0.0.2.2 20-21|0.0.0.2 17-19|0.0.0.2.1.0.1+0.0.0.2.1.0.0+0.0.0.2.1.0+0.0.0.2.1 15-16|0.0.0.2.0 12-13|0.1 11-12|0.1.0 10-11|0 9-10|0.0 8-9|0.0.1 6-7|0.0.0 5-6|0.0.0.1 3-4|0.0.0.0 1-2|0.0.0.0.0.0+0.0.0.0.0 0-1|0.0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:05.211
(a2 / and 
      :op1 (h / harvest-01 
            :ARG1 (l / liver 
                  :ARG2-of (i / isolate-01 
                        :ARG1 (t3 / thing 
                              :ARG1-of (e / extract-01 
                                    :ARG0 (p / protein)))) 
                  :mod (h2 / homogenize) 
                  :time-of (a / and 
                        :op1 (w / wildtype) 
                        :op2 (t2 / thing 
                              :name (n2 / name 
                                    :op1 "Line" 
                                    :op2 "525A")) 
                        :op3 (t / thing 
                              :name (n / name 
                                    :op1 "Line" 
                                    :op2 "A")) 
                        :op4 (m / mouse))) 
            :ARG1-of (f3 / fresh-04)) 
      :op2 (f / freeze-01 
            :ARG1-of (f2 / flash-01)))

# ::snt Protein ( 25 g per sample ) was analyzed by electrophoresis on a 10 % SDS-PAGE Ready Gel ( Bio-Rad , Hercules , CA ) and transferred to PVDF membrane ( Sequi-Blot ; Bio-Rad ) via electroblotting .
# ::tok Protein ( 25 g per sample ) was analyzed by electrophoresis on a 10 % SDS-PAGE Ready Gel ( Bio-Rad , Hercules , CA ) and transferred to PVDF membrane ( Sequi-Blot ; Bio-Rad ) via electroblotting .
# ::alignments 36-37|0.1.3.0.3 32-33|0.1.3.1 29-30|0.1.2 28-29|0.1.2.0.0.0+0.1.2.0.0+0.1.2.0 26-27|0.1 25-26|0.1.3 23-24|0.0.1+0.0.0.0+0.0.0+0.0 21-22|0.1.3.1.0.0.0+0.1.3.1.0.0+0.1.3.1.0 19-20|0.1.0.0.0+0.1.0.0+0.1.0 15-18|0.1.3.0.2.1.2+0.1.3.0.2.1.1+0.1.3.0.2.1.0+0.1.3.0.2.1+0.1.3.0.2 14-15|0.1.3.0.2.0 13-14|0.1.3.0.2.0.0 10-11|0.1.3.0.0 8-9|0.1.3.0 5-6|0 3-4|0.1.3.0.1 2-3|0.1.3.0.1.0 0-1|0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:05.930
(s2 / sample-01 
      :ARG0 (s / state 
            :name (n2 / name 
                  :op1 "CA") 
            :wiki "California") 
      :ARG2 (t / transfer-01 
            :ARG0 (o3 / organization 
                  :name (n4 / name 
                        :op1 "Bio-Rad")) 
            :ARG1 (p2 / protein) 
            :ARG2 (m / membrane 
                  :mod (o / organization 
                        :name (n / name 
                              :op1 "PVDF"))) 
            :op2-of (a2 / and 
                  :op1 (a3 / analyze-01 
                        :ARG0 (e2 / electrophoresi) 
                        :ARG1 (g / g 
                              :quant 25) 
                        :ARG2 (t2 / thing 
                              :mod (p / percentage-entity 
                                    :value 10) 
                              :name (n5 / name 
                                    :op1 "SDS-PAGE" 
                                    :op2 "Ready" 
                                    :op3 "Gel")) 
                        :op1-of (e / electroblott)) 
                  :op3 (a / and 
                        :op1 (o2 / organization 
                              :name (n3 / name 
                                    :op1 "Hercules"))))))

# ::snt All blots were probed for E2 protein using polyclonal rabbit E2 antisera ( 1:5,000 ) , which detects both mouse ( ~ 47 kD ) and human ( ~ 54 kD ) E2 subunits ( [ 30 ] ; gift from Dr. Susan Hutson , Wake Forest University ) .
# ::tok All blots were probed for E2 protein using polyclonal rabbit E2 antisera ( 1:5,000 ) , which detects both mouse ( ~ 47 kD ) and human ( ~ 54 kD ) E2 subunits ( [ 30 ] ; gift from Dr. Susan Hutson , Wake Forest University ) .
# ::alignments 45-48|0.0.0.0.3.3.0.2+0.0.0.0.3.3.0.1+0.0.0.0.3.3.0.0+0.0.0.0.3.3.0+0.0.0.0.3.3 42-44|0.1.0.0.1.1+0.1.0.0.1.0+0.1.0.0.1+0.1.0.0 41-42|0.1.0.0.0 39-40|0.1.0+0.1 38-39|0 36-37|0.0.0.0.0.0.0 33-34|0.0.0.0.3.2 29-30|0.0.0.0.1 26-27|0.0.0.0.2.0 25-26|0.0.0.0.3 22-23|0.0.0.0.2.1.0 19-20|0.0.0.0.3.1 18-19|0.0.0.0.3.1.0 17-18|0.0.0.0.3.0 11-12|0.0.0.0.0 9-10|0.0.0.0.0.0 7-8|0.0.0.0 6-7|0.0.0 5-6|0.0.1.0+0.0.1+0.0 3-4|0.0.0.0.2 1-2|0.0.0.0.2.1 0-1|0.0.0.0.2.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:07.789
(a / and 
      :op1 (t2 / thing 
            :mod-of (p2 / protein 
                  :ARG0-of (u / use-01 
                        :ARG1 (a3 / antiserum 
                              :ARG1-of (r / rabbit-01 
                                    :ARG0 30)) 
                        :ARG2 54 
                        :manner-of (p3 / probe-01 
                              :ARG0 (h / human) 
                              :ARG1 (b2 / blot-01 
                                    :ARG1 47 
                                    :mod (a4 / all))) 
                        :op1-of (a2 / and 
                              :ARG1-of (d2 / detect-01) 
                              :op2 (m / mouse 
                                    :mod (b / both)) 
                              :op3 (s / subunit) 
                              :op4 (o / organization 
                                    :name (n / name 
                                          :op1 "Wake" 
                                          :op2 "Forest" 
                                          :op3 "University"))))) 
            :name (n3 / name 
                  :op1 "E2")) 
      :op2 (t / thing 
            :ARG1-of (g / gift-01 
                  :ARG0 (p / person 
                        :mod (d / dr.) 
                        :name (n2 / name 
                              :op1 "Susan" 
                              :op2 "Hutson")))))

# ::snt Blots were re-probed with a rabbit anti-c-myc tag antibody ( 1:10,000 ; abCam , Cambridge , MA ; cat .
# ::tok Blots were re-probed with a rabbit anti-c-myc tag antibody ( 1:10,000 ; abCam , Cambridge , MA ; cat .
# ::alignments 18-19|0.1.0.0 16-17|0.2.1.0+0.2.1+0.2 14-15|0.1.1.0+0.1.1+0.1 12-13|0.0 11-12|0 8-9|0.2.0.0 7-8|0.2.0.0.0 5-6|0.2.0 0-1|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:07.900
(a2 / and 
      :op1 (a / abCam) 
      :op2 (c3 / country 
            :ARG0-of (b / blot-01 
                  :ARG1 (c / cat)) 
            :name (n2 / name 
                  :op1 "Cambridge")) 
      :op3 (c2 / country 
            :ARG0-of (r / rabbit-01 
                  :ARG1 (a3 / antibody 
                        :ARG1-of (t / tag-01))) 
            :name (n / name 
                  :op1 "MA")))

# ::snt # ab9106-100 ) .
# ::tok # ab9106-100 ) .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:07.904
(a / amr-empty)

# ::snt Blots were also re-probed with an antibody for -actin ( 43 kD ; 1:10,000 ; abCam ; cat .
# ::tok Blots were also re-probed with an antibody for -actin ( 43 kD ; 1:10,000 ; abCam ; cat .
# ::alignments 17-18|0.1 15-16|0.0 12-13|0 10-11|0.0.0.0 6-7|0.1.0 2-3|0.0.0.0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:07.953
(a2 / and 
      :op1 (a / abCam 
            :ARG1-of (b / blot-01 
                  :ARG0 (4 / 43 
                        :mod (a4 / also)))) 
      :op2 (c / cat 
            :poss (a3 / antibody)))

# ::snt # ab8227-50 ) to allow for loading comparisons .
# ::tok # ab8227-50 ) to allow for loading comparisons .
# ::alignments 7-8|0.0.0 6-7|0.0 4-5|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:07.968
(a / allow-01 
      :ARG1 (l / load-01 
            :ARG1 (c / compare-01)))

# ::snt A goat anti-rabbit secondary antibody conjugated to horseradish peroxidase ( 1:10,000 ; Novus , Littleton , CO ; cat .
# ::tok A goat anti-rabbit secondary antibody conjugated to horseradish peroxidase ( 1:10,000 ; Novus , Littleton , CO ; cat .
# ::alignments 18-19|0.2.0 16-17|0.2.3+0.2.1.0+0.2.1+0.2 14-15|0.1.0.0+0.1.0+0.1 12-13|0.0 11-12|0 8-9|0.0.0.1 5-6|0.0.0 4-5|0.0.0.0 3-4|0.2.2 1-2|0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:08.377
(a / and 
      :op1 (n3 / novu 
            :ARG2-of (c3 / conjugate-01 
                  :ARG0 (a2 / antibody 
                        :mod (g / goat)) 
                  :ARG1 (p / peroxidase))) 
      :op2 (c2 / country 
            :name (n2 / name 
                  :op1 "Littleton")) 
      :op3 (s / small-molecule 
            :mod-of (c / cat) 
            :name (n / name 
                  :op1 "CO2") 
            :poss (s2 / secondary) 
            :wiki "Carbon_dioxide"))

# ::snt # NB730-H ) was used for detection using the Western Lightning chemiluminescence reagent ( Perkin Elmer , Boston , MA ) and exposed to X-ray film .
# ::tok # NB730-H ) was used for detection using the Western Lightning chemiluminescence reagent ( Perkin Elmer , Boston , MA ) and exposed to X-ray film .
# ::alignments 25-26|0.0.1 24-25|0.0 22-23|0.4 21-22|0 19-20|0.1.0.0.0+0.1.0.0+0.1.0 17-18|0.0.0.1+0.0.0.0.0+0.0.0.0+0.0.0 14-16|0.3.0.1+0.3.0.0+0.3.0+0.3 12-13|0.2.1 11-12|0.2.1.0 9-11|0.1.1.0.1+0.1.1.0.0+0.1.1.0+0.1.1 7-8|0.2 6-7|0.2.0 4-5|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:09.293
(a / and 
      :ARG0-of (x / x-ray-01 
            :ARG1 (c2 / city 
                  :name (n2 / name 
                        :op1 "Boston") 
                  :wiki "Boston") 
            :mod-of (f / film)) 
      :op1 (u2 / use-01 
            :ARG0 (c / country 
                  :name (n / name 
                        :op1 "MA")) 
            :ARG1 (t / thing 
                  :name (n4 / name 
                        :op1 "Western" 
                        :op2 "Lightning"))) 
      :op2 (u / use-01 
            :ARG0 (d / detect-01) 
            :ARG1 (r / reagent 
                  :mod (c3 / chemiluminescence))) 
      :op3 (p / person 
            :name (n3 / name 
                  :op1 "Perkin" 
                  :op2 "Elmer")) 
      :op4 (e / expose-01))

# ::snt All BCAA and BCKDH enzyme activity data are presented as the mean + / - the standard error of the mean ( S.E.M. ) .
# ::tok All BCAA and BCKDH enzyme activity data are presented as the mean + / - the standard error of the mean ( S.E.M. ) .
# ::alignments 22-23|0.0.1.0.0.0.0+0.0.1.0.0.0+0.0.1.0.0 20-21|0 17-18|0.1 16-17|0.1.0 13-14|0.0.1.0.1 11-12|0.0.1.0.1.0 8-9|0.0.1.0 6-7|0.0.0.0 5-6|0.0.0.0.0 4-5|0.0.0 2-3|0.0 1-2|0.0.1.1.0+0.0.1.1+0.0.1 0-1|0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:09.702
(m / mean-01 
      :ARG2 (a2 / and 
            :mod (e2 / enzyme 
                  :mod-of (d / data 
                        :source (a / activity-06))) 
            :op1 (t / thing 
                  :ARG1-of (p2 / present-01 
                        :ARG0 (p / person 
                              :name (n / name 
                                    :op1 "S.E.M.")) 
                        :ARG3 (s2 / slash 
                              :ARG1-of (m2 / mean-01))) 
                  :name (n2 / name 
                        :op1 "BCAA")) 
            :quant (a3 / all)) 
      :domain-of (e / error 
            :ARG1-of (s / standard-02)))

# ::snt Differences between genotypes were compared by Student 's t test [ 32 ] .
# ::tok Differences between genotypes were compared by Student 's t test [ 32 ] .
# ::alignments 11-12|0.0.0.0.0.0 9-10|0.0.0.0 8-9|0.0.0.1 6-7|0.0+0.0.0 4-5|0.1 2-3|0.0.0.0.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:09.803
(d / difference 
      :ARG1-of (s / study-01 
            :ARG0 (p / person 
                  :ARG1-of (t / test-01 
                        :ARG0 (g / genotyp 
                              :mod-of 32)) 
                  :poss-of (t2 / t))) 
      :ARG1-of (c / compare-01))

# ::snt Production of E2 gene knockout mice .
# ::tok Production of E2 gene knockout mice .
# ::alignments 5-6|0.0 4-5|0.0.1 3-4|0.0.0 2-3|0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:09.824
(p / production 
      :mod (m / mouse 
            :mod (g / gene 
                  :mod (t / thing 
                        :name (n / name 
                              :op1 "E2"))) 
            :mod (k / knockout)))

# ::snt To create E2 knockout mice , we used gene targeting in mouse ES cells to disrupt the E2 gene .
# ::tok To create E2 knockout mice , we used gene targeting in mouse ES cells to disrupt the E2 gene .
# ::alignments 18-19|0.2.1 15-16|0.2 13-14|0.2.0 12-13|0.2.0.0 11-12|0.2.0.0.0 9-10|0.3 8-9|0.3.0 7-8|0 6-7|0.0 4-5|0.1 3-4|0.1.1 2-3|0.1.2.0.0+0.1.2.0+0.1.2 1-2|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:10.556
(u / use-01 
      :ARG0 (w / we) 
      :ARG1 (m2 / mouse 
            :ARG1-of (c2 / create-01) 
            :mod (k / knockout) 
            :mod (t2 / thing 
                  :name (n / name 
                        :op1 "E2"))) 
      :ARG2 (d / disrupt-01 
            :ARG0 (c / cell 
                  :mod (e / e 
                        :mod (m / mouse))) 
            :ARG1 (g / gene)) 
      :ARG3 (t / target-01 
            :ARG1 (g2 / gene)))

# ::snt The overall strategy for disrupting the E2 gene is illustrated in Fig. 1A .
# ::tok The overall strategy for disrupting the E2 gene is illustrated in Fig. 1A .
# ::alignments 11-13|0.1.0.1+0.1.0.0+0.1.0+0.1 9-10|0 7-8|0.0.0.0 6-7|0.0.0.0.0.0.0+0.0.0.0.0.0+0.0.0.0.0 4-5|0.0.0 2-3|0.0 1-2|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:10.823
(i / illustrate-01 
      :ARG1 (s / strategy 
            :ARG0-of (d / disrupt-01 
                  :ARG1 (g / gene 
                        :mod (t2 / thing 
                              :name (n2 / name 
                                    :op1 "E2")))) 
            :mod (o / overall)) 
      :ARG2 (t / thing 
            :name (n / name 
                  :op1 (f / Fig.) 
                  :op2 1A)))

# ::snt The gene targeting construct was designed to replace a 1.67 kb EcoRV/Smal genomic DNA fragment encompassing part of Exon 4 and all of Exon 5 with the PGKneo selectable marker cassette .
# ::tok The gene targeting construct was designed to replace a 1.67 kb EcoRV/Smal genomic DNA fragment encompassing part of Exon 4 and all of Exon 5 with the PGKneo selectable marker cassette .
# ::alignments 30-31|0.0.0.1.1 29-30|0.0.0.1.1.0 28-29|0.0.0.1.1.0.0.0 27-28|0.0.0.1.1.0.0.1.0+0.0.0.1.1.0.0.1+0.0.0.1.1.0.0 24-25|0.0.0.1.2.1.0.0.0 21-22|0.0.0.1.2.0 20-21|0 19-20|0.0.0.1.2.1.0.0.1 18-19|0.0.0.1.0.0.0+0.0.0.1.0.0+0.0.0.1.0 15-16|0.0 14-15|0.0.0 13-14|0.0.0.0 7-8|0.0.0.1 5-6|0.0.0.1.2 3-4|0.0.0.1.2.1.0.0 2-3|0.0.0.1.2.1.0 1-2|0.0.0.1.2.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:11.510
(a2 / and 
      :ARG1-of (e / encompass-01 
            :ARG0 (f / fragment-01 
                  :ARG1 (d / DNA) 
                  :ARG1-of (r / replace-01 
                        :ARG0 (o / organization 
                              :name (n2 / name 
                                    :op1 "Exon")) 
                        :ARG2 (c / cassette 
                              :ARG0-of (m / mark-01 
                                    :ARG1 (c2 / country 
                                          :mod-of (s / selectable) 
                                          :name (n / name 
                                                :op1 "PGKneo")))) 
                        :ARG3-of (d2 / design-01 
                              :ARG0 (a / all) 
                              :ARG1 (g / gene 
                                    :ARG0-of (t / target-01 
                                          :ARG1 (c3 / construct-01 
                                                :ARG0 5 
                                                :ARG1 4))))))))

# ::snt Of 522 ES cell clones screened for targeting by Southern blot analysis , 29 ( 5 % ) displayed the predicted restriction fragment length polymorphisms indicative of gene targeting at the E2 locus .
# ::tok Of 522 ES cell clones screened for targeting by Southern blot analysis , 29 ( 5 % ) displayed the predicted restriction fragment length polymorphisms indicative of gene targeting at the E2 locus .
# ::alignments 32-33|0.1.1.1 28-29|0.1.1 27-28|0.1.1.0 25-26|0.2.1.1.0.1 23-24|0.2.1.1.0 22-23|0.2.1 21-22|0.2.1.1 20-21|0.2.1.1.0.0 18-19|0.2 16-17|0.2.0 15-16|0.2.0.0 13-14|0.1.0.0.0 11-12|0.1.0 10-11|0.1.0.0 9-10|0.1.0.1.0.0+0.1.0.1.0+0.1.0.1 7-8|0.1 5-6|0 4-5|0.0 3-4|0.0.0 2-3|0.0.0.0 1-2|0.2.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:11.948
(s / screen-01 
      :ARG1 (c / clone-01 
            :ARG1 (c2 / cell 
                  :mod (e / e))) 
      :ARG2 (t3 / target-01 
            :ARG0 (a / analyze-01 
                  :ARG1 (b / blot-01 
                        :ARG1 29) 
                  :manner (t2 / thing 
                        :name (n / name 
                              :op1 "Southern"))) 
            :ARG1 (t / target-01 
                  :ARG1 (g / gene) 
                  :time (l / locu))) 
      :purpose-of (d / display-01 
            :ARG1 (p2 / percentage-entity 
                  :value 5) 
            :ARG2 (f / fragment-01 
                  :ARG0 522 
                  :ARG1 (r / restrict-01 
                        :ARG1 (l2 / length 
                              :ARG1-of (p / predict-01) 
                              :domain-of (i / indicative))))))

# ::snt As illustrated in Fig. 1A and 1B , an E2 Exon 6 specific probe , which is external to the targeting construct , hybridizes to only a ~ 16 kb BglI restriction fragment from the wild type allele in the parental R1 ES cell line .
# ::tok As illustrated in Fig. 1A and 1B , an E2 Exon 6 specific probe , which is external to the targeting construct , hybridizes to only a ~ 16 kb BglI restriction fragment from the wild type allele in the parental R1 ES cell line .
# ::alignments 44-45|0.0.0.5.2.0.1.0 43-44|0.0.0.5.2.0.1 41-43|0.0.0.5.2.0.1.0.0.0.1+0.0.0.5.2.0.1.0.0.0.0+0.0.0.5.2.0.1.0.0.0+0.0.0.5.2.0.1.0.0 40-41|0.0.0.2 37-38|0.0.0.5.2.0 36-37|0.0.0.5.2 35-36|0.0.0.5.2.0.0 32-33|0.0.0.5 31-32|0.0.0.5.1 29-31|0.0.0.5.0.0.1+0.0.0.5.0.0.0+0.0.0.5.0.0+0.0.0.5.0 28-29|0.0.0.3.0 25-26|0.0.0.5.1.1 23-24|0.0.0.4 21-22|0.0 20-21|0 17-18|0.0.1 13-14|0.0.0 12-13|0.0.0.3 11-12|0.0.0.5.1.0 9-11|0.0.0.0.0.1+0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 5-6|0.0.0.1.0 3-4|0.0.0.1.1.0.0+0.0.0.1.1.0+0.0.0.1.1 1-2|0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:13.063
(t4 / target-01 
      :ARG1 (c2 / construct-01 
            :ARG1 (p2 / probe-01 
                  :ARG0 (t5 / thing 
                        :name (n3 / name 
                              :op1 (e3 / E2) 
                              :op2 (e4 / Exon))) 
                  :ARG0-of (i / illustrate-01 
                        :ARG1 (a2 / and) 
                        :location (c3 / country 
                              :name (n4 / name 
                                    :op1 "Fig."))) 
                  :ARG1 (p / parental) 
                  :ARG1-of (s / specific-02 
                        :ARG0 16) 
                  :ARG1-of (h / hybridize-01) 
                  :ARG3-of (f / fragment-01 
                        :ARG0 (t3 / thing 
                              :name (n2 / name 
                                    :op1 (k / kb) 
                                    :op2 (b / BglI))) 
                        :ARG1 (r2 / restrict-01 
                              :ARG0 6 
                              :ARG1 (o / only)) 
                        :ARG2 (t2 / type 
                              :mod-of (a / allele 
                                    :mod (w / wild) 
                                    :poss (c / cell 
                                          :mod-of (l / line 
                                                :mod (t / thing 
                                                      :name (n / name 
                                                            :op1 (r / R1) 
                                                            :op2 (e / ES))))))))) 
            :prep-to-of (e2 / external)))

# ::snt In correctly targeted ES cells , this probe also hybridizes to a ~ 11 kb BglI restriction fragment .
# ::tok In correctly targeted ES cells , this probe also hybridizes to a ~ 11 kb BglI restriction fragment .
# ::alignments 17-18|0.2 16-17|0.2.0 14-15|0.0.0.0 13-14|0.0.0 9-10|0 8-9|0.3 7-8|0.0 6-7|0.0.1 4-5|0.1 3-4|0.1.1 2-3|0.1.0 1-2|0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:13.149
(h / hybridize-01 
      :ARG0 (p / probe-01 
            :ARG1 (1 / 11 
                  :quant-of (k / kb)) 
            :mod (t / this)) 
      :ARG1 (c / cell 
            :ARG1-of (t2 / target-01 
                  :ARG1-of (c2 / correct-02)) 
            :mod (e / e)) 
      :ARG3 (f / fragment-01 
            :ARG1 (r / restrict-01)) 
      :mod (a / also))

# ::snt Targeting was confirmed with several additional restriction enzymes and probes ( data not shown ) .
# ::tok Targeting was confirmed with several additional restriction enzymes and probes ( data not shown ) .
# ::alignments 13-14|0.1.0 12-13|0.1.0.1 11-12|0.1.0.0 9-10|0.0.1 8-9|0.0 7-8|0.2 6-7|0.0.0.0 5-6|0.0.0 4-5|0.2.0 2-3|0 0-1|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:13.248
(c / confirm-01 
      :ARG0 (a / and 
            :mod (a2 / additional 
                  :mod-of (r / restrict-01)) 
            :op1 (p / probe)) 
      :ARG1 (t / target-01 
            :ARG1 (s / show-01 
                  :ARG1 (d / data) 
                  :polarity -)) 
      :ARG2 (e / enzym 
            :quant (s2 / several)))

# ::snt Correctly targeted ES cells were microinjected into blastocysts to produce chimeric mice .
# ::tok Correctly targeted ES cells were microinjected into blastocysts to produce chimeric mice .
# ::alignments 11-12|0.0.0.0.0 10-11|0.0.0.0.0.0 9-10|0.0.0.0 7-8|0.0.0.0.1 3-4|0.0.0 2-3|0.0.0.1 1-2|0.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:13.324
(c3 / correctly 
      :degree-of (t / target-01 
            :ARG1 (c2 / cell 
                  :ARG0-of (p / produce-01 
                        :ARG1 (m / mouse 
                              :mod (c / chimeric)) 
                        :purpose-of (b / blastocyst)) 
                  :mod (e / e))))

# ::snt Chimerics were bred to C57BL/6J mice .
# ::tok Chimerics were bred to C57BL/6J mice .
# ::alignments 5-6|0.1 2-3|0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:13.338
(b / breed-01 
      :ARG1 (c / chimeric) 
      :ARG2 (m / mouse))

# ::snt Following germline transmission of the targeted allele , heterozygous mice were interbred to produce wild type ( + / + ) , heterozygous ( + / - ) and homozygous ( - / - ) animals .
# ::tok Following germline transmission of the targeted allele , heterozygous mice were interbred to produce wild type ( + / + ) , heterozygous ( + / - ) and homozygous ( - / - ) animals .
# ::alignments 35-36|0.0.0.0.2 32-33|0.3 29-30|0.2 28-29|0.0.0.0 25-26|0.1.0.0.0 22-23|0.0.0.0.1 18-19|0.1.0.0.1 15-16|0.0.0.0.0 14-15|0.0.0.0.0.0 13-14|0.0.0 9-10|0.0 8-9|0.0.1 6-7|0.1 5-6|0 2-3|0.1.0 0-1|0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:13.722
(t2 / target-01 
      :ARG0 (m / mouse 
            :ARG0-of (p / produce-01 
                  :ARG1 (a2 / and 
                        :op1 (t / type 
                              :mod (w / wild)) 
                        :op2 (h2 / heterozygou) 
                        :op3 (a / animal))) 
            :mod (h3 / heterozygou)) 
      :ARG1 (a3 / allele 
            :poss-of (t3 / transmission 
                  :ARG2-of (f / follow-01 
                        :ARG0 (s2 / slash) 
                        :ARG1 (s3 / slash)))) 
      :ARG2 (h / homozygou) 
      :op1-of (s / slash))

# ::snt Mice were genotyped by Southern blot analysis .
# ::tok Mice were genotyped by Southern blot analysis .
# ::alignments 6-7|0.0.0 5-6|0.0 4-5|0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:13.759
(m / mouse 
      :ARG1-of (b / blot-01 
            :manner-of (a / analyze-01 
                  :ARG1 (t / thing 
                        :name (n / name 
                              :op1 "Southern")))))

# ::snt The Exon 6 specific probe hybridized to only a ~ 16 kb BglI restriction fragment in + / + mice , a ~ 11 kb BglI fragment in - / - mice , and to both of these fragments in + / - mice ( Fig. 1B ) .
# ::tok The Exon 6 specific probe hybridized to only a ~ 16 kb BglI restriction fragment in + / + mice , a ~ 11 kb BglI fragment in - / - mice , and to both of these fragments in + / - mice ( Fig. 1B ) .
# ::alignments 45-46|0.0.0.0.0.0.0+0.0.0.0.0.0+0.0.0.0.0 43-44|0.0.0.1.1 41-42|0.0.0.2.0.1.1 38-39|0.0.0.1 37-38|0.0.0.1.2 35-36|0.0.0.1.3 33-34|0 31-32|0.0.0.0.1.2 29-30|0.0.0.2.0.1.0 26-27|0.0.0.0.1 24-26|0.0.0.0.1.1.0.1+0.0.0.0.1.1.0.0+0.0.0.0.1.1.0+0.0.0.0.1.1 23-24|0.0.0.0.1.3 19-20|0.0.0.3 17-18|0.0.0.3.0 14-15|0.0.0 13-14|0.0.0.0 11-13|0.0.1.1+0.0.1.0+0.0.1+0.0 10-11|0.0.0.4 7-8|0.0.0.1.0 5-6|0.0.0.2 4-5|0.0.0.2.0 3-4|0.0.0.2.0.1 2-3|0.0.0.0.1.0 1-2|0.0.0.2.0.0.0.0+0.0.0.2.0.0.0+0.0.0.2.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:15.306
(a / and 
      :op1 (t3 / thing 
            :ARG0-of (f3 / fragment-01 
                  :ARG1 (r / restrict-01 
                        :ARG0 (c / country 
                              :name (n / name 
                                    :op1 "Fig.")) 
                        :ARG1 (f2 / fragment-01 
                              :ARG0 6 
                              :ARG1 (t2 / thing 
                                    :name (n2 / name 
                                          :op1 (k / kb) 
                                          :op2 (b2 / BglI))) 
                              :ARG2 (m2 / mouse) 
                              :time 11)) 
                  :ARG2 (f / fragment-01 
                        :ARG0 (o / only) 
                        :ARG1 (m / mouse) 
                        :mod (t / this) 
                        :mod (b / both)) 
                  :ARG2-of (h / hybridize-01 
                        :ARG1 (p / probe-01 
                              :ARG0 (o2 / organization 
                                    :name (n4 / name 
                                          :op1 "Exon")) 
                              :ARG1-of (s4 / specific-02 
                                    :ARG0 (s2 / slash) 
                                    :op1-of (s / slash)))) 
                  :beneficiary (m3 / mouse 
                        :op1-of (s3 / slash)) 
                  :quant 16) 
            :name (n3 / name 
                  :op1 (k2 / kb) 
                  :op2 (b3 / BglI))))

# ::snt Mice homozygous for the E2 mutation were born at the expected frequency .
# ::tok Mice homozygous for the E2 mutation were born at the expected frequency .
# ::alignments 11-12|0.0.0.0.0 10-11|0.0.0.0.0.0 7-8|0.0.0.0 5-6|0.0 4-5|0.1.0+0.1+0 1-2|0.0.0 0-1|0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:15.414
(t / thing 
      :mod-of (m / mutation 
            :prep-for-of (h / homozygou 
                  :ARG1-of (b / bear-02 
                        :location (f / frequency 
                              :ARG1-of (e / expect-01))) 
                  :mod (m2 / mouse))) 
      :name (n / name 
            :op1 "E2"))

# ::snt Genotype analysis of pups derived from + / - by + / - matings revealed that + / + , + / - , and - / - mice were present at nearly the expected 1:2:1 frequency .
# ::tok Genotype analysis of pups derived from + / - by + / - matings revealed that + / + , + / - , and - / - mice were present at nearly the expected 1:2:1 frequency .
# ::alignments 36-37|0.0.1.1.2.1 34-35|0.0.1.1.2 32-33|0.0.1.1.2.1.0 30-31|0.0.1.0 28-29|0.0.1.0.0 26-27|0.0.1.0.0.0.0 24-25|0.0.1.0.0.0 21-22|0.0.1.1.0 17-18|0.0.0 14-15|0 13-14|0.1 11-12|0.0.1.1.2.0 7-8|0.0.1.1.1 4-5|0.0.1.1 3-4|0.0.1 1-2|0.0 0-1|0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:15.821
(r / reveal-01 
      :ARG0 (a2 / analyze-01 
            :ARG0 (s3 / slash) 
            :ARG1 (p2 / pup-01 
                  :ARG0 (p / present 
                        :domain (m / mouse 
                              :op2-of (a / and 
                                    :op1 (s / slash)))) 
                  :ARG1-of (d / derive-01 
                        :ARG0 (s2 / slash) 
                        :ARG2 (s5 / slash) 
                        :ARG2-of (e / expect-01 
                              :ARG0 (s4 / slash) 
                              :ARG1 (f / frequency 
                                    :quant (n / nearly))))) 
            :manner (g / genotype)) 
      :ARG1 (m2 / mating))

# ::snt Of the initial 60 animals genotyped , 19 ( 32 % ) were + / + , 27 ( 45 % ) were + / - , and 14 ( 23 % ) were - / - .
# ::tok Of the initial 60 animals genotyped , 19 ( 32 % ) were + / + , 27 ( 45 % ) were + / - , and 14 ( 23 % ) were - / - .
# ::alignments 35-36|0.0.0.0.0.0.0.0.0.0 31-32|0.0.0.0.0.0.0.0.3 30-31|0.0.0.0.0.0.0.0 28-29|0.0.0.0.0 27-28|0 24-25|0.0.0.0.0.0.0.0.2 20-21|0.0.0 19-20|0.0 17-18|0.0.0.0.0.0.0.0.3.1 14-15|0.0.0.0.0.0.0.0.3.0 10-11|0.0.0.0.0.0.0.0.0.1 9-10|0.0.0.0.0.0.0.0.0 7-8|0.0.0.0.0.0.0.0.1 4-5|0.0.0.0.0.0.0 3-4|0.0.0.0 2-3|0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:15.969
(a / and 
      :mod-of (4 / 45 
            :value-of (p2 / percentage-entity 
                  :poss-of (6 / 60 
                        :mod (1 / 14 
                              :mod (i / initial 
                                    :mod-of (a2 / animal 
                                          :mod (2 / 23 
                                                :mod (3 / 32 
                                                      :mod (s / slash) 
                                                      :value-of (p3 / percentage-entity)) 
                                                :mod 19 
                                                :op1-of (s2 / slash) 
                                                :value-of (p / percentage-entity 
                                                      :poss-of (s3 / slash) 
                                                      :value 27)))))))))

# ::snt Thus , the E2 gene was dispensable for normal embryonic development .
# ::tok Thus , the E2 gene was dispensable for normal embryonic development .
# ::alignments 10-11|0.0 9-10|0.0.2 8-9|0.0.1 4-5|0.0.0.0 3-4|0.0.0.1.0+0.0.0.1+0.0.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:16.025
(t2 / thu 
      :ARG0-of (d / develop-02 
            :ARG1 (t / thing 
                  :mod-of (g / gene) 
                  :name (n2 / name 
                        :op1 "E2")) 
            :ARG1-of (n / normal-02) 
            :mod (e / embryonic)))

# ::snt However , as expected , nearly all homozygous mice died in the perinatal period .
# ::tok However , as expected , nearly all homozygous mice died in the perinatal period .
# ::alignments 13-14|0.2 12-13|0.2.0 9-10|0 8-9|0.1 7-8|0.0 6-7|0.1.1.0 5-6|0.1.1 3-4|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:16.113
(d / die-01 
      :ARG0 (h / homozygou) 
      :ARG1 (m / mouse 
            :ARG0-of (e / expect-01) 
            :manner (n / nearly 
                  :mod-of (a / all))) 
      :location (p / period 
            :mod (p2 / perinatal)))

# ::snt Immediately following birth , homozygous pups were indistinguishable from their + / + and + / - littermates ; they were vigorous , active and able to suckle .
# ::tok Immediately following birth , homozygous pups were indistinguishable from their + / + and + / - littermates ; they were vigorous , active and able to suckle .
# ::alignments 27-28|0.0.2 25-26|0.0 24-25|0 23-24|0.0.1.0 21-22|0.0.1.1 19-20|0.0.1 18-19|0.0.3.0 17-18|0.0.1.0.0.0 15-16|0.0.1.0.0.1.0 13-14|0.0.3 11-12|0.0.0 7-8|0.0.1.0.0.1.1.1 5-6|0.0.1.0.0.1.1 4-5|0.0.1.0.0.1.1.0 2-3|0.0.1.0.0 1-2|0.0.1.0.0.1 0-1|0.0.1.0.0.1.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:16.459
(a / and 
      :op1 (p / possible-01 
            :ARG0 (s3 / slash) 
            :ARG1 (t / they 
                  :ARG1-of (a2 / activity-06 
                        :ARG1-of (b / birth-01 
                              :ARG0 (l / littermat) 
                              :ARG2-of (f / follow-01 
                                    :ARG0 (s2 / slash) 
                                    :ARG1 (p2 / pup-01 
                                          :ARG1 (h / homozygou) 
                                          :domain-of (i / indistinguishable)) 
                                    :manner (i2 / immediately)))) 
                  :domain-of (v / vigorou)) 
            :ARG2 (s / suckle-01) 
            :op1-of (a4 / and 
                  :op1-of (a3 / and))))

# ::snt By mid to late day on postnatal day one , most - / - pups became moribund and were readily identifiable as they were lethargic , pale , and exhibited gasping respiratory movements .
# ::tok By mid to late day on postnatal day one , most - / - pups became moribund and were readily identifiable as they were lethargic , pale , and exhibited gasping respiratory movements .
# ::alignments 32-33|0.1.0 31-32|0.1.0.2 30-31|0.1 29-30|0 28-29|0.3 26-27|0.2 24-25|0.0.0 22-23|0.0 20-21|0.1.0.1.2 19-20|0.1.0.1.2.0 17-18|0.1.0.1 16-17|0.1.0.1.1.2 15-16|0.1.0.1.1 14-15|0.1.0.1.1.1 12-13|0.1.0.1.0 10-11|0.1.0.1.1.1.0 8-9|0.1.0.1.1.0.0 7-8|0.1.0.1.1.0.0.0 6-7|0.1.0.0 4-5|0.1.0.1.1.0.1 3-4|0.1.0.1.1.0.1.0 1-2|0.1.0.1.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:17.118
(e / exhibit-01 
      :ARG0 (t / they 
            :domain-of (l / lethargic)) 
      :ARG1 (g / gasp-01 
            :ARG1 (m / move-01 
                  :ARG1 (p3 / postnatal) 
                  :ARG2 (a2 / and 
                        :op1 (s / slash) 
                        :op2 (b / become-01 
                              :ARG0 (m4 / mid 
                                    :prep-on (o / one 
                                          :mod (d / day)) 
                                    :purpose (d2 / day 
                                          :mod (l2 / late))) 
                              :ARG1 (p2 / pup-01 
                                    :ARG1 (m3 / most)) 
                              :ARG2 (m2 / moribund)) 
                        :op3 (i / identifiable 
                              :ARG1-of (r2 / ready-02))) 
                  :mod (r / respiratory))) 
      :ARG2 (p / pale-03) 
      :op1-of (a / and))

# ::snt With few exceptions , - / - pups died within 72 hours of birth .
# ::tok With few exceptions , - / - pups died within 72 hours of birth .
# ::alignments 13-14|0.0.0.0 11-12|0.0.0.0.0.1+0.0.0.0.0 10-11|0.0.0.0.0.0 8-9|0.1 7-8|0 5-6|0.0 2-3|0.0.0 1-2|0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:17.173
(p / pup-01 
      :ARG1 (s / slash 
            :op1 (e / exception 
                  :ARG1-of (b / birth-01 
                        :duration (t / temporal-quantity 
                              :quant 72 
                              :unit (h / hour))) 
                  :quant (f / few))) 
      :ARG1-of (d / die-01))

# ::snt We have observed one rare - / - pup that survived to postnatal day 13 .
# ::tok We have observed one rare - / - pup that survived to postnatal day 13 .
# ::alignments 14-15|0.0 13-14|0.3.1 10-11|0.3 8-9|0 6-7|0.3.0 4-5|0.2 2-3|0.1 0-1|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:17.329
(p / pup-01 
      :ARG0 13 
      :ARG1-of (o / observe-01 
            :ARG0 (w / we)) 
      :ARG1-of (r / rare-02) 
      :ARG1-of (s / survive-01 
            :ARG0 (s2 / slash) 
            :time (d / day)))

# ::snt The reason for the prolonged survival of this pup is unknown .
# ::tok The reason for the prolonged survival of this pup is unknown .
# ::alignments 10-11|0.1+0 8-9|0.0.0.0 7-8|0.0.0.0.0 5-6|0.0.0 4-5|0.0.0.1 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:17.386
(k / know-01 
      :ARG1 (r / reason 
            :purpose (s / survive-01 
                  :ARG0 (p / pup-01 
                        :mod (t / this)) 
                  :ARG1-of (p2 / prolong-01))) 
      :polarity -)

# ::snt E2 deficient mice accurately model classic MSUD .
# ::tok E2 deficient mice accurately model classic MSUD .
# ::alignments 6-7|0.1 5-6|0.1.0 4-5|0 3-4|0.2 2-3|0.0 1-2|0.0.0 0-1|0.0.1.0.0+0.0.1.0+0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:17.436
(m2 / model-01 
      :ARG0 (m3 / mouse 
            :mod (d / deficient) 
            :mod (t / thing 
                  :name (n / name 
                        :op1 "E2"))) 
      :ARG1 (m / MSUD 
            :mod (c / classic)) 
      :manner (a / accurate))

# ::snt To demonstrate that the gene targeting event created a true E2 null allele , we determined BCKDH activity in liver homogenates of postnatal day 1 mouse pups derived from + / - by + / - mating pairs .
# ::tok To demonstrate that the gene targeting event created a true E2 null allele , we determined BCKDH activity in liver homogenates of postnatal day 1 mouse pups derived from + / - by + / - mating pairs .
# ::alignments 37-38|0.2.0 36-37|0.2 34-35|0.1.2 30-31|0.1.0.2 27-28|0.1.0 26-27|0.1.0.0 25-26|0.1.0.0.0 24-25|0.3.0 23-24|0.1.1 22-23|0.1.0.3 20-21|0.1.0.1 19-20|0.1.0.1.0 17-18|0.1 15-16|0 14-15|0.0 12-13|0.2.0.0 11-12|0.3.1.1.0 10-11|0.3.1.1.2.0+0.3.1.1.2+0.3.1.1 9-10|0.3.1.1.1 7-8|0.3.1 6-7|0.3.1.0 5-6|0.3.1.0.0 4-5|0.3.1.0.1 1-2|0.3 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:18.438
(d3 / determine-01 
      :ARG0 (w / we) 
      :ARG1 (a / activity-06 
            :ARG1 (d / derive-01 
                  :ARG0 (p2 / pup-01 
                        :ARG1 (m2 / mouse)) 
                  :ARG1 (h / homogenat 
                        :mod (l / liver)) 
                  :ARG2 (s2 / slash) 
                  :time (p3 / postnatal)) 
            :ARG2 (d2 / day) 
            :op1-of (s / slash)) 
      :ARG1-of (m / mate-01 
            :ARG1-of (p / pair-01 
                  :ARG0 (a2 / allele))) 
      :time (d4 / demonstrate-01 
            :ARG0 1 
            :ARG1 (c / create-01 
                  :ARG0 (e / event 
                        :ARG1-of (t3 / target-01) 
                        :mod (g / gene)) 
                  :ARG1 (t / thing 
                        :ARG1-of (n / null-02) 
                        :mod (t2 / true) 
                        :name (n2 / name 
                              :op1 "E2")))))

# ::snt As shown in Figure 2A , the BCKDH activity in + / + mice was readily detectable .
# ::tok As shown in Figure 2A , the BCKDH activity in + / + mice was readily detectable .
# ::alignments 16-17|0 15-16|0.0 13-14|0.1.0 11-12|0.1.0.0 8-9|0.1 3-4|0.1.1.0 1-2|0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:18.492
(d / detectable 
      :ARG1-of (r / ready-02) 
      :domain (a / activity-06 
            :ARG1 (m / mouse 
                  :op1-of (s / slash)) 
            :ARG1-of (s2 / show-01 
                  :ARG0 (f / figure))))

# ::snt In marked contrast , BCKDH activity was completely absent in - / - mouse livers .
# ::tok In marked contrast , BCKDH activity was completely absent in - / - mouse livers .
# ::alignments 14-15|0.1 13-14|0 11-12|0.0.1.0 8-9|0.0.1 7-8|0.0.1.2 5-6|0.0.1.1 2-3|0.0 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:18.531
(m / mouse 
      :ARG1-of (c2 / contrast-01 
            :ARG1-of (m2 / mark-01) 
            :manner-of (a / absent-01 
                  :ARG0 (s / slash) 
                  :ARG1 (a2 / activity-06) 
                  :ARG1-of (c / complete-02))) 
      :mod-of (l / liver))

# ::snt As expected , homogenates from + / - mice had approximately half the activity of their + / + littermates ( Figure 2A ) .
# ::tok As expected , homogenates from + / - mice had approximately half the activity of their + / + littermates ( Figure 2A ) .
# ::alignments 21-22|0.1 19-20|0.0.1.1 17-18|0.0.1.1.0 13-14|0.0.1 11-12|0.0.0 10-11|0.0.1.2 8-9|0 6-7|0.0.1.0.0 3-4|0.0.1.0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:18.690
(m / mouse 
      :ARG2-of (e / expect-01 
            :ARG1 (h / half) 
            :time-of (a / activity-06 
                  :ARG0 (h2 / homogenat 
                        :source (s2 / slash)) 
                  :ARG1 (l / littermat 
                        :op1-of (s / slash)) 
                  :op1-of (a2 / approximately))) 
      :poss-of (f / figure))

# ::snt The results from - / - mice are similar to that observed in humans with classic MSUD [ 1 ] .
# ::tok The results from - / - mice are similar to that observed in humans with classic MSUD [ 1 ] .
# ::alignments 18-19|0.1.0.0 15-16|0.0 13-14|0.2.0.2 11-12|0.2.0 10-11|0.2 8-9|0 6-7|0.2.0.0 4-5|0.2.0.1 1-2|0.1.0+0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:18.797
(r / resemble-01 
      :ARG0 (c / classic) 
      :ARG1 (t2 / thing 
            :ARG2-of (r2 / result-01 
                  :ARG1 1)) 
      :ARG2 (t / that 
            :ARG1-of (o / observe-01 
                  :ARG0 (m / mouse) 
                  :ARG2 (s / slash) 
                  :location (h / human))))

# ::snt Biochemical characterization of the classic MSUD murine model .
# ::tok Biochemical characterization of the classic MSUD murine model .
# ::alignments 7-8|0.0 6-7|0.0.1 4-5|0.0.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:18.812
(b / biochemical 
      :topic-of (m / model 
            :mod (c / classic) 
            :mod (m2 / murine)))

# ::snt A , BCKDH enzyme activity in liver of newborn wild type control ( + / + ) , heterozygous ( + / - ) , and homozygous ( - / - ) knockout mice .
# ::tok A , BCKDH enzyme activity in liver of newborn wild type control ( + / + ) , heterozygous ( + / - ) , and homozygous ( - / - ) knockout mice .
# ::alignments 33-34|0.1 32-33|0 29-30|0.0.4 26-27|0.0.1.3.1 25-26|0.0.1.3 21-22|0.0.3 18-19|0.0.1.3.0 14-15|0.0.1.0 11-12|0.0.1 10-11|0.0.1.1 9-10|0.0.1.1.0 8-9|0.0.0 6-7|0.0.1.2 4-5|0.0 3-4|0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:19.030
(k / knockout 
      :ARG0-of (a2 / activity-06 
            :ARG1 (n / newborn) 
            :ARG2 (c / control-01 
                  :ARG0 (s3 / slash) 
                  :ARG1 (t / type 
                        :mod (w / wild)) 
                  :mod-of (l / liver) 
                  :op1-of (a / and 
                        :op2 (h2 / heterozygou) 
                        :op3 (h / homozygou))) 
            :mod (e / enzyme) 
            :op1-of (s2 / slash) 
            :op1-of (s / slash)) 
      :mod-of (m / mouse))

# ::snt Enzyme activity was significantly reduced in + / - liver compared to + / + , and was below the level of detection in - / - liver .
# ::tok Enzyme activity was significantly reduced in + / - liver compared to + / + , and was below the level of detection in - / - liver .
# ::alignments 27-28|0.1.1.0 25-26|0.1.0.2 22-23|0.0.0 20-21|0.0 18-19|0.2 16-17|0 13-14|0.1.0.0.0.0 10-11|0.1.0.0.0 9-10|0.1.0.0 7-8|0.0.0.0 4-5|0.1 3-4|0.1.1 1-2|0.1.0 0-1|0.1.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:19.156
(a / and 
      :manner (l2 / level 
            :mod (d / detect-01 
                  :ARG1 (s3 / slash))) 
      :op1 (r / reduce-01 
            :ARG1 (a2 / activity-06 
                  :ARG1 (l3 / liver 
                        :mod (c / compare-01 
                              :ARG1 (s2 / slash))) 
                  :mod (e / enzyme) 
                  :op1-of (s / slash)) 
            :ARG2 (s4 / significant-02 
                  :ARG1 (l / liver))) 
      :time (b / below))

# ::snt B , Total BCAA concentrations in blood of mice .
# ::tok B , Total BCAA concentrations in blood of mice .
# ::alignments 8-9|0.3 6-7|0.1 4-5|0 3-4|0.2.0.0+0.2.0+0.2 2-3|0.0 0-1|0.0.0.1+0.0.0.0.0+0.0.0.0+0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:19.240
(c / concentration 
      :ARG2-of (t2 / total-01 
            :ARG1 (l / location 
                  :name (n2 / name 
                        :op1 "B") 
                  :wiki -)) 
      :location (b / blood) 
      :mod (t / thing 
            :name (n / name 
                  :op1 "BCAA")) 
      :poss (m / mouse))

# ::snt Total BCAA represent the sum of leucine , isoleucine , and valine .
# ::tok Total BCAA represent the sum of leucine , isoleucine , and valine .
# ::alignments 11-12|0.1.2 10-11|0.1 8-9|0.1.1 6-7|0.1.0 4-5|0.1.0.0 2-3|0 1-2|0.0.1.0+0.0.1+0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:19.679
(r / represent-01 
      :ARG0 (t / thing 
            :ARG2-of (t2 / total-01) 
            :name (n / name 
                  :op1 "BCAA")) 
      :ARG1 (a / and 
            :op1 (l / leucine 
                  :mod-of (s / sum)) 
            :op2 (i / isoleucine) 
            :op3 (v / valine)))

# ::snt Total BCAA concentrations in blood from - / - mice were significantly elevated compared to + / + and + / - .
# ::tok Total BCAA concentrations in blood from - / - mice were significantly elevated compared to + / + and + / - .
# ::alignments 20-21|0.0.1.1.1.0 18-19|0 16-17|0.0.0 13-14|0.0.1.0 12-13|0.0.1.1 11-12|0.0.1.1.1 9-10|0.0.1.1.0 7-8|0.0.1.0.0 4-5|0.0.1.2 2-3|0.0.1 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:19.828
(a / and 
      :ARG2-of (t / total-01 
            :ARG0 (s2 / slash) 
            :ARG1 (c2 / concentration 
                  :ARG1-of (c / compare-01 
                        :ARG0 (s4 / slash)) 
                  :ARG1-of (e / elevate-01 
                        :ARG0 (m / mouse) 
                        :ARG1-of (s3 / significant-02 
                              :ARG0 (s / slash))) 
                  :location (b / blood))))

# ::snt C , Ratio of total BCAA to alanine in blood of mice .
# ::tok C , Ratio of total BCAA to alanine in blood of mice .
# ::alignments 11-12|0.1.0.0 9-10|0.1.0.0.0 5-6|0.1.1.0+0.1.1+0.1 4-5|0.1.0 2-3|0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:19.881
(r / ratio 
      :part (c / C) 
      :quant-of (t / thing 
            :ARG2-of (t2 / total-01 
                  :ARG0 (m / mouse 
                        :mod-of (b / blood))) 
            :name (n / name 
                  :op1 "BCAA")))

# ::snt This ratio was significantly elevated in - / - mice compared to + / + and + / - mice .
# ::tok This ratio was significantly elevated in - / - mice compared to + / + and + / - mice .
# ::alignments 19-20|0.2.0.0.0 17-18|0.2 15-16|0 13-14|0.1 10-11|0.2.0.0.1.0 9-10|0.2.0.0.1.0.0 7-8|0.0 4-5|0.2.0.0 3-4|0.2.0 1-2|0.2.0.0.1 0-1|0.2.0.0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:19.969
(a / and 
      :op1 (s3 / slash) 
      :op2 (s2 / slash) 
      :op3 (s / slash 
            :ARG0-of (s4 / significant-02 
                  :ARG1 (e / elevate-01 
                        :ARG0 (m / mouse) 
                        :ARG1 (r / ratio 
                              :ARG1-of (c / compare-01 
                                    :ARG0 (m2 / mouse)) 
                              :mod (t / this))))))

# ::snt The numbers on the bars indicates the number of mice analyzed .
# ::tok The numbers on the bars indicates the number of mice analyzed .
# ::alignments 10-11|0.0.0 9-10|0.1.0 7-8|0.1 5-6|0 4-5|0.0.0.0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:19.995
(i / indicate-01 
      :ARG0 (n2 / number 
            :ARG1-of (a / analyze-01 
                  :ARG0 (b / bar))) 
      :ARG1 (n / number 
            :quant-of (m / mouse)))

# ::snt * , Significantly different from + / + ( P < 0.001 ) ; ** , significantly different from + / + and + / - ( P < 0.001 ) .
# ::tok * , Significantly different from + / + ( P < 0.001 ) ; ** , significantly different from + / + and + / - ( P < 0.001 ) .
# ::alignments 27-28|0.0.2 24-25|0.0.1.2.0 22-23|0 20-21|0.0.1.0 17-18|0.0.0 16-17|0.0.0.0 13-14|0.0.1.1 9-10|0.0.1.1.0 6-7|0.0 3-4|0.0.1 2-3|0.0.1.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:20.341
(a / and 
      :op1 (s4 / slash 
            :ARG0-of (d / differ-02 
                  :ARG1-of (s3 / significant-02)) 
            :ARG2-of (d2 / differ-02 
                  :ARG0 (s2 / slash) 
                  :ARG1 (a2 / and 
                        :op1 (p2 / P60)) 
                  :mod (s5 / significantly 
                        :mod-of (s / slash))) 
            :mod-of (p / P60)))

# ::snt Immunohistochemistry with an E2 specific antibody was used to examine E2 protein in the mice .
# ::tok Immunohistochemistry with an E2 specific antibody was used to examine E2 protein in the mice .
# ::alignments 14-15|0.0.2 11-12|0.0.1 9-10|0.0 7-8|0 5-6|0.0.2.0.0 4-5|0.0.2.0 3-4|0.0.2.0.1.0.0+0.0.2.0.1.0+0.0.2.0.1 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:20.736
(u / use-01 
      :ARG2 (e / examine-01 
            :ARG0 (i / immunohistochemistry) 
            :ARG1 (p / protein) 
            :location (m / mouse 
                  :ARG0-of (s / specific-02 
                        :ARG1 (a / antibody) 
                        :ARG2 (t / thing 
                              :name (n / name 
                                    :op1 "E2"))))))

# ::snt As shown in Figure 1C and 1D , immunoreactive E2 protein was abundant in liver and embryonic fibroblasts of + / + mice .
# ::tok As shown in Figure 1C and 1D , immunoreactive E2 protein was abundant in liver and embryonic fibroblasts of + / + mice .
# ::alignments 22-23|0 20-21|0.1 17-18|0.0 16-17|0.0.0 15-16|0.0.1 14-15|0.0.1.2 12-13|0.0.1.1 10-11|0.0.1.1.0 9-10|0.0.1.1.0.0.0.0+0.0.1.1.0.0.0+0.0.1.1.0.0 5-6|0.0.1.0 3-4|0.0.1.0.0.0 1-2|0.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:21.301
(m / mouse 
      :mod-of (f / fibroblast 
            :mod (e / embryonic) 
            :op4-of (a / and 
                  :op1 (a3 / and 
                        :ARG1-of (s2 / show-01 
                              :ARG0 (f2 / figure))) 
                  :op2 (a2 / abundance 
                        :domain (p / protein 
                              :mod (t / thing 
                                    :name (n / name 
                                          :op1 "E2")))) 
                  :op3 (l / liver))) 
      :op1-of (s / slash))

# ::snt In marked contrast , immunoreactive E2 protein was absent in these same tissues of - / - mice .
# ::tok In marked contrast , immunoreactive E2 protein was absent in these same tissues of - / - mice .
# ::alignments 17-18|0.0.3 15-16|0.0.2 12-13|0.0.1 11-12|0.0.1.0 10-11|0.0.1.1 8-9|0.0 6-7|0.0.0 5-6|0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 2-3|0 1-2|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:21.447
(c / contrast-01 
      :ARG1 (a / absent-01 
            :ARG1 (p / protein 
                  :mod (t3 / thing 
                        :name (n / name 
                              :op1 "E2"))) 
            :ARG2 (t / tissue 
                  :ARG1-of (s2 / same-01) 
                  :mod (t2 / this)) 
            :path (s / slash) 
            :path (m / mouse)) 
      :ARG1-of (m2 / mark-01))

# ::snt Homozygous E2 knockout mice had a nearly 3-fold increase in blood ( Figure 2B ) and urine ( data not shown ) levels of BCAA ( sum of leucine , isoleucine , and valine ) as compared to their + / + littermates .
# ::tok Homozygous E2 knockout mice had a nearly 3-fold increase in blood ( Figure 2B ) and urine ( data not shown ) levels of BCAA ( sum of leucine , isoleucine , and valine ) as compared to their + / + littermates .
# ::alignments 42-43|0.1.0.2.0.0 40-41|0.1.0.2.0.0.0 36-37|0.1.0.2.0 33-34|0.1.0.0.2.2 32-33|0.1.0.0.2 30-31|0.1.0.0.2.1 28-29|0.1.0.0.2.0 26-27|0.1.0.0.2.0.0 24-25|0.1.0.0.0.0.0.0+0.1.0.0.0.0.0+0.1.0.0.0.0 22-23|0.1.0.0.0 20-21|0 19-20|0.2 18-19|0.1 16-17|0.1.0.3 15-16|0.1.0 12-13|0.1.0.2 10-11|0.1.0.1 8-9|0.1.0.0 6-7|0.0 3-4|0.1.0.0.1 2-3|0.1.0.0.1.0 0-2|0.1.0.0.1.1.0.1+0.1.0.0.1.1.0.0+0.1.0.0.1.1.0+0.1.0.0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:22.221
(s3 / show-01 
      :ARG0 (n2 / nearly) 
      :ARG1 (d / data 
            :op5-of (a2 / and 
                  :op1 (i2 / increase-01 
                        :ARG0 (l3 / level 
                              :poss (t / thing 
                                    :name (n / name 
                                          :op1 "BCAA"))) 
                        :ARG1 (m / mouse 
                              :mod (k / knockout) 
                              :mod (t2 / thing 
                                    :name (n3 / name 
                                          :op1 (h / Homozygous) 
                                          :op2 (e / E2)))) 
                        :op1-of (a / and 
                              :op2 (l2 / leucine 
                                    :mod-of (s2 / sum)) 
                              :op3 (i / isoleucine) 
                              :op4 (v / valine))) 
                  :op2 (b / blood) 
                  :op3 (f / figure 
                        :ARG1-of (c / compare-01 
                              :ARG2 (l / littermat 
                                    :op1-of (s / slash)))) 
                  :op4 (u / urine))) 
      :polarity -)

# ::snt Because amino acids were analyzed by tandem mass spectrometry , the sum of BCAA shown in Figure 2B also may include alloisoleucine that may have been produced in - / - MSUD mice .
# ::tok Because amino acids were analyzed by tandem mass spectrometry , the sum of BCAA shown in Figure 2B also may include alloisoleucine that may have been produced in - / - MSUD mice .
# ::alignments 32-33|0.1.0.0.2 29-30|0.0 26-27|0.1.0.0 23-24|0.1.0.0.1 21-22|0.1.0 20-21|0.1 19-20|0 18-19|0.1.0.1 16-17|0.1.0.0.0.0.0 14-15|0.1.0.0.0.0 13-14|0.1.0.0.0.0.1.0.0+0.1.0.0.0.0.1.0+0.1.0.0.0.0.1 11-12|0.1.0.0.0 8-9|0.2.0.0 7-8|0.2.0.0.0 6-7|0.2.0.0.0.0 4-5|0.2.0 2-3|0.2.0.1 1-2|0.2.0.1.0 0-1|0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:23.098
(p3 / possible-01 
      :ARG0 (s / slash) 
      :ARG1 (i / include-01 
            :ARG1 (a / alloisoleucine 
                  :ARG1-of (p / produce-01 
                        :ARG0 (s3 / sum 
                              :ARG1-of (s2 / show-01 
                                    :ARG0 (f / figure) 
                                    :manner (t / thing 
                                          :name (n / name 
                                                :op1 "BCAA")))) 
                        :ARG1-of (p2 / possible-01) 
                        :manner (m / mouse)) 
                  :mod (a2 / also))) 
      :ARG1-of (c / cause-01 
            :ARG0 (a3 / analyze-01 
                  :ARG0 (s4 / spectrometry 
                        :mod (m2 / mass 
                              :mod (t2 / tandem))) 
                  :ARG1 (a4 / acid 
                        :mod (a5 / amino)))))

# ::snt The metabolism of BCAA is linked with the synthesis of alanine , glutamate , and glutamine [ 33 ] .
# ::tok The metabolism of BCAA is linked with the synthesis of alanine , glutamate , and glutamine [ 33 ] .
# ::alignments 17-18|0.0 15-16|0.2.0.2 14-15|0.2.0 12-13|0.2.0.1 10-11|0.2.0.0 8-9|0.2 5-6|0 3-4|0.1.0.0.0+0.1.0.0+0.1.0 1-2|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:23.266
(l / link-01 
      :ARG0 33 
      :ARG1 (m / metabolism 
            :poss (t / thing 
                  :name (n / name 
                        :op1 "BCAA"))) 
      :ARG2 (s / synthesi 
            :domain (a / and 
                  :op1 (a2 / alanine) 
                  :op2 (g2 / glutamate) 
                  :op3 (g / glutamine))))

# ::snt Because of impaired metabolism of BCAA in MSUD mice , and to further characterize the abnormal biochemistry in this model , we analyzed the blood levels of the alanine , glutamate , and glutamine .
# ::tok Because of impaired metabolism of BCAA in MSUD mice , and to further characterize the abnormal biochemistry in this model , we analyzed the blood levels of the alanine , glutamate , and glutamine .
# ::alignments 33-34|0.0.1.4 32-33|0.0.1 30-31|0.0.1.3 28-29|0.0.1.2 25-26|0.0.0.0 24-25|0.0.0.0.0 22-23|0.0 21-22|0.0.0 19-20|0.0.1.0.0.0 18-19|0.0.1.0.0.0.0 16-17|0.0.1.0.0 15-16|0.0.1.0.0.1 13-14|0.0.1.0 12-13|0.0.1.0.1 10-11|0.0.1.1 8-9|0.0.1.1.0.1.0.0 5-6|0.0.1.1.0.0.0+0.0.1.1.0.0+0.0.1.1.0 3-4|0.0.1.1.0.1 2-3|0.0.1.1.0.1.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:23.857
(c2 / cause-01 
      :ARG1 (a3 / analyze-01 
            :ARG0 (w / we 
                  :poss-of (l / level 
                        :mod (b / blood))) 
            :ARG1 (a / and 
                  :ARG2-of (c / characterize-01 
                        :ARG1 (b2 / biochemistry 
                              :location (m / model 
                                    :mod (t / this)) 
                              :mod (a4 / abnormal)) 
                        :degree (f / further)) 
                  :op1 (a5 / and 
                        :op1 (t2 / thing 
                              :name (n / name 
                                    :op1 "BCAA") 
                              :poss-of (m3 / metabolism 
                                    :ARG1-of (i / impair-01 
                                          :ARG0 (m2 / mouse))))) 
                  :op2 (a2 / alanine) 
                  :op3 (g2 / glutamate) 
                  :op4 (g / glutamine))))

# ::snt As shown in Table 1 , the levels of all three amino acids in homozygous mice were markedly lower than the levels in + / + or + / - mice .
# ::tok As shown in Table 1 , the levels of all three amino acids in homozygous mice were markedly lower than the levels in + / + or + / - mice .
# ::alignments 30-31|0.0.1.0.0 28-29|0.0.3 26-27|0 24-25|0.0.2 21-22|0.0.1.0.1 18-19|0.0.1.0 17-18|0.0.1.0.2 15-16|0.0.1.1.1 14-15|0.0.1.1.1.0 12-13|0.0.1.1 11-12|0.0.1.1.0 10-11|0.0.1.1.3 9-10|0.0.1.1.2 7-8|0.0.1 4-5|0.0.0.0 3-4|0.0.0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:24.068
(o / or 
      :op1 (s3 / show-01 
            :ARG0 (t / table 
                  :mod 1) 
            :ARG1 (l3 / level 
                  :ARG1-of (l2 / low-04 
                        :ARG0 (m / mouse) 
                        :compared-to (l / level) 
                        :degree (m2 / markedly)) 
                  :mod (a / acid 
                        :mod (a2 / amino) 
                        :mod (m3 / mouse 
                              :mod (h / homozygou)) 
                        :quant (a3 / all) 
                        :quant 3)) 
            :ARG2 (s2 / slash) 
            :op1-of (s / slash)))

# ::snt The levels of these amino acids in the + / - mice were comparable to those in + / + mice ( Table 1 ) .
# ::tok The levels of these amino acids in the + / - mice were comparable to those in + / + mice ( Table 1 ) .
# ::alignments 23-24|0.0.0.1 22-23|0.0.0.2 20-21|0 18-19|0.0 13-14|0.0.0 11-12|0.0.0.0 9-10|0.0.0.0.0.0.1.0 5-6|0.0.0.0.0.0 4-5|0.0.0.0.0 3-4|0.0.0.0.0.0.0 1-2|0.0.0.0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:24.189
(m / mouse 
      :mod (s / slash 
            :ARG2-of (c / comparable-03 
                  :ARG1 (m2 / mouse 
                        :mod (a2 / amino 
                              :mod-of (a / acid 
                                    :mod (t2 / this) 
                                    :mod-of (l / level 
                                          :location (s2 / slash))))) 
                  :op1-of 1 
                  :op1-of (t / table))))

# ::snt Because of the abnormal decrease in the blood alanine level and marked rise in blood BCAA levels that are characteristic of MSUD , a recent report on MSUD patients has suggested that the ratio of BCAA/alanine provides a more sensitive measure of the abnormal biochemistry of MSUD than BCAA level alone [ 8 ] .
# ::tok Because of the abnormal decrease in the blood alanine level and marked rise in blood BCAA levels that are characteristic of MSUD , a recent report on MSUD patients has suggested that the ratio of BCAA/alanine provides a more sensitive measure of the abnormal biochemistry of MSUD than BCAA level alone [ 8 ] .
# ::alignments 52-53|0.0.1.0.0.0.1.2.0 50-51|0.0.1.0.0.0.3 49-50|0.0.1.0.0.0.1.0 44-45|0.0.1.0.0.0.1.1 43-44|0.0.1.0.0.0.1.1.0 40-41|0.0.1.0.0.0.1 39-40|0.0.1.0.0.0.1.2 38-39|0.0.1.0.0.0.1.2.1 36-37|0.0.1.0.0.0 33-34|0.0.1.0.0.0.0 30-31|0.0.1.0.0.0.2 28-29|0.0.1.0.0.0.2.0.1.0.0+0.0.1.0.0.0.2.0.1.0+0.0.1.0.0.0.2.0.1 25-26|0.0.1.0.0.0.2.0 24-25|0.0.1.0.0.0.2.0.0 19-20|0.0.0.0 16-17|0.0.0 15-16|0.0.0.1.0.0+0.0.0.1.0+0.0.0.1 14-15|0.0.0.2 12-13|0.0 11-12|0 10-11|0.0.1 9-10|0.0.1.1 8-9|0.0.1.1.1 7-8|0.0.1.1.0 4-5|0.0.1.0 3-4|0.0.1.0.1 0-1|0.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:24.891
(m3 / mark-01 
      :ARG1 (r4 / rise-01 
            :ARG1 (l2 / level 
                  :ARG1-of (c / characteristic-02) 
                  :mod (c2 / country 
                        :name (n / name 
                              :op1 "BCAA")) 
                  :mod (b2 / blood)) 
            :op2-of (a3 / and 
                  :ARG1-of (d / decrease-01 
                        :ARG0-of (c3 / cause-01 
                              :ARG1 (p / provide-01 
                                    :ARG0 (r / ratio) 
                                    :ARG1 (m / measure-01 
                                          :ARG0 (l / level) 
                                          :ARG1 (b / biochemistry 
                                                :mod (a2 / abnormal)) 
                                          :ARG1-of (s / sensitive-03 
                                                :ARG0 8 
                                                :degree (m2 / more))) 
                                    :ARG1-of (s2 / suggest-01 
                                          :ARG0 (r2 / report 
                                                :time (r3 / recent) 
                                                :topic (p2 / person 
                                                      :ARG0-of (h / have-rel-role-91 
                                                            :ARG2 (p3 / patient))))) 
                                    :manner (a / alone))) 
                        :mod (a5 / abnormal)) 
                  :op1 (l3 / level 
                        :mod (b3 / blood) 
                        :mod (a4 / alanine)))))

# ::snt Therefore , we also expressed the amino acid results as BCAA/alanine ratio .
# ::tok Therefore , we also expressed the amino acid results as BCAA/alanine ratio .
# ::alignments 11-12|0.2 8-9|0.1.0+0.1 7-8|0.1.1 6-7|0.1.0.0 4-5|0 3-4|0.3 2-3|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:25.202
(e / express-01 
      :ARG0 (w / we) 
      :ARG1 (t / thing 
            :ARG2-of (r2 / result-01 
                  :mod (a2 / amino)) 
            :mod (a / acid)) 
      :ARG2 (r / ratio) 
      :mod (a3 / also))

# ::snt As shown in Figure 2C , this ratio in - / - pups was more than 6-fold higher than + / + or + / - littermates .
# ::tok As shown in Figure 2C , this ratio in - / - pups was more than 6-fold higher than + / + or + / - littermates .
# ::alignments 26-27|0.0.1.0.0 24-25|0.0.3 22-23|0 20-21|0.0.2 17-18|0.0.1.1 14-15|0.0.1.0.1 12-13|0.0.1.0 10-11|0.0.1.1.0 7-8|0.0.1 6-7|0.0.1.2 3-4|0.0.0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:25.363
(o / or 
      :op1 (s4 / show-01 
            :ARG0 (f / figure) 
            :ARG1 (r / ratio 
                  :ARG1-of (p / pup-01 
                        :ARG0 (l / littermat) 
                        :op1-of (m / more)) 
                  :compared-to-of (h / high-02 
                        :ARG1 (s3 / slash)) 
                  :mod (t / this)) 
            :ARG2 (s2 / slash) 
            :op1-of (s / slash)))

# ::snt These blood amino acid results are consistent with the concentrations seen in patients with MSUD [ 1,8,15 ] .
# ::tok These blood amino acid results are consistent with the concentrations seen in patients with MSUD [ 1,8,15 ] .
# ::alignments 12-13|0.1.0.0.0.0+0.1.0.0.0+0.1.0.0 10-11|0.1.0 9-10|0.1 6-7|0 4-5|0.0.0+0.0 3-4|0.0.0.1 2-3|0.0.2 1-2|0.0.0.0 0-1|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:25.487
(c2 / consistent-01 
      :ARG1 (t / thing 
            :ARG2-of (r / result-01 
                  :ARG1 (b / blood) 
                  :mod (a / acid)) 
            :mod (t2 / this) 
            :mod (a2 / amino)) 
      :ARG2 (c / concentration 
            :ARG1-of (s / see-01 
                  :ARG0 (p / person 
                        :ARG0-of (h / have-rel-role-91 
                              :ARG2 (p2 / patient))))))

# ::snt Summary of additional blood amino acid levels in the classic MSUD model and control littermates as determined by tandem mass spectrometry .
# ::tok Summary of additional blood amino acid levels in the classic MSUD model and control littermates as determined by tandem mass spectrometry .
# ::alignments 20-21|0.1.1.0 19-20|0.1.1.0.0 18-19|0.1.1.0.0.0 16-17|0.1.1 13-14|0.1 12-13|0 11-12|0.0 9-10|0.0.0 6-7|0.1.0 5-6|0.1.0.1 4-5|0.1.0.2 3-4|0.1.0.0.0 2-3|0.1.0.0 0-1|0.1.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:25.831
(a / and 
      :op1 (m2 / model 
            :mod (c2 / classic)) 
      :op2 (c / control-01 
            :ARG1 (l / level 
                  :mod (a4 / additional 
                        :mod-of (b / blood)) 
                  :mod (a2 / acid) 
                  :mod (a3 / amino)) 
            :ARG2-of (d / determined-02 
                  :ARG0 (s / spectrometry 
                        :mod (m / mass 
                              :mod (t / tandem))) 
                  :ARG1 (s2 / summary))))

# ::snt All samples were collected on the day of birth .
# ::tok All samples were collected on the day of birth .
# ::alignments 8-9|0.1.0 6-7|0.1 3-4|0 1-2|0.0.0+0.0 0-1|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:25.852
(c / collect-01 
      :ARG1 (t / thing 
            :ARG1-of (s / sample-01) 
            :quant (a / all)) 
      :time (d / day 
            :time-of (b / birth-01)))

# ::snt All values are mean + / - SEM .
# ::tok All values are mean + / - SEM .
# ::alignments 7-8|0.2.0.0+0.2.0+0.2 5-6|0.1 3-4|0 1-2|0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:25.985
(m / mean-01 
      :ARG1 (v / value 
            :quant (a / all)) 
      :ARG2 (s / slash) 
      :degree (o / organization 
            :name (n / name 
                  :op1 "SEM")))

# ::snt * : Significantly different from + / + and + / - ( P < 0.001 ) .
# ::tok * : Significantly different from + / + and + / - ( P < 0.001 ) .
# ::alignments 13-14|0.0.0.0 10-11|0.0 8-9|0 6-7|0.0.0.1 3-4|0.0.0 2-3|0.0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:26.059
(a / and 
      :op1 (s / slash 
            :ARG2-of (d / differ-02 
                  :ARG0 (p / P60) 
                  :ARG1 (s2 / slash) 
                  :mod (s3 / significantly))))

# ::snt In summary , E2 knockout mice lack BCKDH enzymatic activity , E2 immunoreactivity , and have markedly elevated levels of BCAA in the blood and urine .
# ::tok In summary , E2 knockout mice lack BCKDH enzymatic activity , E2 immunoreactivity , and have markedly elevated levels of BCAA in the blood and urine .
# ::alignments 25-26|0.1.2.1 24-25|0.1.2 23-24|0.1.2.0 20-21|0.1.1.0.0+0.1.1.0+0.1.1 18-19|0.1 17-18|0.1.0 16-17|0.1.0.1 14-15|0 12-13|0.1.0.0 9-10|0.0.1 8-9|0.0.1.0 6-7|0.0 5-6|0.0.0 4-5|0.0.0.0 3-4|0.0.0.1.0.0+0.0.0.1.0+0.0.0.1 1-2|0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:26.287
(a2 / and 
      :op1 (l2 / lack-01 
            :ARG0 (m2 / mouse 
                  :mod (k / knockout) 
                  :mod (t / thing 
                        :name (n2 / name 
                              :op1 "E2"))) 
            :ARG1 (a3 / activity-06 
                  :mod (e2 / enzymatic)) 
            :location (s / summary)) 
      :op2 (l / level 
            :ARG1-of (e / elevate-01 
                  :ARG0 (i / immunoreactivity) 
                  :degree (m / markedly)) 
            :mod (c / country 
                  :name (n / name 
                        :op1 "BCAA")) 
            :op1-of (a / and 
                  :op2 (b / blood) 
                  :op3 (u / urine))))

# ::snt These metabolic derangements ultimately result in neonatal lethality .
# ::tok These metabolic derangements ultimately result in neonatal lethality .
# ::alignments 7-8|0.1 6-7|0.1.0 4-5|0 3-4|0.2 2-3|0.0 1-2|0.0.1 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:26.325
(r / result-01 
      :ARG1 (d / derangement 
            :mod (t / this) 
            :mod (m / metabolic)) 
      :ARG2 (l / lethality 
            :mod (n / neonatal)) 
      :time (u / ultimate))

# ::snt These phenotypes are remarkably similar to that observed in humans with the classic form of MSUD .
# ::tok These phenotypes are remarkably similar to that observed in humans with the classic form of MSUD .
# ::alignments 13-14|0.2.0.1 12-13|0.2.0.1.0 9-10|0.2.0.0 7-8|0.2.0 6-7|0.2 4-5|0 3-4|0.1 1-2|0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:26.453
(r / resemble-01 
      :ARG1 (p / phenotyp 
            :mod (t2 / this)) 
      :ARG1-of (r2 / remarkable-02) 
      :ARG2 (t / that 
            :ARG1-of (o / observe-01 
                  :location (h / human) 
                  :prep-in (f / form 
                        :mod (c / classic)))))

# ::snt Thus , E2 knockout mice closely model classic MSUD .
# ::tok Thus , E2 knockout mice closely model classic MSUD .
# ::alignments 7-8|0.1 6-7|0 5-6|0.2 4-5|0.0 3-4|0.0.0 2-3|0.0.1.0.0+0.0.1.0+0.0.1 0-1|0.3 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:26.495
(m / model-01 
      :ARG0 (m2 / mouse 
            :mod (k / knockout) 
            :mod (t / thing 
                  :name (n / name 
                        :op1 "E2"))) 
      :ARG1 (c / classic) 
      :manner (c2 / close) 
      :manner (t2 / thu))

# ::snt Knockout mice expressing a human E2 transgene model a variant form of MSUD that mimics intermediate MSUD .
# ::tok Knockout mice expressing a human E2 transgene model a variant form of MSUD that mimics intermediate MSUD .
# ::alignments 15-16|0.1 14-15|0 10-11|0.2 9-10|0.2.0 7-8|0.0 6-7|0.0.1 5-6|0.0.2.0.0+0.0.2.0+0.0.2 4-5|0.0.3 2-3|0.0.0 1-2|0.0.0.0 0-1|0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:26.856
(m / mimic-01 
      :ARG0 (m2 / model 
            :ARG1-of (e / express-01 
                  :ARG0 (m3 / mouse 
                        :mod (k / knockout))) 
            :mod (t / transgene) 
            :mod (t2 / thing 
                  :name (n / name 
                        :op1 "E2")) 
            :mod (h / human)) 
      :ARG1 (i / intermediate) 
      :ARG2 (f / form 
            :mod (v / variant)))

# ::snt To create a murine model of the intermediate variant form of MSUD , we used a transgenic strategy to rescue the severe elevation of BCAA and neonatal lethality that occurs in the classic MSUD mouse model .
# ::tok To create a murine model of the intermediate variant form of MSUD , we used a transgenic strategy to rescue the severe elevation of BCAA and neonatal lethality that occurs in the classic MSUD mouse model .
# ::alignments 35-36|0.0.0.0.1.0.0 34-35|0.0.0.0.1.0.0.1 32-33|0.0.0.0.1.0.0.0 29-30|0.0.0.0.1.0 27-28|0.0 26-27|0 25-26|0.0.0 24-25|0.0.0.1.0.0+0.0.0.1.0+0.0.0.1 22-23|0.0.0.0.1 21-22|0.0.0.0.1.1 19-20|0.0.0.0 17-18|0.0.0.0.0 14-15|0.0.0.0.2 13-14|0.0.0.0.2.0 9-10|0.0.0.0.1.2 8-9|0.0.0.0.1.2.0 7-8|0.0.0.0.1.2.1 4-5|0.0.0.0.2.1 3-4|0.0.0.0.2.1.1 1-2|0.0.0.0.2.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:27.817
(n / neonatal 
      :mod-of (l / lethality 
            :op3-of (a / and 
                  :op1 (r / rescue-01 
                        :ARG0 (s2 / strategy) 
                        :ARG1 (e / elevation 
                              :ARG1-of (o / occur-01 
                                    :location (m / model 
                                          :mod (c / classic) 
                                          :mod (m2 / mouse))) 
                              :mod (s / severe) 
                              :poss (f / form 
                                    :mod (v / variant) 
                                    :mod (i / intermediate))) 
                        :ARG2-of (u / use-01 
                              :ARG0 (w / we) 
                              :ARG1 (m3 / model 
                                    :ARG1-of (c3 / create-01) 
                                    :mod (m4 / murine)))) 
                  :op2 (c2 / country 
                        :name (n2 / name 
                              :op1 "BCAA")))))

# ::snt Our strategy was composed of a two part transgenic system to express human E2 in liver on the E2 knockout background .
# ::tok Our strategy was composed of a two part transgenic system to express human E2 in liver on the E2 knockout background .
# ::alignments 20-21|0.0.0.0.2.0 19-20|0.0.0.0.2 15-16|0.0.0.1 13-14|0.0.0.0.1.0+0.0.0.0.1+0.0.0.0 12-13|0.0.0.0.0 11-12|0.0.0 9-10|0.1 8-9|0.1.0 6-7|0.1.1 3-4|0 1-2|0.0 0-1|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:27.949
(c / compose-01 
      :ARG1 (s2 / strategy 
            :ARG0-of (e / express-01 
                  :ARG1 (t / thing 
                        :mod (h / human) 
                        :name (n / name 
                              :op1 "E2") 
                        :prep-with (k / knockout 
                              :mod-of (b / background))) 
                  :manner (l / liver)) 
            :poss (w / we)) 
      :ARG2 (s / system 
            :mod (t2 / transgenic) 
            :quant 2))

# ::snt This bi-transgenic system consisted of a LAP-tTA transgene and a TRE-E2 transgene ( Fig. 3A ) .
# ::tok This bi-transgenic system consisted of a LAP-tTA transgene and a TRE-E2 transgene ( Fig. 3A ) .
# ::alignments 13-14|0.1.2.0.0+0.1.2.0+0.1.2 11-12|0.1.1 10-11|0.1.1.0.0.0+0.1.1.0.0+0.1.1.0 8-9|0.1 7-8|0.1.0 6-7|0.1.0.0.0.0+0.1.0.0.0+0.1.0.0 3-4|0 2-3|0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:28.017
(c3 / consist-01 
      :ARG0 (s / system 
            :mod (t4 / this)) 
      :ARG2 (a / and 
            :op1 (t3 / transgene 
                  :mod (c2 / country 
                        :name (n3 / name 
                              :op1 "LAP-tTA"))) 
            :op2 (t / transgene 
                  :mod (t2 / thing 
                        :name (n2 / name 
                              :op1 "TRE-E2"))) 
            :op3 (c / country 
                  :name (n / name 
                        :op1 "Fig."))))

# ::snt The LAP-tTA transgene [ 34 ] directs high levels of liver specific expression of the tetracycline-controlled transactivator ( tTA ) , a transcription factor that stimulates expression of promoters that harbor a transactivator response element ( TRE ) .
# ::tok The LAP-tTA transgene [ 34 ] directs high levels of liver specific expression of the tetracycline-controlled transactivator ( tTA ) , a transcription factor that stimulates expression of promoters that harbor a transactivator response element ( TRE ) .
# ::alignments 34-35|0.2 33-34|0 30-31|0.2.0 28-29|0.2.0.0.1+0.2.0.0 26-27|0.2.0.0.2 25-26|0.2.0.0.2.1 23-24|0.3 22-23|0.1 16-17|0.2.0.0.0.0 15-16|0.2.0.0.0.0.0 12-13|0.2.0.0.0 11-12|0.2.0.0.0.1 10-11|0.2.0.0.0.1.0 8-9|0.2.0.0.0.2 7-8|0.2.0.0.0.2.1 6-7|0.2.0.0.0.2.0 4-5|0.2.0.0.2.0 2-3|0.0.0 1-2|0.0.1.0+0.0.1+0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:29.183
(r / respond-01 
      :ARG0 (c / country 
            :mod-of (t4 / transgene) 
            :name (n / name 
                  :op1 "LAP-tTA")) 
      :ARG1 (t / transcription) 
      :mod-of (e / element 
            :ARG1-of (h / harbor-01 
                  :ARG0 (p / person 
                        :ARG0-of (e3 / express-01 
                              :ARG1 (t2 / transactivator 
                                    :mod (t3 / tetracycline-controll)) 
                              :ARG2-of (s2 / specific-02 
                                    :ARG0 (l / liver)) 
                              :source-of (l2 / level 
                                    :ARG1-of (d / direct-01) 
                                    :ARG1-of (h2 / high-02))) 
                        :ARG0-of (p2 / promote-02) 
                        :ARG0-of (e2 / express-01 
                              :ARG1 34 
                              :ARG1-of (s / stimulate-01))))) 
      :part (f / factor))

# ::snt The TRE-E2 transgene was designed to express a human E2 cDNA from a TRE containing minimal promoter upon stimulation by tTA .
# ::tok The TRE-E2 transgene was designed to express a human E2 cDNA from a TRE containing minimal promoter upon stimulation by tTA .
# ::alignments 20-21|0 18-19|0.0.0.0.0 16-17|0.0.0.0 15-16|0.0.0.0.1 14-15|0.0.0.0.2 10-11|0.0.1.0 9-10|0.0.1.0.0.1.0+0.0.1.0.0.1+0.0.1.0.0 8-9|0.0.1.0.0.0 6-7|0.0.1 4-5|0.0 2-3|0.0.0 1-2|0.0.0.1.0.0+0.0.0.1.0+0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:29.442
(t / tTA 
      :ARG0-of (d / design-01 
            :ARG1 (t3 / transgene 
                  :ARG1-of (p / promote-01 
                        :ARG0 (s / stimulation) 
                        :ARG1-of (m / minimal-02) 
                        :ARG1-of (c / contain-01)) 
                  :mod (t4 / thing 
                        :name (n2 / name 
                              :op1 "TRE-E2"))) 
            :ARG3 (e / express-01 
                  :ARG1 (c2 / cdna 
                        :mod (t2 / thing 
                              :mod (h / human) 
                              :name (n / name 
                                    :op1 "E2"))))))

# ::snt Transgenic mouse production and characterization .
# ::tok Transgenic mouse production and characterization .
# ::alignments 4-5|0.1 3-4|0 2-3|0.0 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:29.454
(a / and 
      :op1 (p / produce-01 
            :ARG1 (m / mouse)) 
      :op2 (c / characterization))

# ::snt A , Transgenic strategy used to produce mice that express human E2 .
# ::tok A , Transgenic strategy used to produce mice that express human E2 .
# ::alignments 11-12|0.1.0.0.0.1.0+0.1.0.0.0.1+0.1.0.0.0 10-11|0.1.0.0.0.0 9-10|0.1.0.0 7-8|0.1.0 6-7|0.1 4-5|0 3-4|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:29.506
(u / use-01 
      :ARG0 (s / strategy) 
      :ARG2 (p / produce-01 
            :ARG1 (m / mouse 
                  :ARG0-of (e / express-01 
                        :ARG1 (t / thing 
                              :mod (h / human) 
                              :name (n / name 
                                    :op1 "E2"))))))

# ::snt LAP-tTA transgenic mice have been previously described [ 34 ] .
# ::tok LAP-tTA transgenic mice have been previously described [ 34 ] .
# ::alignments 8-9|0.0.1 6-7|0 5-6|0.1 2-3|0.0 0-1|0.0.0.0.0+0.0.0.0+0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:29.581
(d / describe-01 
      :ARG1 (m / mouse 
            :mod (c / country 
                  :name (n / name 
                        :op1 "LAP-tTA")) 
            :op1-of 34) 
      :time (p / previous))

# ::snt These mice express the tetracycline-controlled transactivator ( tTA ) from the liver specific LAP promoter .
# ::tok These mice express the tetracycline-controlled transactivator ( tTA ) from the liver specific LAP promoter .
# ::alignments 14-15|0.2 13-14|0.2.0 12-13|0.2.1 11-12|0.2.1.0 5-6|0.1 4-5|0.1.0 2-3|0 1-2|0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:29.730
(e / express-01 
      :ARG0 (m / mouse 
            :mod (t3 / this)) 
      :ARG1 (t / transactivator 
            :mod (t2 / tetracycline-controll)) 
      :manner (p / promote-01 
            :ARG1 (l / lap-01) 
            :ARG1-of (s / specific-02 
                  :ARG0 (l2 / liver))))

# ::snt The TRE-E2 transgene contains the tetracycline response element ( TRE ) as part of the promoter , a synthetic intron ( thin line ) , the human E2 cDNA , an alanine spacer , a c-myc epitope tag , and SV40 derived polyadenylation sequence .
# ::tok The TRE-E2 transgene contains the tetracycline response element ( TRE ) as part of the promoter , a synthetic intron ( thin line ) , the human E2 cDNA , an alanine spacer , a c-myc epitope tag , and SV40 derived polyadenylation sequence .
# ::alignments 43-44|0.1.0.0.5 42-43|0.1.0.0.5.0 41-42|0.1.0.0.4.0 40-41|0.1.0.0.4.1.0+0.1.0.0.4.1+0.1.0.0.4 39-40|0.1.0.0 37-38|0.1.0.0.3 36-37|0.1.0.0.3.0 32-33|0.1.0.0.2 31-32|0.1.0.0.2.0 28-29|0.1.0.0.1 27-28|0.1.0.0.1.0.1.0+0.1.0.0.1.0.1+0.1.0.0.1.0 26-27|0.1.0.0.1.0.0 22-23|0.1.1.1.0 21-22|0.1.1.1 19-20|0.1.0.0.0 18-19|0.1.1.0 15-16|0.1.0 7-8|0.1 6-7|0.1.1 5-6|0.1.2 3-4|0 2-3|0.0 1-2|0.0.0.0.0+0.0.0.0+0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:30.306
(c2 / contain-01 
      :ARG0 (t6 / transgene 
            :mod (t7 / thing 
                  :name (n3 / name 
                        :op1 "TRE-E2"))) 
      :ARG1 (e2 / element 
            :ARG1-of (p2 / promote-01 
                  :op1-of (a / and 
                        :op2 (i / intron) 
                        :op3 (c / cdna 
                              :mod (t3 / thing 
                                    :mod (h / human) 
                                    :name (n2 / name 
                                          :op1 "E2"))) 
                        :op4 (s2 / space-01 
                              :mod (a2 / alanine)) 
                        :op5 (t2 / tag-01 
                              :ARG1 (e / epitope)) 
                        :op6 (t / thing 
                              :ARG1-of (d / derive-01) 
                              :name (n / name 
                                    :op1 "SV40")) 
                        :op7 (s / sequence 
                              :mod (p / polyadenylation)))) 
            :mod (r / respond-01 
                  :ARG0 (s3 / synthetic) 
                  :ARG1 (t4 / thin-03 
                        :ARG1 (l / line))) 
            :mod (t5 / tetracycline)))

# ::snt This construct was used to create several lines of transgenic mice .
# ::tok This construct was used to create several lines of transgenic mice .
# ::alignments 10-11|0.1.0.0 7-8|0.1.0 6-7|0.1.0.1 5-6|0.1 3-4|0 1-2|0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:30.341
(u / use-01 
      :ARG1 (c2 / construct-01 
            :ARG1 (t / this)) 
      :ARG2 (c / create-01 
            :ARG1 (l / line 
                  :consist-of (m / mouse) 
                  :quant (s / several))))

# ::snt B , Western blot analysis of E2 protein in liver of control and intermediate MSUD mice .
# ::tok B , Western blot analysis of E2 protein in liver of control and intermediate MSUD mice .
# ::alignments 15-16|0.2 13-14|0.2.0 12-13|0 11-12|0.1 9-10|0.1.1 7-8|0.0.0.0 4-5|0.0.0 3-4|0.0 2-3|0.0.0.1.1+0.0.0.1.0.0+0.0.0.1.0+0.0.0.1 0-1|0.1.0.1+0.1.0.0.0+0.1.0.0+0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:30.842
(a / and 
      :ARG1-of (b / blot-01 
            :ARG2-of (a2 / analyze-01 
                  :ARG1 (p / protein) 
                  :manner (w / world-region 
                        :name (n / name 
                              :op1 "West") 
                        :wiki "Western_world"))) 
      :op1 (c / control-01 
            :ARG1 (l2 / location 
                  :name (n2 / name 
                        :op1 "B") 
                  :wiki -) 
            :topic-of (l / liver)) 
      :op2 (m / mouse 
            :mod (i / intermediate)))

# ::snt Note that the amount of human E2 protein ( predicted MW ~ 54 Kd ) in mice from Lines A and 525 A was variable but in many of the animals the amount was similar to the amount of mouse E2 ( MW = ~ 47 Kd ) in control animals .
# ::tok Note that the amount of human E2 protein ( predicted MW ~ 54 Kd ) in mice from Lines A and 525 A was variable but in many of the animals the amount was similar to the amount of mouse E2 ( MW = ~ 47 Kd ) in control animals .
# ::alignments 50-51|0.0.0 49-50|0.0 45-46|0.1.0.1.0.1.0 39-40|0.1.0.1.0.0 37-38|0.1.0.1.0.1.2 34-35|0.1.0.1.0.1 32-33|0.1.0.1.0.1.1 30-31|0.1.0.1.0.1.3 27-28|0.1.0.1.0.1.3.0 25-26|0 21-23|0.1.2.0.1+0.1.2.0.0+0.1.2.0+0.1.2 20-21|0.1 18-20|0.1.1.0.1+0.1.1.0.0+0.1.1.0+0.1.1 16-17|0.2 12-13|0.1.0.0 9-10|0.1.0.1.0 7-8|0.1.0.1 6-7|0.1.0.1.1.1.0+0.1.0.1.1.1+0.1.0.1.1 5-6|0.1.0.1.1.0 3-4|0.1.0.1.2 0-1|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:31.583
(c2 / contrast-01 
      :ARG1 (c / control-01 
            :ARG1 (a / animal)) 
      :ARG2 (a6 / and 
            :op1 (n4 / note-01 
                  :ARG0 54 
                  :ARG1 (p2 / protein 
                        :ARG1-of (p / predict-01 
                              :ARG0 (m / mouse) 
                              :ARG2 (r / resemble-01 
                                    :ARG0 47 
                                    :ARG1 (a3 / amount) 
                                    :ARG2 (a2 / amount) 
                                    :topic (a4 / animal 
                                          :quant (m2 / many)))) 
                        :mod (t3 / thing 
                              :mod (h / human) 
                              :name (n3 / name 
                                    :op1 "E2")) 
                        :quant (a7 / amount))) 
            :op2 (t2 / thing 
                  :name (n2 / name 
                        :op1 "Lines" 
                        :op2 "A")) 
            :op3 (t / thing 
                  :name (n / name 
                        :op1 525 
                        :op2 (a5 / A)))) 
      :domain-of (m3 / mouse))

# ::snt Re-probing with a c-myc tag antibody confirmed the presence of the transgene derived , c-myc tagged , human E2 in transgenic mice but not in controls .
# ::tok Re-probing with a c-myc tag antibody confirmed the presence of the transgene derived , c-myc tagged , human E2 in transgenic mice but not in controls .
# ::alignments 25-26|0.0.0 23-24|0.1.0.0.0.1.0 22-23|0 21-22|0.1.0.0.0.0 18-19|0.0.3.0+0.0.3+0.0 17-18|0.0.2 15-16|0.0.1 12-13|0.1.0.0.0.1 11-12|0.0.0.0 8-9|0.1.1 6-7|0.1 5-6|0.1.0.0 4-5|0.1.0.0.0 0-1|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:31.995
(c2 / contrast-01 
      :ARG1 (t / thing 
            :ARG1-of (c / control-01 
                  :ARG0 (t3 / transgene)) 
            :ARG1-of (t2 / tag-01) 
            :mod (h / human) 
            :name (n / name 
                  :op1 "E2")) 
      :ARG2 (c3 / confirm-01 
            :ARG0 (r / re-prob 
                  :prep-with (a / antibody 
                        :ARG1-of (t4 / tag-01 
                              :ARG0 (m / mouse) 
                              :ARG1-of (d / derive-01 
                                    :ARG0 -)))) 
            :ARG1 (p / presence)))

# ::snt Western blot analysis of brain ( C ) , kidney ( D ) , and muscle ( E ) revealed negligible amounts of transgene derived E2 in those tissues .
# ::tok Western blot analysis of brain ( C ) , kidney ( D ) , and muscle ( E ) revealed negligible amounts of transgene derived E2 in those tissues .
# ::alignments 28-29|0.2 25-26|0.1.1.2.0+0.1.1.2+0.1.1 24-25|0.1.1.0 23-24|0.1.1.1 21-22|0.1 20-21|0.1.0 19-20|0 17-18|0.3.1.0 15-16|0.0.1 14-15|0.0 11-12|0.1.1.0.1 9-10|0.0.0 6-7|0.1.1.0.0 4-5|0.3.0 2-3|0.3 1-2|0.3.1 0-1|0.3.2.1+0.3.2.0.0+0.3.2.0+0.3.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:32.972
(r / reveal-01 
      :ARG0 (a2 / and 
            :op1 (k / kidney) 
            :op2 (m / muscle-01)) 
      :ARG1 (a / amount 
            :mod (n2 / negligible) 
            :quant-of (t2 / thing 
                  :ARG2-of (d / derive-01 
                        :ARG0 (c / C) 
                        :ARG1 (d2 / D)) 
                  :mod (t3 / transgene) 
                  :name (n / name 
                        :op1 "E2"))) 
      :medium (t / tissue) 
      :topic (a3 / analyze-01 
            :ARG1 (b / brain) 
            :ARG2 (b2 / blot-01 
                  :ARG1 (e / E)) 
            :manner (w / world-region 
                  :name (n3 / name 
                        :op1 "West") 
                  :wiki "Western_world")))

# ::snt All blots were re-probed with an actin antibody to allow amount of protein loaded in each lane to be compared .
# ::tok All blots were re-probed with an actin antibody to allow amount of protein loaded in each lane to be compared .
# ::alignments 19-20|0.0 16-17|0 15-16|0.1 13-14|0.0.0.0 12-13|0.0.0.1 10-11|0.0.0 9-10|0.0.0.0.1 7-8|0.0.0.0.0 6-7|0.0.0.0.0.0 1-2|0.0.0.0.1.0 0-1|0.0.0.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:33.198
(l / lane-01 
      :ARG1-of (c / compare-01 
            :ARG0 (a / amount 
                  :ARG1-of (l2 / load-01 
                        :ARG0 (a3 / antibody 
                              :mod (a4 / actin)) 
                        :ARG1-of (a2 / allow-01 
                              :ARG0 (b / blot-01 
                                    :mod (a5 / all)))) 
                  :quant-of (p / protein))) 
      :mod (e / each))

# ::snt LAP-tTA mice were previously produced and characterized by the Bujard laboratory [ 34 ] .
# ::tok LAP-tTA mice were previously produced and characterized by the Bujard laboratory [ 34 ] .
# ::alignments 12-13|0.1.0 10-11|0.0.0 9-10|0.0.1.0+0.0.1+0.0 6-7|0.1 5-6|0 4-5|0.1.1.0 3-4|0.1.1.0.0 1-2|0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:33.262
(a / and 
      :manner (t / thing 
            :mod-of (l / laboratory) 
            :name (n / name 
                  :op1 "Bujard")) 
      :op1 (c / characterize-01 
            :ARG0 34 
            :ARG1 (m / mouse 
                  :ARG1-of (p / produce-01 
                        :time (p2 / previous)))))

# ::snt Pronuclear microinjection was used to produce transgenic mice that harbored the TRE-E2 transgene .
# ::tok Pronuclear microinjection was used to produce transgenic mice that harbored the TRE-E2 transgene .
# ::alignments 12-13|0.1.0.0.0 11-12|0.1.0.0.0.0.0.0+0.1.0.0.0.0.0+0.1.0.0.0.0 9-10|0.1.0.0 7-8|0.1.0 5-6|0.1 3-4|0 0-2|0.0.0.1+0.0.0.0+0.0.0+0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:33.481
(u / use-01 
      :ARG1 (t3 / thing 
            :name (n2 / name 
                  :op1 (p2 / Pronuclear) 
                  :op2 (m2 / microinjection))) 
      :ARG2 (p / produce-01 
            :ARG1 (m / mouse 
                  :ARG0-of (h / harbor-01 
                        :ARG1 (t / transgene 
                              :mod (t2 / thing 
                                    :name (n / name 
                                          :op1 "TRE-E2"))))) 
            :ARG0 t3))

# ::snt From injections at the University of Pittsburgh , 2 transgene positive founders were identified that led to the generation of 3 different transgenic lines ( Lines A , B , & D ) .
# ::tok From injections at the University of Pittsburgh , 2 transgene positive founders were identified that led to the generation of 3 different transgenic lines ( Lines A , B , & D ) .
# ::alignments 31-32|0 28-29|0.0.0.0.1.0.0.0.1+0.0.0.0.1.0.0.0.0.0+0.0.0.0.1.0.0.0.0+0.0.0.0.1.0.0.0 25-27|0.0.0.0.0.1.0.1+0.0.0.0.0.1.0.0+0.0.0.0.0.1.0+0.0.0.0.0.1 23-24|0.0.0.0.1.0 21-22|0.0.0.0.0 20-21|0.0.0.0.1.0.0 18-19|0.0.0.0.1 15-16|0.0.0.0 13-14|0.0 11-12|0.0.0.1+0.0.0 10-11|0.0.0.2 9-10|0.0.0.3 8-9|0.0.0.4 6-7|0.0.0.0.0.0.1+0.0.0.0.0.0.0.0+0.0.0.0.0.0.0+0.0.0.0.0.0 1-2|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:33.876
(d / D 
      :ARG0-of (i / identify-01 
            :ARG1 (p / person 
                  :ARG0-of (l3 / lead-02 
                        :ARG1 (d2 / differ-02 
                              :ARG0 (c / city 
                                    :name (n3 / name 
                                          :op1 "Pittsburgh") 
                                    :wiki "Pittsburgh") 
                              :ARG1 (t / thing 
                                    :name (n2 / name 
                                          :op1 "Lines" 
                                          :op2 "A"))) 
                        :ARG2 (g / generation 
                              :consist-of (l2 / line 
                                    :quant (3 / 3 
                                          :li-of (l / location 
                                                :name (n / name 
                                                      :op1 "B") 
                                                :wiki -))))) 
                  :ARG0-of (f / found-01) 
                  :mod (p2 / positive) 
                  :mod (t2 / transgene) 
                  :quant 2) 
            :ARG2 (i2 / injection)))

# ::snt From the injections at the University of Cincinnati , we obtained 8 transgene positive founders .
# ::tok From the injections at the University of Cincinnati , we obtained 8 transgene positive founders .
# ::alignments 14-15|0.1.0+0.1 13-14|0.1.1 12-13|0.1.2 11-12|0.1.2.0 10-11|0 9-10|0.0 5-8|0.2.0.0.2+0.2.0.0.1+0.2.0.0.0+0.2.0.0+0.2.0 2-3|0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:33.941
(o / obtain-01 
      :ARG0 (w / we) 
      :ARG1 (p / person 
            :ARG0-of (f / found-01) 
            :mod (p2 / positive) 
            :mod (t / transgene 
                  :quant 8)) 
      :manner (i / injection 
            :location (o2 / organization 
                  :name (n / name 
                        :op1 "University" 
                        :op2 "of" 
                        :op3 "Cincinnati"))))

# ::snt Subsequent breeding of these founders revealed that many of the animals had multiple transgene insertion sites that segregated .
# ::tok Subsequent breeding of these founders revealed that many of the animals had multiple transgene insertion sites that segregated .
# ::alignments 17-18|0.2 15-16|0.2.0 14-15|0.2.0.0 13-14|0.2.0.1 12-13|0.2.0.2 10-11|0.2.1 7-8|0.2.1.0 5-6|0 4-5|0.1.0+0.1 3-4|0.1.1 1-2|0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:34.463
(r / reveal-01 
      :ARG0 (b / breed-01 
            :mod (s3 / subsequent)) 
      :ARG1 (p / person 
            :ARG0-of (f / found-01) 
            :mod (t2 / this)) 
      :time (s / segregate-01 
            :ARG0 (s2 / site 
                  :ARG1-of (i / insert-01) 
                  :mod (t / transgene) 
                  :quant (m / multiple)) 
            :ARG1 (a / animal 
                  :quant (m2 / many))))

# ::snt We established a total of 15 different transgenic lines from these founders .
# ::tok We established a total of 15 different transgenic lines from these founders .
# ::alignments 11-12|0.0.0.0.0+0.0.0.0 10-11|0.0.0.0.1 8-9|0.1 6-7|0.0.0.0.1.0 5-6|0.1.0 3-4|0.0.0 1-2|0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:34.508
(e / establish-01 
      :ARG0 (w / we 
            :ARG0-of (t2 / total-01 
                  :ARG1 (p / person 
                        :ARG0-of (f / found-01) 
                        :mod (t / this 
                              :ARG1-of (d / differ-02))))) 
      :ARG1 (l / line 
            :quant 15))

# ::snt Limited resources allowed us to only focus on a total of 9 of these lines .
# ::tok Limited resources allowed us to only focus on a total of 9 of these lines .
# ::alignments 14-15|0.0.1 13-14|0.0.1.0 11-12|0.0.1.1 9-10|0.0.2 6-7|0.0 5-6|0.0.3 2-3|0 1-2|0.0.0 0-1|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:34.553
(a / allow-01 
      :ARG1 (f / focus-01 
            :ARG0 (r / resource 
                  :mod "Limited") 
            :ARG1 (l / line 
                  :mod (t / this) 
                  :quant 9) 
            :ARG2 (t2 / total-01) 
            :mod (o / only)))

# ::snt These lines differed substantially in transgene copy number as compared by Southern blot analysis of tail DNA ( data not shown ) .
# ::tok These lines differed substantially in transgene copy number as compared by Southern blot analysis of tail DNA ( data not shown ) .
# ::alignments 20-21|0 19-20|0.3 18-19|0.1 16-17|0.2.1.1 15-16|0.2.1.1.0 13-14|0.2.1 12-13|0.2.1.2 11-12|0.2.1.0.0.0+0.2.1.0.0+0.2.1.0 9-10|0.2 7-8|0.2.1.3.1 6-7|0.2.1.3.0+0.2.1.3 5-6|0.0 3-4|0.2.0.0.0 2-3|0.2.0.0 1-2|0.2.0 0-1|0.2.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:35.091
(s / show-01 
      :ARG0 (t4 / transgene) 
      :ARG1 (d / data) 
      :ARG1-of (c / compare-01 
            :ARG0 (l / line 
                  :ARG1-of (d3 / differ-01 
                        :manner (s2 / substantial)) 
                  :mod (t5 / this)) 
            :ARG2 (a / analyze-01 
                  :ARG0 (t2 / thing 
                        :name (n / name 
                              :op1 "Southern")) 
                  :ARG1 (d2 / DNA 
                        :ARG1-of (t / tail-01)) 
                  :ARG1-of (b / blot-01) 
                  :ARG2 (t3 / thing 
                        :ARG2-of (c2 / copy-01) 
                        :mod-of (n2 / number)))) 
      :polarity -)

# ::snt Transgenic TRE-E2 mice from each line ( either founders or F1 offspring ) were crossed to mice that were positive for the LAP-tTA transgene and were heterozygous for the E2 knockout .
# ::tok Transgenic TRE-E2 mice from each line ( either founders or F1 offspring ) were crossed to mice that were positive for the LAP-tTA transgene and were heterozygous for the E2 knockout .
# ::alignments 30-31|0.0.1.2.0 29-30|0.0.1.2.1.0+0.0.1.2.1+0.0.1.2 26-27|0.1 24-25|0 23-24|0.0.1.2.2 22-23|0.0.1.2.2.1.0.0+0.0.1.2.2.1.0+0.0.1.2.2.1 19-20|0.0.1.2.2.0 16-17|0.0.1.2.2.0.0 14-15|0.0.1.2.2.0.0.0 11-12|0.0.1.1 10-11|0.0.1.1.0 9-10|0.0.1 8-9|0.0.0+0.0 7-8|0.0.1.0 5-6|0.0.1.2.2.0.0.0.0.1 4-5|0.0.1.2.2.0.0.0.0.1.0 2-3|0.0.1.2.2.0.0.0.0 1-2|0.0.1.2.2.0.0.0.0.0.0.0+0.0.1.2.2.0.0.0.0.0.0+0.0.1.2.2.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:35.367
(a / and 
      :op1 (p2 / person 
            :ARG0-of (f2 / found-01) 
            :op1-of (o2 / or 
                  :mod (e / either) 
                  :op2 (o / offspr 
                        :mod (f / F1)) 
                  :op3 (t / thing 
                        :mod-of (k / knockout) 
                        :name (n / name 
                              :op1 "E2") 
                        :op1-of (t2 / transgene 
                              :domain-of (p / positive 
                                    :domain (m / mouse 
                                          :ARG2-of (c2 / cross-02 
                                                :ARG1 (m2 / mouse 
                                                      :mod (t3 / thing 
                                                            :name (n3 / name 
                                                                  :op1 "TRE-E2")) 
                                                      :source (l / line 
                                                            :mod (e2 / each)))))) 
                              :mod (c / country 
                                    :name (n2 / name 
                                          :op1 "LAP-tTA")))))) 
      :op2 (h / heterozygou))

# ::snt Ultimately , breeding pairs were used in which the mice were heterozygous for the LAP-tTA transgene , the TRE-E2 transgene , and the E2 knockout .
# ::tok Ultimately , breeding pairs were used in which the mice were heterozygous for the LAP-tTA transgene , the TRE-E2 transgene , and the E2 knockout .
# ::alignments 24-25|0.0.2 23-24|0.0.2.0.0.0+0.0.2.0.0+0.0.2.0 21-22|0.0 19-20|0.0.1 18-19|0.0.1.0.0.0+0.0.1.0.0+0.0.1.0 15-16|0.0.0 14-15|0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 11-12|0.2 9-10|0.2.0 5-6|0 3-4|0.1 2-3|0.1.0 0-1|0.3 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:35.855
(u / use-01 
      :ARG0 (a / and 
            :op1 (t4 / transgene 
                  :mod (c / country 
                        :name (n3 / name 
                              :op1 "LAP-tTA"))) 
            :op2 (t2 / transgene 
                  :mod (t3 / thing 
                        :name (n2 / name 
                              :op1 "TRE-E2"))) 
            :op3 (k / knockout 
                  :mod (t / thing 
                        :name (n / name 
                              :op1 "E2")))) 
      :ARG1 (p / pair-01 
            :ARG1 (b / breed-01)) 
      :ARG2 (h / heterozygou 
            :domain (m / mouse)) 
      :mod (u2 / ultimate))

# ::snt To efficiently screen for the ability of the transgenes to rescue the knockout from neonatal lethality , we genotyped litters at weaning .
# ::tok To efficiently screen for the ability of the transgenes to rescue the knockout from neonatal lethality , we genotyped litters at weaning .
# ::alignments 21-22|0.0.0.2.0.0.0.0 19-20|0.0.0.2.0.0.0 17-18|0.0.0.2.0.0 15-16|0.0 14-15|0 12-13|0.0.0.1 10-11|0.0.0 8-9|0.0.0.0 5-6|0.0.0.2 2-3|0.0.0.2.0.1 1-2|0.0.0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:36.008
(n / neonatal 
      :mod-of (l2 / lethality 
            :ARG2-of (r / rescue-01 
                  :ARG0 (t / transgen) 
                  :ARG1 (k / knockout) 
                  :purpose-of (a / ability 
                        :ARG2-of (e / efficient-01 
                              :ARG0 (w2 / we 
                                    :ARG0-of (l / litter-01 
                                          :ARG1 (w / wean-01))) 
                              :ARG1 (s / screen))))))

# ::snt This breeding strategy is expected to result in a theoretical maximum of animals with the rescue genotype ( i.e. , homozygous E2 knockout and positive for both transgenes ) of 14 % .
# ::tok This breeding strategy is expected to result in a theoretical maximum of animals with the rescue genotype ( i.e. , homozygous E2 knockout and positive for both transgenes ) of 14 % .
# ::alignments 31-32|0.2 30-31|0.2.0 27-28|0.0.2.0.0.0 26-27|0.0.2.0.0 24-25|0.0.2.0.0.0.0 23-24|0 22-23|0.0.0.0.0 20-21|0.1 18-19|0.0.1.0 16-17|0.0.2.3 15-16|0.0.2.0 12-13|0.0.2.1 10-11|0.0.2 9-10|0.0.2.2 6-7|0.0 4-5|0.0.1 2-3|0.0.0 1-2|0.0.0.0 0-1|0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:36.281
(a / and 
      :ARG1-of (r2 / result-01 
            :ARG0 (s / strategy 
                  :ARG1-of (b2 / breed-01 
                        :ARG0 (k / knockout)) 
                  :mod (t3 / this)) 
            :ARG1-of (e / expect-01 
                  :ARG0 (i / i.e.)) 
            :ARG2 (m / maximum 
                  :ARG0-of (r / rescue-01 
                        :ARG1 (b / both 
                              :mod-of (t / transgen 
                                    :time-of (p2 / positive)))) 
                  :mod (a2 / animal) 
                  :mod (t2 / theory) 
                  :prep-with (g / genotype))) 
      :op1 (h / homozygou) 
      :poss-of (p / percentage-entity 
            :value 14))

# ::snt Fig. 4A shows the percentage of mice alive at weaning with the rescue genotype from each transgenic line tested .
# ::tok Fig. 4A shows the percentage of mice alive at weaning with the rescue genotype from each transgenic line tested .
# ::alignments 18-19|0.3.1.0 17-18|0.3.1.0.0 15-16|0.3.1.0.0.0 13-14|0.3.1 12-13|0.2 9-10|0.3 7-8|0.3.2 6-7|0.3.0 4-5|0.1 2-3|0 0-1|0.0.0.0+0.0.0+0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:36.503
(s / show-01 
      :ARG0 (c / country 
            :name (n / name 
                  :op1 "Fig.")) 
      :ARG1 (p / percentage) 
      :ARG2 (r / rescue-01) 
      :concession-of (w / wean-01 
            :ARG1 (m / mouse) 
            :ARG2 (g / genotype 
                  :ARG0-of (t / test-01 
                        :ARG1 (l / line 
                              :mod (e / each)))) 
            :compared-to-of (a / alive)))

# ::snt Considerable variability was observed between lines .
# ::tok Considerable variability was observed between lines .
# ::alignments 5-6|0.0 3-4|0 1-2|0.1 0-1|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:36.517
(o / observe-01 
      :ARG0 (l / line) 
      :ARG1 (v / variability 
            :mod (c / considerable)))

# ::snt The line with the highest percentage of rescue mice at weaning was line 525 A. Approximately 10 % of weaned , surviving pups from this line had the rescue genotype .
# ::tok The line with the highest percentage of rescue mice at weaning was line 525 A. Approximately 10 % of weaned , surviving pups from this line had the rescue genotype .
# ::alignments 29-30|0.0.0.0.0.1.0 28-29|0.0.0.0.0.0 25-26|0.0.0.0.0 24-25|0.0.0.0.0.1 22-23|0.0.0.0 21-22|0.0.0.0.1 19-20|0.0.0.0.1.0 17-18|0.0.0.0.1.0.1 16-17|0.0.0.0.1.0.1.1 15-16|0.0.0.0.1.0.1.0 12-13|0.0.0.0.0.0.0.0 10-11|0.0.0.0.0.0.0.1 8-9|0 7-8|0.0.0.0.0.0.0 5-6|0.0 4-5|0.0.0.1+0.0.0 1-2|0.0.0.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:36.759
(m / mouse 
      :part (p3 / percentage 
            :ARG1-of (h / high-02 
                  :ARG1-of (p / pup-01 
                        :ARG0 (l / line 
                              :ARG0-of (r / rescue-01 
                                    :ARG1 (r2 / rescue-01 
                                          :ARG1 (l2 / line) 
                                          :time (w2 / wean-01))) 
                              :mod (t / this 
                                    :polarity-of (g / genotype))) 
                        :ARG1-of (s / survive-01 
                              :manner-of (w / wean-01 
                                    :ARG1 (l3 / line) 
                                    :location-of (p2 / percentage-entity 
                                          :op1-of (a / approximately) 
                                          :value 10)))) 
                  :degree (m2 / most))))

# ::snt Thus , the 525A transgene appears to be highly effective at rescuing the neonatal lethal phenotype of the E2 knockout .
# ::tok Thus , the 525A transgene appears to be highly effective at rescuing the neonatal lethal phenotype of the E2 knockout .
# ::alignments 19-20|0.1.0.1.2 18-19|0.1.0.1.2.0.0.0+0.1.0.1.2.0.0+0.1.0.1.2.0 15-16|0.1.0.1 14-15|0.1.0.1.0 13-14|0.1.0.1.1 11-12|0.1.0 9-10|0.1 8-9|0.1.1 5-6|0 4-5|0.0 0-1|0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:37.084
(a / appear-02 
      :ARG1 (t2 / transgene) 
      :ARG2 (e / effective-04 
            :ARG1 (r / rescue-01 
                  :ARG0 (t3 / thu) 
                  :ARG1 (p / phenotype 
                        :mod (l / lethal) 
                        :mod (n2 / neonatal) 
                        :poss (k / knockout 
                              :mod (t / thing 
                                    :name (n / name 
                                          :op1 "E2"))))) 
            :degree (h / high)))

# ::snt In contrast , line 520B completely failed to rescue the neonatal lethal phenotype .
# ::tok In contrast , line 520B completely failed to rescue the neonatal lethal phenotype .
# ::alignments 12-13|0.0.2.0 11-12|0.0.2.0.0 10-11|0.0.2.0.1 8-9|0.0.2 6-7|0.0 5-6|0.0.1 4-5|0.0.0 3-4|0.0.0.0 1-2|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:37.126
(c2 / contrast-01 
      :ARG1 (f / fail-01 
            :ARG1 (5 / 520B 
                  :mod (l2 / line)) 
            :ARG1-of (c / complete-02) 
            :ARG2 (r / rescue-01 
                  :ARG1 (p / phenotype 
                        :mod (l / lethal) 
                        :mod (n / neonatal)))))

# ::snt All other lines tested produced surviving rescue animals at a frequency between 1 and 5 % of weaned pups .
# ::tok All other lines tested produced surviving rescue animals at a frequency between 1 and 5 % of weaned pups .
# ::alignments 18-19|0.0.1 17-18|0.0.1.0 15-16|0.0.1.1 14-15|0.0.2.0 13-14|0 12-13|0.0.3 10-11|0.0.0.0.2 7-8|0.0.0 6-7|0.0.2 5-6|0.0 4-5|0.0.0.0 3-4|0.0.0.0.1 2-3|0.0.0.0.0 1-2|0.0.0.0.0.1 0-1|0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:37.427
(a / and 
      :op1 (s / survive-01 
            :ARG1 (a2 / animal 
                  :ARG1-of (p3 / produce-01 
                        :ARG0 (l / line 
                              :mod (a3 / all) 
                              :mod (o / other)) 
                        :ARG1-of (t / test-01) 
                        :time (f / frequency))) 
            :ARG1-of (p / pup-01 
                  :ARG1-of (w / wean-01) 
                  :ARG2 (p2 / percentage-entity)) 
            :ARG3-of (r / rescue-01 
                  :ARG1 5) 
            :time 1))

# ::snt Characterization of the intermediate MSUD murine model .
# ::tok Characterization of the intermediate MSUD murine model .
# ::alignments 6-7|0.0 5-6|0.0.0 3-4|0.0.1 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:37.443
(c / characterization 
      :poss (m / model 
            :mod (m2 / murine) 
            :mod (i / intermediate)))

# ::snt A , Survival analysis of transgenic rescue lines .
# ::tok A , Survival analysis of transgenic rescue lines .
# ::alignments 7-8|0.0.0 6-7|0.0.1 3-4|0.0 2-3|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:37.502
(s / survival 
      :ARG0-of (a / analyze-01 
            :ARG1 (l / line) 
            :ARG2 (r / rescue-01)))

# ::snt Presented are percentages of mice alive at weaning from each transgenic line tested that had the rescue genotype ( i.e. , homozygous for knockout of endogenous E2 and positive for both the LAP-tTA and TRE-E2 transgenes ) .
# ::tok Presented are percentages of mice alive at weaning from each transgenic line tested that had the rescue genotype ( i.e. , homozygous for knockout of endogenous E2 and positive for both the LAP-tTA and TRE-E2 transgenes ) .
# ::alignments 35-36|0.2.0 34-35|0.2.1.0+0.2.1+0.2 33-34|0 32-33|0.1.0.0+0.1.0+0.1 30-31|0.0.1.0 28-29|0.0.2.2 27-28|0.0.2 26-27|0.0.2.1.1.0+0.0.2.1.1+0.0.2.1 25-26|0.0.2.1.0 23-24|0.0.2.1.2 21-22|0.0.2.0 19-20|0.0.0.0 17-18|0.0.1.1 16-17|0.0.1 12-13|0.0 11-12|0.0.0.2 9-10|0.0.0.2.0 7-8|0.0.0 5-6|0.0.0.3 4-5|0.0.0.1 2-3|0.0.0.4.0 0-1|0.0.0.4 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:38.353
(a / and 
      :op1 (t4 / test-01 
            :ARG1 (w / wean-01 
                  :ARG0 (i / i.e.) 
                  :ARG1 (m / mouse) 
                  :ARG2 (l / line 
                        :mod (e2 / each)) 
                  :compared-to-of (a3 / alive) 
                  :purpose (p3 / present-01 
                        :ARG1 (p2 / percentage))) 
            :ARG2-of (r / rescue-01 
                  :ARG1 (b / both) 
                  :mod-of (g / genotype)) 
            :op1-of (a2 / and 
                  :op2 (h / homozygou) 
                  :op3 (t3 / thing 
                        :mod (e / endogenou) 
                        :name (n3 / name 
                              :op1 "E2") 
                        :poss-of (k / knockout)) 
                  :op4 (p / positive))) 
      :op2 (c / country 
            :name (n2 / name 
                  :op1 "LAP-tTA")) 
      :op3 (t2 / thing 
            :mod-of (t / transgen) 
            :name (n / name 
                  :op1 "TRE-E2")))

# ::snt Also plotted is the theoretical maximum frequency at which this genotype is expected in this population of animals .
# ::tok Also plotted is the theoretical maximum frequency at which this genotype is expected in this population of animals .
# ::alignments 17-18|0.0.1.1 15-16|0.0.1 14-15|0.0.1.0 12-13|0.0 10-11|0 9-10|0.1 6-7|0.0.0 5-6|0.0.0.1.0 4-5|0.0.0.1 1-2|0.0.0.0 0-1|0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:38.571
(g / genotype 
      :ARG1-of (e / expect-01 
            :ARG0 (f / frequency 
                  :ARG1-of (p2 / plot-01 
                        :mod (a2 / also)) 
                  :mod (t3 / theory 
                        :mod-of (m / maximum))) 
            :location (p / population 
                  :mod (t / this) 
                  :mod (a / animal))) 
      :mod (t2 / this))

# ::snt The numbers on the bars indicates the numbers of observations for each line .
# ::tok The numbers on the bars indicates the numbers of observations for each line .
# ::alignments 12-13|0.1.0.0 11-12|0.1.0.0.0 9-10|0.1.0 7-8|0.1 5-6|0 4-5|0.0.0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:38.628
(i / indicate-01 
      :ARG0 (n2 / number 
            :topic (b / bar)) 
      :ARG1 (n / number 
            :quant-of (o / observation 
                  :beneficiary (l / line 
                        :mod (e / each)))))

# ::snt B , Ratio of total BCAA to alanine in blood of mice from controls and Lines A and 525A .
# ::tok B , Ratio of total BCAA to alanine in blood of mice from controls and Lines A and 525A .
# ::alignments 17-18|0.0.0.1.0.1 15-17|0.0.0.1.0.0.1+0.0.0.1.0.0.0+0.0.0.1.0.0+0.0.0.1.0 14-15|0.0.0.1 13-14|0.0.0 11-12|0.0.0.1.0.1.0.0 9-10|0.0.0.1.0.1.0 5-6|0.0.2.0+0.0.2+0.0 4-5|0.0.1 2-3|0 0-1|0.0.0.0.1+0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:38.709
(r / ratio 
      :poss (o / organization 
            :ARG0-of (c / control-01 
                  :ARG1 (l / location 
                        :name (n3 / name 
                              :op1 "B") 
                        :wiki -) 
                  :op1-of (a2 / and 
                        :op2 (t / thing 
                              :name (n / name 
                                    :op1 "Lines" 
                                    :op2 "A") 
                              :op2-of (a / and 
                                    :op1 (b / blood 
                                          :mod (m / mouse)))))) 
            :ARG2-of (t2 / total-01) 
            :name (n2 / name 
                  :op1 "BCAA")))

# ::snt Total BCAA represent the sum of leucine , isoleucine , and valine .
# ::tok Total BCAA represent the sum of leucine , isoleucine , and valine .
# ::alignments 11-12|0.1.2 10-11|0.1 8-9|0.1.1 6-7|0.1.0 4-5|0.1.0.0 2-3|0 1-2|0.0.1.0+0.0.1+0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:39.136
(r / represent-01 
      :ARG0 (o / organization 
            :ARG1-of (t / total-01) 
            :name (n / name 
                  :op1 "BCAA")) 
      :ARG1 (a / and 
            :op1 (l / leucine 
                  :mod-of (s / sum)) 
            :op2 (i / isoleucine) 
            :op3 (v / valine)))

# ::snt BCAA/alanine values were significantly greater for Lines A and 525A compared to controls at all ages tested .
# ::tok BCAA/alanine values were significantly greater for Lines A and 525A compared to controls at all ages tested .
# ::alignments 16-17|0 15-16|0.0.0 14-15|0.0.1.0.0.0.0 12-13|0.0 10-11|0.0.1 8-9|0.0.1.0 6-8|0.0.1.0.1.0.1+0.0.1.0.1.0.0+0.0.1.0.1.0+0.0.1.0.1 4-5|0.0.1.0.0 3-4|0.0.1.0.0.0 1-2|0.0.1.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:39.267
(t / test-01 
      :ARG1 (c / control-01 
            :ARG1 (a / age) 
            :ARG2-of (c2 / compare-01 
                  :ARG1 (a3 / and 
                        :domain-of (g / great 
                              :ARG1-of (s / significant-02 
                                    :ARG0 (a2 / all)) 
                              :domain (v / value)) 
                        :op1 (t2 / thing 
                              :name (n / name 
                                    :op1 "Lines" 
                                    :op2 "A"))))))

# ::snt The numbers on the bars indicates the numbers of samples analyzed .
# ::tok The numbers on the bars indicates the numbers of samples analyzed .
# ::alignments 10-11|0.1.0.0 9-10|0.1.0.1+0.1.0 7-8|0.1 5-6|0 4-5|0.1.0.0.0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:39.301
(i / indicate-01 
      :ARG0 (n2 / number) 
      :ARG1 (n / number 
            :quant-of (t / thing 
                  :ARG1-of (a / analyze-01 
                        :ARG0 (b / bar)) 
                  :ARG1-of (s / sample-01))))

# ::snt * , P  0.01 ; ** , P < 0.005 .
# ::tok * , P  0.01 ; ** , P < 0.005 .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:39.302
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt C , BCKDH enzyme activity in liver of control and Lines A and 525A mice .
# ::tok C , BCKDH enzyme activity in liver of control and Lines A and 525A mice .
# ::alignments 14-15|0.1 12-13|0 10-12|0.0.0.1+0.0.0.0+0.0.0+0.0 9-10|0.0.1 8-9|0.0.1.1 6-7|0.2 4-5|0.0.1.0 3-4|0.0.1.0.1 0-1|0.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:39.425
(a / and 
      :op1 (t / thing 
            :name (n / name 
                  :op1 "Lines" 
                  :op2 "A") 
            :op2-of (a2 / and 
                  :ARG1-of (a3 / activity-06 
                        :ARG0 (c2 / C) 
                        :mod (e / enzyme)) 
                  :op1 (c / control-01))) 
      :op2 (m / mouse) 
      :poss-of (l / liver))

# ::snt * , P  0.001 ; ** , P  0.0001 .
# ::tok * , P  0.001 ; ** , P  0.0001 .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:39.426
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt D , Survival curves for mice from Lines A and 525A .
# ::tok D , Survival curves for mice from Lines A and 525A .
# ::alignments 9-10|0.1.0 7-9|0.1.0.0.0.1+0.1.0.0.0.0+0.1.0.0.0+0.1.0.0 5-6|0.1 3-4|0 2-3|0.0 0-1|0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:39.470
(c / curve-01 
      :ARG0 (s / survival) 
      :ARG1 (m / mouse 
            :topic (a / and 
                  :op1 (t / thing 
                        :name (n / name 
                              :op1 "Lines" 
                              :op2 "A")))) 
      :time (d / D))

# ::snt Rescue mice alive at weaning were monitored until they were moribund and subsequently sacrificed or were found dead in their cages .
# ::tok Rescue mice alive at weaning were monitored until they were moribund and subsequently sacrificed or were found dead in their cages .
# ::alignments 20-21|0.1.0 16-17|0.1 14-15|0 13-14|0.0 12-13|0.0.2 11-12|0.0.1 10-11|0.0.0.0 8-9|0.0.0 7-8|0.0.1.0.1 6-7|0.0.1.0 4-5|0.0.1.0.0.0 2-3|0.0.1.0.0.0.0 1-2|0.0.1.0.0 0-1|0.0.1.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:39.618
(o / or 
      :op1 (s / sacrifice-01 
            :ARG0 (t / they 
                  :domain-of (m / moribund)) 
            :op1-of (a / and 
                  :ARG3-of (m2 / monitor-01 
                        :ARG1 (m3 / mouse 
                              :ARG1-of (w / wean-01 
                                    :concession-of (a2 / alive)) 
                              :mod (r / rescue-01)) 
                        :time (u / until))) 
            :time (s2 / subsequent)) 
      :op2 (f / find-01 
            :location (c / cage)))

# ::snt Lines A and 525A were selected for detailed characterization .
# ::tok Lines A and 525A were selected for detailed characterization .
# ::alignments 8-9|0.1.0 7-8|0.1 5-6|0 2-3|0.0 0-2|0.0.0.0.1+0.0.0.0.0+0.0.0.0+0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:39.643
(s / select-01 
      :ARG1 (a / and 
            :op1 (t / thing 
                  :name (n / name 
                        :op1 "Lines" 
                        :op2 "A"))) 
      :ARG2 (d / detail-01 
            :ARG1 (c / characterization)))

# ::snt Fig. 4B shows the results of blood amino acid analysis presented as a ratio of total BCAA to alanine .
# ::tok Fig. 4B shows the results of blood amino acid analysis presented as a ratio of total BCAA to alanine .
# ::alignments 18-19|0.1.0.0.1.1 15-16|0.1.0.0.2 13-14|0.1.0.0.1.0 10-11|0.1.0.0.1 9-10|0.1.0.0 8-9|0.1.0.0.3 7-8|0.1.0.0.4 6-7|0.1.0.0.0 4-5|0.1.0+0.1 2-3|0 0-2|0.0.0.1+0.0.0.0+0.0.0+0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:40.424
(s / show-01 
      :ARG0 (t3 / thing 
            :name (n / name 
                  :op1 (f / Fig.) 
                  :op2 4B)) 
      :ARG1 (t2 / thing 
            :ARG2-of (r2 / result-01 
                  :ARG1 (a2 / analyze-01 
                        :ARG1 (b / blood) 
                        :ARG1-of (p / present-01 
                              :ARG3 (r / ratio) 
                              :manner (a / alanine)) 
                        :ARG1-of (t / total-01) 
                        :manner (a3 / acid) 
                        :mod (a4 / amino)))))

# ::snt The BCAA/alanine values for mice from both lines were significantly elevated compared to controls for all of the time points analyzed .
# ::tok The BCAA/alanine values for mice from both lines were significantly elevated compared to controls for all of the time points analyzed .
# ::alignments 20-21|0.0 19-20|0 18-19|0.0.0.0.0 15-16|0.0.0.0 13-14|0.0.0 11-12|0.0.0.1 10-11|0.0.0.1.0.0 9-10|0.0.0.1.0.0.1 7-8|0.0.0.1.0.0.0 6-7|0.0.0.1.0.0.0.0 4-5|0.0.0.1.0.0.0.1 2-3|0.0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:40.691
(p / point 
      :ARG1-of (a / analyze-01 
            :ARG1-of (c / control-01 
                  :ARG0 (a2 / all 
                        :mod-of (t / time)) 
                  :ARG2-of (c2 / compare-01 
                        :ARG1 (v / value 
                              :ARG1-of (e / elevate-01 
                                    :ARG0 (l / line 
                                          :mod (b / both) 
                                          :source-of (m / mouse)) 
                                    :ARG1-of (s / significant-02)))))))

# ::snt Note that the BCAA/alanine values for the transgenic mice are intermediate between controls and knockouts ( see Figure 2C ) .
# ::tok Note that the BCAA/alanine values for the transgenic mice are intermediate between controls and knockouts ( see Figure 2C ) .
# ::alignments 17-18|0.0.1.1.0.0 16-17|0.0.1.1.0 14-15|0.0.1.2 13-14|0.0.1 12-13|0.0.1.1 10-11|0.0 8-9|0.0.1.0 4-5|0.0.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:40.745
(n / note-01 
      :ARG1 (i / intermediate 
            :domain (v / value) 
            :op2-of (a / and 
                  :op1 (m / mouse) 
                  :op3 (c / control-01 
                        :ARG1 (s / see-01 
                              :ARG1 (f / figure))) 
                  :op4 (k / knockout))))

# ::snt Blood levels of alanine , glutamate , and glutamine were reduced in Line A mice , as was glutamate in Line 525A mice , compared to controls ( Table 2 ) .
# ::tok Blood levels of alanine , glutamate , and glutamine were reduced in Line A mice , as was glutamate in Line 525A mice , compared to controls ( Table 2 ) .
# ::alignments 29-30|0.0 28-29|0.0.0 26-27|0.1.0.0 24-25|0.1.0.0.0 22-23|0.1.0.2.0 18-19|0.1.0.1 14-15|0.2 12-14|0.2.0.0.1+0.2.0.0.0+0.2.0.0+0.2.0 10-11|0 8-9|0.1.3 7-8|0.1 5-6|0.1.2 3-4|0.1.1 1-2|0.1.0 0-1|0.1.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:40.974
(r / reduce-01 
      :ARG0 (2 / 2 
            :mod-of (t / table)) 
      :ARG1 (a / and 
            :extent (l / level 
                  :ARG1-of (c / control-01 
                        :ARG2-of (c2 / compare-01)) 
                  :domain-of (g / glutamate) 
                  :mod (b / blood-01 
                        :ARG0 (m / mouse))) 
            :op1 (a2 / alanine) 
            :op2 (g3 / glutamate) 
            :op3 (g2 / glutamine)) 
      :ARG2 (m2 / mouse 
            :mod (t2 / thing 
                  :name (n / name 
                        :op1 "Line" 
                        :op2 "A"))))

# ::snt Summary of additional blood amino acid levels in the intermediate MSUD model and littermate controls as determined by tandem mass spectrometry .
# ::tok Summary of additional blood amino acid levels in the intermediate MSUD model and littermate controls as determined by tandem mass spectrometry .
# ::alignments 20-21|0.0.0.1 19-20|0.0 18-19|0 16-17|0.0.0 14-15|0.0.0.0 13-14|0.0.0.0.0 12-13|0.0.0.0.2 11-12|0.0.0.0.2.0 9-10|0.0.0.0.2.0.0 6-7|0.0.0.0.2.1 5-6|0.0.0.0.2.1.1 4-5|0.0.0.0.2.1.2 3-4|0.0.0.0.2.1.0.0 2-3|0.0.0.0.2.1.0 0-1|0.0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:41.185
(t / tandem 
      :mod-of (m / mass 
            :ARG0-of (d / determined-02 
                  :ARG1 (c / control-01 
                        :ARG1 (l / littermate) 
                        :op1-of (s2 / summary) 
                        :op2-of (a / and 
                              :op1 (m2 / model 
                                    :mod (i / intermediate)) 
                              :topic-of (l2 / level 
                                    :mod (a4 / additional 
                                          :mod-of (b / blood)) 
                                    :mod (a2 / acid) 
                                    :mod (a3 / amino)))) 
                  :ARG2 (s / spectrometry))))

# ::snt Samples were collected from mice that were 4 -- 6 weeks of age .
# ::tok Samples were collected from mice that were 4 -- 6 weeks of age .
# ::alignments 12-13|0 10-11|0.0.1.0.0.0+0.0.1.0.0 9-10|0.0.1.0 7-8|0.0.0 4-5|0.0.1.1 2-3|0.0.1 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:41.257
(a / age-01 
      :ARG1 (s / sample-01 
            :ARG0 4 
            :ARG1-of (c / collect-01 
                  :ARG0 (6 / 6 
                        :quant-of (t / temporal-quantity 
                              :unit (w / week))) 
                  :ARG2 (m / mouse))))

# ::snt All values are mean + / - SEM .
# ::tok All values are mean + / - SEM .
# ::alignments 7-8|0.2.0.0+0.2.0+0.2 5-6|0.1 3-4|0 1-2|0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:41.378
(m / mean-01 
      :ARG1 (v / value 
            :quant (a / all)) 
      :ARG2 (s / slash) 
      :degree (o / organization 
            :name (n / name 
                  :op1 "SEM")))

# ::snt * : Significantly different from control ( P < 0.05 ) .
# ::tok * : Significantly different from control ( P < 0.05 ) .
# ::alignments 7-8|0 5-6|0.0.0 3-4|0.0 2-3|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:41.393
(p / P60 
      :ARG1-of (d / differ-02 
            :ARG2 (c / control-01) 
            :mod (s / significantly)))

# ::snt ** : Significantly different from control ( P < 0.01 ) .
# ::tok ** : Significantly different from control ( P < 0.01 ) .
# ::alignments 7-8|0 5-6|0.0.0 3-4|0.0 2-3|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:41.411
(p / P60 
      :ARG1-of (d / differ-02 
            :ARG2 (c / control-01) 
            :mod (s / significantly)))

# ::snt *** : Significantly different from Line 525A ( P < 0.05 ) .
# ::tok *** : Significantly different from Line 525A ( P < 0.05 ) .
# ::alignments 8-9|0.0.0 5-7|0.1.1+0.1.0+0.1+0 3-4|0.0 2-3|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:41.432
(t / thing 
      :ARG2-of (d / differ-02 
            :ARG1 (p / P60) 
            :mod (s / significantly)) 
      :name (n / name 
            :op1 "Line" 
            :op2 "525A"))

# ::snt Because the LAP-tTA mice that were used to drive expression of transgenic human E2 have been demonstrated to produce liver specific expression [ 34 ] , BCKDH enzyme activity and production of human E2 protein in liver of Lines A and 525A was examined .
# ::tok Because the LAP-tTA mice that were used to drive expression of transgenic human E2 have been demonstrated to produce liver specific expression [ 34 ] , BCKDH enzyme activity and production of human E2 protein in liver of Lines A and 525A was examined .
# ::alignments 43-44|0.3.0.1.0.0.0.0 40-41|0.3.0.1.0.0.0.1.1 38-40|0.3.0.1.0.0.0.1.1.1.0.1+0.3.0.1.0.0.0.1.1.1.0.0+0.3.0.1.0.0.0.1.1.1.0+0.3.0.1.0.0.0.1.1.1 36-37|0.3.0.1.0.0.0.1.1.0 34-35|0.3.0.1.0.0.0.2.0 32-33|0.3.0.0 30-31|0.3.0.1.0.0.0.2 29-30|0.3.0.1.0.0.0 28-29|0.3.0.1.0.0.0.1 27-28|0.3.0.1.0.0.0.1.0 23-24|0.0 21-22|0.2 20-21|0.2.0 19-20|0.2.0.0 18-19|0.3.0.1.0 16-17|0.3.0.1.0.0 13-14|0.1.1.0+0.1.1+0.1 12-13|0.1.0 9-10|0 8-9|0.3 6-7|0.3.0 3-4|0.3.0.1 2-3|0.3.0.1.1.0.0+0.3.0.1.1.0+0.3.0.1.1 0-1|0.3.0.1.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:42.315
(e4 / express-01 
      :ARG0 34 
      :ARG1 (t2 / thing 
            :mod (h2 / human) 
            :name (n2 / name 
                  :op1 "E2")) 
      :ARG1-of (e3 / express-01 
            :ARG1-of (s / specific-02 
                  :ARG0 (l2 / liver))) 
      :ARG1-of (d2 / drive-01 
            :ARG2-of (u / use-01 
                  :ARG0 (h / human) 
                  :ARG1 (m / mouse 
                        :ARG0-of (p3 / produce-01 
                              :ARG1-of (d / demonstrate-01 
                                    :ARG0 (a2 / and 
                                          :ARG1-of (e / examine-01) 
                                          :op1 (a3 / activity-06 
                                                :ARG1 (e2 / enzyme) 
                                                :op1-of (a / and 
                                                      :op2 (l / liver) 
                                                      :op3 (t / thing 
                                                            :name (n / name 
                                                                  :op1 "Lines" 
                                                                  :op2 "A")))) 
                                          :op2 (p2 / produce-01 
                                                :ARG1 (p / protein))) 
                                    :ARG0-of (c2 / cause-01))) 
                        :mod (c / country 
                              :name (n3 / name 
                                    :op1 "LAP-tTA"))))))

# ::snt BCKDH enzymatic activity in liver from Lines A and 525A was ~ 6 and 5 % , respectively , of the enzymatic activity present in control liver ( Fig. 4C ) .
# ::tok BCKDH enzymatic activity in liver from Lines A and 525A was ~ 6 and 5 % , respectively , of the enzymatic activity present in control liver ( Fig. 4C ) .
# ::alignments 28-29|0.0.3.0.0+0.0.3.0+0.0.3 26-27|0.0.2.1 25-26|0.0.2 23-24|0.0.1.0 22-23|0.0.1 21-22|0.0.1.0.0 17-18|0.0.2.2 15-16|0.0.2.0 14-15|0.0.0 13-14|0.2 12-13|0.3.0 8-9|0 6-8|0.1.0.1+0.1.0.0+0.1.0+0.1 4-5|0.3 2-3|0.0 1-2|0.0.4 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:42.671
(a3 / and 
      :ARG0-of (a4 / activity-06 
            :ARG1 5 
            :ARG1-of (a / activity-06 
                  :mod-of (p / present 
                        :mod (e / enzymatic))) 
            :ARG2-of (c2 / control-01 
                  :ARG1 (p2 / percentage-entity) 
                  :mod-of (l / liver) 
                  :op1-of (r / respective)) 
            :location (c / country 
                  :name (n / name 
                        :op1 "Fig.")) 
            :mod (e2 / enzymatic)) 
      :op1 (t / thing 
            :name (n2 / name 
                  :op1 "Lines" 
                  :op2 "A")) 
      :op1-of (a2 / and) 
      :poss-of (l2 / liver 
            :quant 6))

# ::snt As shown in Fig. 3B , the amount of human E2 ( predicted MW ~ 54 Kd ) in these transgenic mice was quite variable between mice .
# ::tok As shown in Fig. 3B , the amount of human E2 ( predicted MW ~ 54 Kd ) in these transgenic mice was quite variable between mice .
# ::alignments 26-27|0.1.1.0 24-25|0 23-24|0.0 21-22|0.1.0.0.0 19-20|0.1.0.0 15-16|0.1.0.2 12-13|0.1.1 10-11|0.1.2 9-10|0.1.2.0 7-8|0.1 3-4|0.1.0.1.0.0+0.1.0.1.0+0.1.0.1 1-2|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:42.814
(v / variable 
      :degree (q / quite) 
      :domain (a / amount 
            :ARG1-of (s / show-01 
                  :ARG0 (t / this 
                        :mod-of (m2 / mouse)) 
                  :location (c / country 
                        :name (n / name 
                              :op1 "Fig.")) 
                  :op1-of 54) 
            :ARG1-of (p / predict-01 
                  :ARG0 (m / mouse)) 
            :quant-of (e / E2 
                  :mod (h / human))))

# ::snt In some of these transgenic mice , the level of human E2 was approximately equal to the amount of mouse E2 ( ~ 47 Kd ) produced in liver of nontransgenic control mice .
# ::tok In some of these transgenic mice , the level of human E2 was approximately equal to the amount of mouse E2 ( ~ 47 Kd ) produced in liver of nontransgenic control mice .
# ::alignments 32-33|0.1.0.1.0 31-32|0.1.0.1.0.0 28-29|0.1.0.1 26-27|0.1.0 23-24|0.1.0.1.0.0.1 19-20|0.1.0.1.0.0.0 17-18|0.1 14-15|0 13-14|0.3 11-12|0.0.0.1.0+0.0.0.1+0.0.0 10-11|0.0.0.0 8-9|0.0 5-6|0.1.0.0 3-4|0.1.0.0.0 1-2|0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:43.106
(e / equal-01 
      :ARG1 (l2 / level 
            :mod (t / thing 
                  :mod (h / human) 
                  :name (n / name 
                        :op1 "E2"))) 
      :ARG2 (a / amount 
            :ARG1-of (p / produce-01 
                  :ARG0 (m3 / mouse 
                        :mod (t2 / this)) 
                  :manner (l / liver 
                        :mod (m / mouse 
                              :mod (c / control-01 
                                    :ARG0 (m2 / mouse) 
                                    :ARG1 47))))) 
      :compared-to (s / some) 
      :mod (a2 / approximately))

# ::snt The observations that these near normal amounts of E2 protein result in only ~ 5 -- 6 % of normal BCKDH enzyme activity suggest that transgene derived E2 is functioning at a suboptimal level .
# ::tok The observations that these near normal amounts of E2 protein result in only ~ 5 -- 6 % of normal BCKDH enzyme activity suggest that transgene derived E2 is functioning at a suboptimal level .
# ::alignments 33-34|0.0.0.3.1.1.1 29-30|0.0.0.3.1.1 26-27|0.0.0.3.1 25-26|0.0.0.3.1.0 23-24|0.0.0.3 22-23|0.0.0 21-22|0.0.0.1 19-20|0.0.0.2 17-18|0.0.0.3.0 16-17|0.2.0.0.0 14-15|0.0.0.4 12-13|0.0.0.3.1.1.0 10-11|0.0 9-10|0 8-9|0.1.0.0+0.1.0+0.1 6-7|0.2 5-6|0.2.0 4-5|0.2.0.0 3-4|0.2.1 1-2|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:43.763
(p2 / protein 
      :ARG0-of (r / result-01 
            :ARG1 (a / activity-06 
                  :ARG0 (o2 / observation) 
                  :ARG1 (e / enzyme) 
                  :ARG1-of (n / normal-02) 
                  :manner-of (s / suggest-01 
                        :ARG0 (p / percentage-entity) 
                        :ARG1 (d / derive-01 
                              :ARG0 (t / transgene) 
                              :ARG1 (f / function-01 
                                    :ARG0 (o / only) 
                                    :ARG1 (l / level)))) 
                  :quant 5)) 
      :mod (t2 / thing 
            :name (n2 / name 
                  :op1 "E2")) 
      :quant (a2 / amount 
            :ARG1-of (n3 / normal-02 
                  :ARG1-of (n4 / near-02 
                        :ARG0 6)) 
            :mod (t3 / this)))

# ::snt It is probable that the c-myc tag at the carboxy terminus of the transgene derived human E2 interfered with enzymatic activity .
# ::tok It is probable that the c-myc tag at the carboxy terminus of the transgene derived human E2 interfered with enzymatic activity .
# ::alignments 20-21|0.0.0.0.1 19-20|0.0.0.0.1.0 17-18|0.0.0.0 16-17|0.0.0.0.2.0.0+0.0.0.0.2.0+0.0.0.0.2 15-16|0.0.0.0.3 14-15|0.0.0 13-14|0.0.0.0.0.0.0 10-11|0.0.0.0.0.0 6-7|0.0.0.0.0 2-3|0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:43.942
(p / probable 
      :domain (i2 / it 
            :ARG0-of (d / derive-01 
                  :ARG1 (i / interfere-01 
                        :ARG0 (t4 / tag-01 
                              :ARG1 (t3 / terminu 
                                    :poss (t2 / transgene))) 
                        :ARG1 (a / activity-06 
                              :mod (e / enzymatic)) 
                        :ARG2 (t / thing 
                              :name (n / name 
                                    :op1 "E2")) 
                        :mod (h / human)))))

# ::snt This interpretation is consistent with previous studies which have revealed that the carboxy terminus of an analogous subunit of the pyruvate dehydrogenase complex is essential for subunit interactions [ 35 ] and insertion of a Hisx6 tag on the carboxy terminus of an analogous E. coli subunit interfered with normal subunit assembly [ 36 ] .
# ::tok This interpretation is consistent with previous studies which have revealed that the carboxy terminus of an analogous subunit of the pyruvate dehydrogenase complex is essential for subunit interactions [ 35 ] and insertion of a Hisx6 tag on the carboxy terminus of an analogous E. coli subunit interfered with normal subunit assembly [ 36 ] .
# ::alignments 53-54|0.1.1.0.0 51-52|0.1.2 50-51|0.1.2.1 49-50|0.1.2.0 47-48|0.1 46-47|0.1.0 44-46|0.1.0.0.1+0.1.0.0.0.1+0.1.0.0.0.0+0.1.0.0.0+0.1.0.0 40-41|0.1.1.0.2 36-37|0.1.1.0 35-36|0.1.1.0.1.0.0+0.1.1.0.1.0+0.1.1.0.1 32-33|0.1.1 31-32|0 29-30|0.0.0.0.0 27-28|0.0.1 26-27|0.0.1.0 24-25|0.0 22-23|0.0.2.0.0 21-22|0.0.2.0 17-18|0.2 16-17|0.2.0 13-14|0.0.2 9-10|0.0.0 6-7|0.0.0.0 5-6|0.0.0.0.2 3-4|0.0.0.0.1 1-2|0.0.0.0.1.0 0-1|0.0.0.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:45.186
(a2 / and 
      :op1 (e / essential 
            :ARG1-of (r / reveal-01 
                  :ARG0 (s5 / study-01 
                        :ARG1 35 
                        :ARG2-of (c2 / consistent-01 
                              :ARG1 (i4 / interpret-01 
                                    :mod (t5 / this))) 
                        :time (p / previous))) 
            :beneficiary (i3 / interaction 
                  :mod (s3 / subunit)) 
            :domain (t4 / terminu 
                  :location-of (d2 / dehydrogenase 
                        :mod-of (c / complex)))) 
      :op2 (i / interfere-01 
            :ARG0 (s2 / subunit 
                  :mod (d / disease 
                        :name (n2 / name 
                              :op1 "E." 
                              :op2 "coli") 
                        :wiki "Escherichia_coli")) 
            :ARG1 (i2 / insert-01 
                  :ARG1 (t2 / tag-01 
                        :ARG0 36 
                        :ARG1 (t3 / thing 
                              :name (n3 / name 
                                    :op1 "Hisx6")) 
                        :ARG2 (t / terminu))) 
            :ARG2 (a / assembly 
                  :ARG1-of (n / normal-02) 
                  :mod (s / subunit))) 
      :poss (s4 / subunit 
            :mod (a3 / analogou)))

# ::snt It is also possible that human E2 was not fully functional when complexed with mouse E1 and E3 subunits .
# ::tok It is also possible that human E2 was not fully functional when complexed with mouse E1 and E3 subunits .
# ::alignments 18-19|0.2 17-18|0.2.0 16-17|0 15-16|0.1 14-15|0.1.0 10-11|0.0.0 9-10|0.0.0.1 8-9|0.0.0.2 6-7|0.0.0.0.1.0+0.0.0.0.1+0.0.0.0 5-6|0.0.0.0.0 3-4|0.0 2-3|0.0.2 0-1|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:45.327
(a / and 
      :op1 (p / possible-01 
            :ARG1 (f / functional 
                  :domain (t / thing 
                        :mod (h / human) 
                        :name (n / name 
                              :op1 "E2")) 
                  :mod (f2 / full) 
                  :polarity -) 
            :domain (i / it) 
            :mod (a2 / also)) 
      :op2 (e2 / E1 
            :mod (m / mouse)) 
      :op3 (s / subunit 
            :mod (e / E3)))

# ::snt Human E2 shares ~ 88 % identity to mouse E2 at the amino acid level .
# ::tok Human E2 shares ~ 88 % identity to mouse E2 at the amino acid level .
# ::alignments 14-15|0.1.0 13-14|0.1.0.0 12-13|0.1.0.1 8-9|0 6-7|0.1 5-6|0.1.1.0 4-5|0.1.1 2-3|0.0 1-2|0.0.0.0.0+0.0.0.0+0.0.0 0-1|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:45.383
(m / mouse 
      :op1-of (s / share 
            :mod (t / thing 
                  :name (n / name 
                        :op1 "E2")) 
            :mod (h / human)) 
      :purpose-of (i / identity 
            :location (l / level 
                  :mod (a / acid) 
                  :mod (a2 / amino)) 
            :quant (8 / 88 
                  :value-of (p / percentage-entity))))

# ::snt We also used western blot analysis to analyze expression of the E2 transgene in brain , kidney and muscle .
# ::tok We also used western blot analysis to analyze expression of the E2 transgene in brain , kidney and muscle .
# ::alignments 18-19|0 17-18|0.0 16-17|0.0.2 14-15|0.0.1 12-13|0.0.0 11-12|0.0.0.0.0.1.1.0.0+0.0.0.0.0.1.1.0+0.0.0.0.0.1.1 8-9|0.0.0.0 7-8|0.0.0.0.0 5-6|0.0.0.0.0.0 4-5|0.0.0.0.0.0.0 3-4|0.0.0.0.0.0.1.1+0.0.0.0.0.0.1.0.0+0.0.0.0.0.0.1.0+0.0.0.0.0.0.1 2-3|0.0.0.0.0.1 1-2|0.0.0.0.0.1.2 0-1|0.0.0.0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:45.497
(m / muscle-01 
      :op3-of (a / and 
            :location-of (t / transgene 
                  :ARG1-of (e / express-01 
                        :ARG1-of (a2 / analyze-01 
                              :ARG1-of (a3 / analyze-01 
                                    :ARG1-of (b2 / blot-01) 
                                    :mod (w / world-region 
                                          :name (n2 / name 
                                                :op1 "West") 
                                          :wiki "Western_world")) 
                              :ARG2-of (u / use-01 
                                    :ARG0 (w2 / we) 
                                    :ARG1 (t2 / thing 
                                          :name (n / name 
                                                :op1 "E2")) 
                                    :mod (a4 / also))))) 
            :op1 (b / brain) 
            :op2 (k / kidney)))

# ::snt As shown in Figure 3C , D and 3E respectively , expression of E2 is negligible in those tissues .
# ::tok As shown in Figure 3C , D and 3E respectively , expression of E2 is negligible in those tissues .
# ::alignments 18-19|0.0.2.0 15-16|0.0.2 13-14|0.0.0.0.0+0.0.0.0+0.0.0 11-12|0.0 9-10|0.0.1.0.0.0 7-8|0.0.1.0.0 6-7|0 3-4|0.0.1.0 1-2|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:45.724
(d / D 
      :ARG0-of (e / express-01 
            :ARG1 (t2 / thing 
                  :name (n2 / name 
                        :op1 "E2")) 
            :ARG1-of (s / show-01 
                  :ARG0 (f / figure 
                        :op1-of (a / and 
                              :mod (r / respective)))) 
            :domain-of (n / negligible 
                  :location (t / tissue))))

# ::snt Long-term survival of the mice from these two transgenic lines that survived beyond weaning is plotted in Fig. 4D .
# ::tok Long-term survival of the mice from these two transgenic lines that survived beyond weaning is plotted in Fig. 4D .
# ::alignments 17-18|0.0.1.0.0.0+0.0.1.0.0+0.0.1.0 15-16|0.0.1 13-14|0 12-13|0.1 11-12|0.1.0 9-10|0.1.0.0 7-8|0.1.0.0.1 6-7|0.1.0.0.0 4-5|0.0.0 1-2|0.0 0-1|0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:45.960
(w / wean-01 
      :ARG1-of (s2 / survive-01 
            :ARG0 (m / mouse) 
            :ARG1-of (p / plot-01 
                  :location (c / country 
                        :name (n / name 
                              :op1 "Fig."))) 
            :mod (l2 / long-term)) 
      :op1-of (b / beyond 
            :ARG1-of (s / survive-01 
                  :ARG0 (l / line 
                        :mod (t / this) 
                        :quant 2))))

# ::snt Although survival data for control animals was not collected , it is readily apparent that survival of the rescue mice was compromised .
# ::tok Although survival data for control animals was not collected , it is readily apparent that survival of the rescue mice was compromised .
# ::alignments 21-22|0.0.1 19-20|0 18-19|0.0.0 15-16|0.0 13-14|0.0.0.0.0 12-13|0.0.0.0 8-9|0.0.2.1.0 7-8|0.0.2.1.0.0 5-6|0.0.2.0 4-5|0.0.2.0.0 2-3|0.0.2.1 1-2|0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:46.301
(m / mouse 
      :ARG0-of (s / survive-01 
            :ARG1 (r / rescue-01 
                  :ARG1 (r2 / ready-02 
                        :ARG1 (a / apparent))) 
            :ARG1-of (c / compromise-02) 
            :ARG1-of (s2 / survive-01 
                  :ARG0 (a2 / animal 
                        :ARG1-of (c3 / control-01)) 
                  :source-of (d / data 
                        :ARG1-of (c2 / collect-01 
                              :polarity -)))))

# ::snt By 16 weeks , all mice of Line A were moribund and humanely sacrificed , or were found dead in their cage .
# ::tok By 16 weeks , all mice of Line A were moribund and humanely sacrificed , or were found dead in their cage .
# ::alignments 21-22|0.3 17-18|0.2 15-16|0.2.0 13-14|0.1 12-13|0.1.2 11-12|0 10-11|0.2.0.0 7-9|0.0.0.1+0.0.0.0+0.0.0+0.0 5-6|0.1.1 4-5|0.1.1.0 2-3|0.1.0.1+0.1.0 1-2|0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:46.399
(a / and 
      :op1 (t / thing 
            :name (n / name 
                  :op1 "Line" 
                  :op2 "A")) 
      :op2 (s / sacrifice-01 
            :ARG0 (t2 / temporal-quantity 
                  :quant 16 
                  :unit (w / week)) 
            :ARG1 (m2 / mouse 
                  :quant (a2 / all)) 
            :manner (h / humane)) 
      :op3 (f / find-01 
            :op2-of (o / or 
                  :op1 (m / moribund))) 
      :op4 (c / cage))

# ::snt Survival of Line 525A appeared to be somewhat better .
# ::tok Survival of Line 525A appeared to be somewhat better .
# ::alignments 8-9|0.2 7-8|0.2.0 4-5|0 2-4|0.0.0.1+0.0.0.0+0.0.0+0.0 0-1|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:46.508
(a / appear-01 
      :ARG0 (t / thing 
            :name (n / name 
                  :op1 "Line" 
                  :op2 "525A")) 
      :ARG1 (s2 / survival) 
      :ARG2 (g / good 
            :mod (s / somewhat)))

# ::snt At 20 weeks of age , ~ 12 % of mice ( 2 of 16 ) were still alive .
# ::tok At 20 weeks of age , ~ 12 % of mice ( 2 of 16 ) were still alive .
# ::alignments 18-19|0 17-18|0.0 14-15|0.0.0.1 12-13|0.0.0.0.0.0 10-11|0.0.0.0 8-9|0.0.0.0.0 7-8|0.0.0.0.0.1 4-5|0.0.0 2-3|0.0.0.0.1.0.0+0.0.0.0.1.0 1-2|0.0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:46.613
(a / alive 
      :mod (s / still 
            :op1 (a2 / age-01 
                  :ARG2 (m / mouse 
                        :quant (p / percentage-entity 
                              :mod-of 2 
                              :value 12) 
                        :quant (22 / 20 
                              :quant-of (t / temporal-quantity 
                                    :unit (w / week)))) 
                  :op1-of 16)))

# ::snt These two rare survivors died at 40 and 60 weeks of age .
# ::tok These two rare survivors died at 40 and 60 weeks of age .
# ::alignments 11-12|0.0.2 9-10|0.0.1.0.0.0+0.0.1.0.0 8-9|0.0.1.0 7-8|0.1 6-7|0.0.1.1 4-5|0 3-4|0.0.0+0.0 2-3|0.0.1 1-2|0.0.4 0-1|0.0.3 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:46.709
(d / die-01 
      :ARG1 (p / person 
            :ARG0-of (s / survive-01) 
            :ARG1-of (r / rare-02 
                  :ARG0 (6 / 60 
                        :quant-of (t / temporal-quantity 
                              :unit (w / week))) 
                  :ARG2 40) 
            :ARG1-of (a / age-01) 
            :mod (t2 / this) 
            :quant 2) 
      :op1-of (a2 / and))

# ::snt In summary , these surviving mice had BCAA/alanine ratios that were intermediate between controls and knockouts and they expressed ~ 5 -- 6 % of normal BCKDH enzyme activity in the liver .
# ::tok In summary , these surviving mice had BCAA/alanine ratios that were intermediate between controls and knockouts and they expressed ~ 5 -- 6 % of normal BCKDH enzyme activity in the liver .
# ::alignments 31-32|0.1.1.1.2 28-29|0.1.1.1.2.0 27-28|0.1.1.1.2.0.0 25-26|0.1.1.1.2.0.1 23-24|0.1.1.1.2.0.2 22-23|0.1.1.1.1.0.0 20-21|0.1.0 18-19|0.1.1.1 17-18|0.1.1.1.0 16-17|0.1.1 15-16|0.2 14-15|0 13-14|0.1 11-12|0.0 8-9|0.1.1.0 5-6|0.1.1.1.1 4-5|0.1.1.1.1.0 3-4|0.1.1.1.1.1 1-2|0.1.1.1.2.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:47.238
(a3 / and 
      :op1 (i / intermediate) 
      :op2 (c / control-01 
            :ARG1 5 
            :op2-of (a2 / and 
                  :op1 (r / ratio) 
                  :op3 (e2 / express-01 
                        :ARG0 (t / they) 
                        :ARG1 (m / mouse 
                              :ARG1-of (s / survive-01 
                                    :ARG0 6) 
                              :mod (t2 / this)) 
                        :manner (l / liver 
                              :ARG0-of (a / activity-06 
                                    :ARG1 (e / enzyme) 
                                    :ARG1-of (n / normal-02 
                                          :ARG0 (s2 / summary)) 
                                    :quant (p / percentage-entity)))))) 
      :op3 (k / knockout))

# ::snt These phenotypic observations are remarkably similar to the clinical phenotype observed in MSUD patients with the intermediate form of the disease [ 1 ] .
# ::tok These phenotypic observations are remarkably similar to the clinical phenotype observed in MSUD patients with the intermediate form of the disease [ 1 ] .
# ::alignments 22-23|0.0.0.0.0.1 20-21|0.0.1 17-18|0.0 16-17|0 13-14|0.0.0.1+0.0.0+0.0.0.0 10-11|0.0.0.0.0 9-10|0.0.0.0.0.0 8-9|0.0.0.0.0.0.1 5-6|0.0.0.0.0.0.0 4-5|0.0.0.0.0.0.0.1 2-3|0.0.0.0.0.0.0.0 1-2|0.0.0.0.0.0.0.0.1 0-1|0.0.0.0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:47.351
(i / intermediate 
      :mod-of (f / form 
            :ARG1-of (h / have-rel-role-91 
                  :ARG0 (p / person 
                        :ARG0-of (o / observe-01 
                              :ARG1 (p3 / phenotype 
                                    :ARG2-of (r / resemble-01 
                                          :ARG1 (o2 / observation 
                                                :mod (t / this) 
                                                :mod (p4 / phenotypic)) 
                                          :ARG1-of (r2 / remarkable-02)) 
                                    :mod (c / clinical)) 
                              :time 1)) 
                  :ARG2 (p2 / patient)) 
            :poss (d / disease)))

# ::snt Thus , these rescue mice represent a very useful model of the intermediate MSUD phenotype .
# ::tok Thus , these rescue mice represent a very useful model of the intermediate MSUD phenotype .
# ::alignments 14-15|0.1.1 12-13|0.1.1.0 9-10|0.1 8-9|0.1.0 7-8|0.1.0.0 5-6|0 4-5|0.0 3-4|0.2 2-3|0.0.0 0-1|0.3 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:47.626
(r / represent-01 
      :ARG0 (m2 / mouse 
            :mod (t / this)) 
      :ARG1 (m / model 
            :ARG1-of (u / useful-05 
                  :degree (v / very)) 
            :mod (p / phenotype 
                  :mod (i / intermediate))) 
      :ARG1-of (r2 / rescue-01) 
      :manner (t2 / thu))

# ::snt A major hurdle in developing new treatments for MSUD has been the lack of a practical , accurate animal model of the disease .
# ::tok A major hurdle in developing new treatments for MSUD has been the lack of a practical , accurate animal model of the disease .
# ::alignments 22-23|0.0.0.3 19-20|0.0.0 18-19|0.0.0.1 17-18|0.0.0.2 15-16|0.0.0.0 12-13|0.0 6-7|0 5-6|0.2 4-5|0.1 2-3|0.1.0 1-2|0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:47.692
(t / treat-03 
      :ARG1 (l / lack-01 
            :ARG1 (m / model 
                  :mod (p / practical) 
                  :mod (a / animal) 
                  :mod (a2 / accurate) 
                  :poss (d / disease))) 
      :ARG1-of (d2 / develop-02 
            :ARG0 (h / hurdle 
                  :ARG1-of (m2 / major-02))) 
      :mod (n / new))

# ::snt This hurdle has now been overcome .
# ::tok This hurdle has now been overcome .
# ::alignments 5-6|0 3-4|0.1 1-2|0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:47.707
(o / overcome-01 
      :ARG1 (h / hurdle 
            :mod (t / this)) 
      :time (n / now))

# ::snt In this report , we describe the development and characterization of two genetically engineered mouse models that are phenotypically very similar to MSUD patients with the classic and intermediate forms of the disease .
# ::tok In this report , we describe the development and characterization of two genetically engineered mouse models that are phenotypically very similar to MSUD patients with the classic and intermediate forms of the disease .
# ::alignments 32-33|0.3.0 29-30|0.3 28-29|0.2 27-28|0 26-27|0.1 23-24|0.0.1+0.0+0.0.0 20-21|0.0.0.0 19-20|0.0.0.0.1 15-16|0.0.0.0.0.0 14-15|0.0.0.0.0.0.1 13-14|0.0.0.0.0.0.0 12-13|0.0.0.0.0.0.0.1 11-12|0.0.0.0.0.0.2 9-10|0.0.0.0.0.2.0 8-9|0.0.0.0.0.2 7-8|0.0.0.0.0 5-6|0.0.0.0.0.1 4-5|0.0.0.0.0.1.0 2-3|0.0.0.0.0.1.1 1-2|0.0.0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:48.973
(a / and 
      :ARG1-of (h / have-rel-role-91 
            :ARG0 (p / person 
                  :ARG2-of (r / resemble-01 
                        :ARG1 (d2 / develop-02 
                              :ARG1 (m / model 
                                    :ARG1-of (e / engineer-01 
                                          :ARG0 (t / this) 
                                          :ARG2 (g / genetics)) 
                                    :mod (m2 / mouse) 
                                    :quant 2) 
                              :ARG1-of (d3 / describe-01 
                                    :ARG0 (w / we) 
                                    :medium (r2 / report)) 
                              :op1-of (a2 / and 
                                    :op2 (c2 / characterization))) 
                        :degree (v / very))) 
            :ARG2 (p2 / patient)) 
      :op1 (c / classic) 
      :op2 (i / intermediate) 
      :op3 (f / form 
            :poss (d / disease)))

# ::snt Our model of classic MSUD was created by gene knockout of the E2 subunit of BCKDH .
# ::tok Our model of classic MSUD was created by gene knockout of the E2 subunit of BCKDH .
# ::alignments 13-14|0.1 12-13|0.1.0.0.0+0.1.0.0+0.1.0 9-10|0.0 8-9|0.0.0 6-7|0 3-4|0.1.1 1-2|0.1.2 0-1|0.1.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:49.152
(c / create-01 
      :ARG0 (k / knockout 
            :mod (g / gene)) 
      :ARG1 (s / subunit 
            :mod (t / thing 
                  :name (n / name 
                        :op1 "E2")) 
            :mod (c2 / classic) 
            :poss-of (m / model 
                  :poss (w / we))))

# ::snt The phenotype of these knockout animals is strikingly similar to humans with classic MSUD .
# ::tok The phenotype of these knockout animals is strikingly similar to humans with classic MSUD .
# ::alignments 12-13|0.0.0.2 10-11|0.0.0.1 8-9|0.0.0 7-8|0.0.0.3 5-6|0.0 4-5|0 3-4|0.0.1 1-2|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:49.210
(k / knockout 
      :mod-of (a / animal 
            :ARG1-of (r / resemble-01 
                  :ARG0 (p / phenotype) 
                  :ARG2 (h / human) 
                  :compared-to (c / classic) 
                  :degree (s / strikingly)) 
            :mod (t / this)))

# ::snt Knockout mice were born at the expected frequency and appeared normal at birth .
# ::tok Knockout mice were born at the expected frequency and appeared normal at birth .
# ::alignments 12-13|0.0.1 10-11|0.1 9-10|0.0 8-9|0 7-8|0.0.0.0.0 6-7|0.0.0.0.0.0 3-4|0.0.0.0 1-2|0.0.0 0-1|0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:49.250
(a2 / and 
      :op1 (a / appear-01 
            :ARG1 (m / mouse 
                  :ARG1-of (b2 / bear-02 
                        :location (f / frequency 
                              :ARG1-of (e / expect-01))) 
                  :mod (k / knockout)) 
            :time (b / birth-01)) 
      :op2 (n / normal-02))

# ::snt Within a day of birth and following suckling , blood levels of BCAA were markedly elevated .
# ::tok Within a day of birth and following suckling , blood levels of BCAA were markedly elevated .
# ::alignments 15-16|0.0.1 14-15|0.0.1.1 12-13|0.0.1.0.1.0.0+0.0.1.0.1.0+0.0.1.0.1 10-11|0.0.1.0 9-10|0.0.1.0.0 7-8|0.0.0.1 6-7|0.0.0.1.0 5-6|0.0.0 4-5|0.0.0.0 2-3|0.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:49.344
(w / within 
      :op1 (d / day 
            :op1-of (a / and 
                  :op2 (b2 / birth-01) 
                  :op3 (s / suckle-01 
                        :ARG1-of (f / follow-01))) 
            :time-of (e / elevate-01 
                  :ARG1 (l / level 
                        :mod (b / blood) 
                        :mod (o / organization 
                              :name (n / name 
                                    :op1 "BCAA"))) 
                  :degree (m / markedly))))

# ::snt Concomitantly , levels of the amino acids alanine , glutamate , and glutamine , whose synthesis is linked with normal metabolism of BCAA , were decreased ( Table 1 ) .
# ::tok Concomitantly , levels of the amino acids alanine , glutamate , and glutamine , whose synthesis is linked with normal metabolism of BCAA , were decreased ( Table 1 ) .
# ::alignments 28-29|0.1.0 27-28|0.1.2.0.0 25-26|0.1.2.0 22-23|0.2.0.0+0.2.0+0.2 20-21|0 19-20|0.0 17-18|0.1 15-16|0.1.1 12-13|0.1.2.4 11-12|0.1.2 9-10|0.1.2.3 7-8|0.1.2.2 6-7|0.1.2.2.0 5-6|0.1.2.2.1 2-3|0.1.2.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:49.632
(m / metabolism 
      :ARG1-of (n2 / normal-02) 
      :ARG2-of (l / link-01 
            :ARG0 1 
            :ARG1 (s / synthesi) 
            :op4-of (a / and 
                  :ARG1-of (d / decrease-01 
                        :ARG0 (t / table)) 
                  :extent (l2 / level) 
                  :op1 (a2 / alanine 
                        :mod (a3 / acid) 
                        :mod (a4 / amino)) 
                  :op2 (g2 / glutamate) 
                  :op3 (g / glutamine))) 
      :poss (o / organization 
            :name (n / name 
                  :op1 "BCAA")))

# ::snt The activity of BCKDH in livers of homozygous knockout mouse pups was undetectable , accounting for the accumulation of unmetabolized BCAA .
# ::tok The activity of BCKDH in livers of homozygous knockout mouse pups was undetectable , accounting for the accumulation of unmetabolized BCAA .
# ::alignments 20-21|0.0.0.0.0.0.0.1.0+0.0.0.0.0.0.0.1+0.0.0.0.0.0.0 19-20|0.0.0.0.0.0.0.0 17-18|0.0.0.0.0.0 14-15|0.0.0.0.0 12-13|0.0.0.0.0.1 10-11|0.0 9-10|0.0.1 8-9|0.0.1.0 7-8|0 5-6|0.0.2 3-4|0.0.0 1-2|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:49.885
(h / homozygou 
      :mod-of (p / pup-01 
            :ARG0 (b / BCKDH 
                  :ARG1-of (a3 / activity-06 
                        :ARG0-of (a2 / account-01 
                              :ARG1 (a / accumulation 
                                    :poss (o / organization 
                                          :mod (u / unmetaboliz) 
                                          :name (n / name 
                                                :op1 "BCAA"))) 
                              :domain-of (u2 / undetectable)))) 
            :ARG1 (m / mouse 
                  :mod (k / knockout)) 
            :mod-of (l / liver)))

# ::snt Immunoreactive E2 protein was absent in liver and fibroblasts of homozygous pups .
# ::tok Immunoreactive E2 protein was absent in liver and fibroblasts of homozygous pups .
# ::alignments 11-12|0.0.0 10-11|0.0.0.0 8-9|0.1.1 7-8|0.1 6-7|0.1.0 4-5|0 2-3|0.0 1-2|0.0.1.0.0+0.0.1.0+0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:49.927
(a2 / absent-01 
      :ARG1 (p2 / protein 
            :ARG0-of (p / pup-01 
                  :mod (h / homozygou)) 
            :mod (t / thing 
                  :name (n / name 
                        :op1 "E2"))) 
      :op1-of (a / and 
            :op2 (l / liver) 
            :op3 (f / fibroblast)))

# ::snt The phenotypic behavior of homozygous mouse pups resembles symptoms seen in newborn classic MSUD patients .
# ::tok The phenotypic behavior of homozygous mouse pups resembles symptoms seen in newborn classic MSUD patients .
# ::alignments 14-15|0.0.0.0+0.0.0+0.0 12-13|0.0.2 11-12|0 9-10|0.0.1 8-9|0.0.1.0 7-8|0.0.1.0.0 6-7|0.0.1.0.0.0.0 5-6|0.0.1.0.0.0.0.0 4-5|0.0.1.0.0.0.0.1 2-3|0.0.1.0.0.0 1-2|0.0.1.0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:50.203
(n / newborn 
      :mod-of (p / person 
            :ARG0-of (h / have-rel-role-91 
                  :ARG2 (p2 / patient)) 
            :ARG0-of (s / see-01 
                  :ARG1 (s2 / symptom 
                        :ARG2-of (r / resemble-01 
                              :ARG0 (b / behave-01 
                                    :ARG0 (p3 / pup-01 
                                          :ARG1 (m / mouse) 
                                          :mod (h2 / homozygou)) 
                                    :ARG1 (p4 / phenotypic))))) 
            :mod (c / classic)))

# ::snt These include signs of neurologic dysfunction such as seizures , stupor , lethargy , loss of motor activity , and respiratory difficulties [ 1 ] .
# ::tok These include signs of neurologic dysfunction such as seizures , stupor , lethargy , loss of motor activity , and respiratory difficulties [ 1 ] .
# ::alignments 23-24|0.0.0.0.3.0 21-22|0.0.0.0.4 20-21|0.0.0.0.4.0 19-20|0.0.0.0 17-18|0.0.0.0.3 16-17|0.0.0.0.3.1 14-15|0.0.0.0.3.2 12-13|0.0.0.0.2 10-11|0.0.0.0.1 8-9|0.0.0.0.0 6-7|0.0.0.0.0.0 5-6|0.0.0 4-5|0.0.0.1 2-3|0.0 1-2|0 0-1|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:50.519
(i / include-01 
      :ARG1 (s4 / sign 
            :mod (d2 / dysfunction 
                  :example (a / and 
                        :op1 (s2 / seize-01 
                              :ARG1 (s3 / such)) 
                        :op2 (s / stupor) 
                        :op3 (l2 / lethargy) 
                        :op4 (a2 / activity-06 
                              :ARG0 1 
                              :ARG1 (m / motorcycle) 
                              :mod-of (l / loss)) 
                        :op5 (d / difficulty 
                              :mod (r / respiratory))) 
                  :mod (n / neurologic))) 
      :ARG2 (t / this))

# ::snt These neurologic symptoms may result from reduced levels of glutamate , glutamine , alanine , and other similar neuroactive amino acids , which are considered the culprit for MSUD encephalopathies in patients [ 1,37 ] .
# ::tok These neurologic symptoms may result from reduced levels of glutamate , glutamine , alanine , and other similar neuroactive amino acids , which are considered the culprit for MSUD encephalopathies in patients [ 1,37 ] .
# ::alignments 31-32|0.2.0.0.6.0.1+0.2.0.0.6.0+0.2.0.0.6 29-30|0.2.0.0.6.0.0 26-27|0.2.0.0.5.0 24-25|0.2.0.0.5 20-21|0.2.0.0.4.0 19-20|0.2.0.0.4.0.0 17-18|0.2.0.0.4 16-17|0.2.0.0.3 15-16|0.2.0.0 13-14|0.2.0.0.2 11-12|0.2.0.0.1 9-10|0.2.0.0.0 7-8|0.2.0 6-7|0.2 4-5|0 3-4|0.1 2-3|0.0 1-2|0.0.1 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:51.096
(r3 / result-01 
      :ARG1 (s / symptom 
            :mod (t / this) 
            :mod (n / neurologic)) 
      :ARG1-of (p3 / possible-01) 
      :ARG2 (r2 / reduce-01 
            :ARG1 (l / level 
                  :prep-at (a3 / and 
                        :op1 (g2 / glutamate) 
                        :op2 (g / glutamine) 
                        :op3 (a4 / alanine) 
                        :op4 (o / other) 
                        :op5 (r / resemble-01 
                              :ARG1 (a / acid 
                                    :mod (a2 / amino))) 
                        :op6 (c2 / consider-01 
                              :ARG1 (c / culprit)) 
                        :op7 (p / person 
                              :ARG0-of (h / have-rel-role-91 
                                    :ARG1 (e / encephalopathi) 
                                    :ARG2 (p2 / patient)))))))

# ::snt Finally , nearly all of the homozygous pups died within 72 hours of birth .
# ::tok Finally , nearly all of the homozygous pups died within 72 hours of birth .
# ::alignments 13-14|0.0 11-12|0.0.0.1+0.0.0 10-11|0.0.0.0 8-9|0.1.0 7-8|0.1 6-7|0 3-4|0.1.0.0 2-3|0.1.0.0.0 0-1|0.1.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:51.144
(h2 / homozygou 
      :ARG1-of (b / birth-01 
            :duration (t / temporal-quantity 
                  :quant 72 
                  :unit (h / hour))) 
      :mod-of (p / pup-01 
            :ARG1-of (d / die-01 
                  :ARG0 (a / all 
                        :mod (n / nearly)) 
                  :op1-of (f / final))))

# ::snt This neonatal lethality is likely due to the accumulation of BCAA to neurotoxic levels , ketoacidosis , brain edema , dehydration , and malnutrition as observed in the MSUD calf [ 17 ] and in classic MSUD patients [ 1 ] .
# ::tok This neonatal lethality is likely due to the accumulation of BCAA to neurotoxic levels , ketoacidosis , brain edema , dehydration , and malnutrition as observed in the MSUD calf [ 17 ] and in classic MSUD patients [ 1 ] .
# ::alignments 39-40|0.0.1.4.0 37-38|0.0.1.6.0.0+0.0.1.6.0+0.0.1.6 35-36|0.0.1.6.1 33-34|0 31-32|0.0.1.4.1 29-30|0.0.2 25-26|0.0 23-24|0.0.1.5 22-23|0.0.1 20-21|0.0.1.4 18-19|0.0.1.3 17-18|0.0.0.0.0.0 15-16|0.0.1.2 13-14|0.0.1.1 12-13|0.0.1.1.0 10-11|0.0.1.0.0.0+0.0.1.0.0+0.0.1.0 8-9|0.0.1.0.1 4-5|0.0.0.0.0 2-3|0.0.0.0 1-2|0.0.0 0-1|0.0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:51.830
(a / and 
      :ARG3-of (o / observe-01 
            :ARG0 (n3 / neonatal 
                  :mod-of (l3 / lethality 
                        :ARG1-of (l2 / likely-01 
                              :ARG0 (b / brain)) 
                        :mod (t / this))) 
            :ARG1 (a2 / and 
                  :example-of (o2 / organization 
                        :name (n2 / name 
                              :op1 "BCAA") 
                        :poss-of (a3 / accumulation)) 
                  :op1 (l / level 
                        :mod (n / neurotoxic)) 
                  :op2 (k / ketoacidosi) 
                  :op3 (e / edema) 
                  :op4 (d / dehydrate-01 
                        :ARG0 1 
                        :ARG1 17) 
                  :op5 (m / malnutrition) 
                  :op6 (p / person 
                        :ARG0-of (h / have-rel-role-91 
                              :ARG2 (p2 / patient)) 
                        :mod (c / classic))) 
            :ARG2 (c2 / calf)))

# ::snt Heterozygous knockouts were normal and had normal levels of BCAA despite having approximately half of BCKDH enzymatic activity .
# ::tok Heterozygous knockouts were normal and had normal levels of BCAA despite having approximately half of BCKDH enzymatic activity .
# ::alignments 17-18|0.1.1.0 16-17|0.1.1.0.0 13-14|0.1.1.0.1 12-13|0.0.0 9-10|0.1.1.1.0+0.1.1.1+0.1.1 7-8|0.1 6-7|0.1.0 4-5|0 3-4|0.0 1-2|0.0.1 0-1|0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:51.930
(a3 / and 
      :op1 (n3 / normal-02 
            :ARG0 (a2 / approximately) 
            :ARG1 (k / knockout 
                  :mod (h2 / heterozygou))) 
      :op2 (l / level 
            :ARG1-of (n2 / normal-02) 
            :mod (o / organization 
                  :ARG0-of (a / activity-06 
                        :ARG1 (e / enzymatic) 
                        :mod-of (h / half)) 
                  :name (n / name 
                        :op1 "BCAA"))))

# ::snt From the characterization studies completed thus far , the null mutation mouse accurately represents a model of classic MSUD and appears to be a faithful model of the human disease with respect to several biochemical phenotypes [ 1 ] .
# ::tok From the characterization studies completed thus far , the null mutation mouse accurately represents a model of classic MSUD and appears to be a faithful model of the human disease with respect to several biochemical phenotypes [ 1 ] .
# ::alignments 37-38|0.0.0.0 35-36|0.3.2.0 34-35|0.3.2.0.0 33-34|0.3.2.0.1 31-32|0.3.2 29-30|0.3.1.1 28-29|0.3.1.1.0 25-26|0.3.1 24-25|0.3.1.0 20-21|0.3 19-20|0 17-18|0.2.2.0 15-16|0.2.1 13-14|0.2 12-13|0.1 11-12|0.0 10-11|0.2.0 9-10|0.0.0 6-7|0.2.2.2.0 5-6|0.3.0 4-5|0.2.2.2 3-4|0.2.2 2-3|0.2.2.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:52.704
(a2 / and 
      :op1 (m3 / mouse 
            :ARG1-of (n / null-02 
                  :ARG0 1)) 
      :op2 (a3 / accurate) 
      :op3 (r2 / represent-01 
            :ARG0 (m4 / mutation) 
            :ARG1 (m2 / model) 
            :ARG2 (s2 / study-01 
                  :ARG0 (c / classic) 
                  :ARG1 (c3 / characterization) 
                  :ARG1-of (c2 / complete-01 
                        :ARG2 (f2 / far)))) 
      :op4 (a / appear-02 
            :ARG0 (t / thus-far) 
            :ARG1 (m / model 
                  :mod (f / faithful) 
                  :poss (d / disease 
                        :mod (h / human))) 
            :subevent-of (r / respect-01 
                  :ARG1 (p / phenotyp 
                        :mod (b / biochemical) 
                        :quant (s / several)))))

# ::snt To create a model of intermediate MSUD , we used a transgenic strategy to express human E2 in the liver of E2 knockout mice .
# ::tok To create a model of intermediate MSUD , we used a transgenic strategy to express human E2 in the liver of E2 knockout mice .
# ::alignments 23-24|0.0 22-23|0 19-20|0.0.0 16-17|0.0.0.0.1.1.0+0.0.0.0.1.1+0.0.0.0.1 15-16|0.0.0.0.1.0 14-15|0.0.0.0 12-13|0.0.0.0.0 9-10|0.0.0.0.3 8-9|0.0.0.0.3.0 5-6|0.0.0.0.2 3-4|0.0.0.0.3.1 1-2|0.0.0.0.3.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:53.205
(k / knockout 
      :mod-of (m / mouse 
            :mod-of (l / liver 
                  :manner-of (e / express-01 
                        :ARG0 (s / strategy) 
                        :ARG1 (t / thing 
                              :mod (h / human) 
                              :name (n / name 
                                    :op1 "E2")) 
                        :ARG2 (i / intermediate) 
                        :purpose-of (u / use-01 
                              :ARG0 (w / we) 
                              :ARG1 (m2 / model 
                                    :ARG1-of (c / create-01)))))))

# ::snt As mentioned above , E2 knockouts without transgene derived E2 die during the early neonatal period .
# ::tok As mentioned above , E2 knockouts without transgene derived E2 die during the early neonatal period .
# ::alignments 15-16|0.1.1 14-15|0.1.1.0 13-14|0.1.1.1 10-11|0.1 8-9|0 7-8|0.0 5-6|0.1.0 4-5|0.1.0.0.0.0+0.1.0.0.0+0.1.0.0 2-3|0.2.0 1-2|0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:53.352
(d2 / derive-01 
      :ARG0 (t / transgene) 
      :ARG1 (d / die-01 
            :ARG0 (k / knockout 
                  :mod (t2 / thing 
                        :name (n2 / name 
                              :op1 "E2"))) 
            :time (p / period 
                  :mod (n / neonatal) 
                  :mod (e / early))) 
      :condition (m / mention-01 
            :location (a / above)))

# ::snt We show that expression of a human E2 transgene in the liver of these knockout mice is able to rescue the neonatal lethality .
# ::tok We show that expression of a human E2 transgene in the liver of these knockout mice is able to rescue the neonatal lethality .
# ::alignments 22-23|0.1.0.1 21-22|0.1.0.1.0 19-20|0.1.0 17-18|0.1 15-16|0.1.0.2 14-15|0.1.0.2.0 13-14|0.1.0.2.1 11-12|0.1.0.0.1 8-9|0.1.0.0.0 7-8|0.1.0.0.0.0.0.0.0+0.1.0.0.0.0.0.0+0.1.0.0.0.0.0 6-7|0.1.0.0.0.0 3-4|0.1.0.0 1-2|0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:53.979
(s / show-01 
      :ARG0 (w / we) 
      :ARG1 (p / possible-01 
            :ARG1 (r / rescue-01 
                  :ARG0 (e / express-01 
                        :ARG1 (t2 / transgene 
                              :mod (h / human 
                                    :mod-of (t3 / thing 
                                          :name (n2 / name 
                                                :op1 "E2")))) 
                        :location (l2 / liver)) 
                  :ARG1 (l / lethality 
                        :mod (n / neonatal)) 
                  :ARG2 (m / mouse 
                        :mod (k / knockout) 
                        :mod (t / this)))))

# ::snt Many of the rescue mice survived to adulthood .
# ::tok Many of the rescue mice survived to adulthood .
# ::alignments 7-8|0.0.1 5-6|0.0 4-5|0 3-4|0.0.0 0-1|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:53.997
(m / mouse 
      :ARG0-of (s / survive-01 
            :ARG1 (r / rescue-01) 
            :ARG2 (a / adulthood)) 
      :quant (m2 / many))

# ::snt It is interesting to note that in these mouse lines only ~ 5 -- 6 % of normal BCKDH activity in the liver was sufficient to allow survival .
# ::tok It is interesting to note that in these mouse lines only ~ 5 -- 6 % of normal BCKDH activity in the liver was sufficient to allow survival .
# ::alignments 27-28|0.1.0.0.1 26-27|0.1.0.0 24-25|0.1.0 22-23|0.1.0.0.0 19-20|0.1.0.0.0.0 17-18|0.1.0.0.0.0.1 15-16|0.1.0.0.0.0.2 14-15|0.1.0.0.1.1 12-13|0.1.0.0.0.0.0 10-11|0.1.0.0.0.0.1.0 9-10|0.1.0.0.1.0 8-9|0.1.0.0.1.0.1 7-8|0.1.0.0.1.0.0 4-5|0.1 2-3|0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:54.283
(i / interest-01 
      :ARG1 (i2 / it) 
      :ARG2 (n2 / note-01 
            :ARG1 (s2 / suffice-01 
                  :ARG0 (a / allow-01 
                        :ARG0 (l / liver 
                              :ARG1-of (a2 / activity-06 
                                    :ARG0 5 
                                    :ARG1-of (n / normal-02 
                                          :ARG0 (o / only)) 
                                    :quant (p / percentage-entity))) 
                        :ARG1 (s / survive-01 
                              :ARG0 (l2 / line 
                                    :mod (t / this) 
                                    :mod (m / mouse)) 
                              :ARG1 6)))))

# ::snt We also demonstrated that BCAA levels in blood of these rescue mice were intermediate between controls and knockouts .
# ::tok We also demonstrated that BCAA levels in blood of these rescue mice were intermediate between controls and knockouts .
# ::alignments 17-18|0.1.0.2 16-17|0.1.0 15-16|0.1.0.1 13-14|0.1 11-12|0.1.0.0 10-11|0.1.0.1.0.0 9-10|0.1.0.0.0 7-8|0.1.0.0.1 5-6|0.1.0.1.0 4-5|0.1.0.1.0.1.0.0+0.1.0.1.0.1.0+0.1.0.1.0.1 2-3|0 1-2|0.2 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:54.545
(d / demonstrate-01 
      :ARG0 (w / we) 
      :ARG1 (i / intermediate 
            :op2-of (a / and 
                  :op1 (m / mouse 
                        :mod (t / this) 
                        :mod-of (b / blood)) 
                  :op3 (c / control-01 
                        :ARG1 (l / level 
                              :ARG0-of (r / rescue-01) 
                              :mod (o / organization 
                                    :name (n / name 
                                          :op1 "BCAA")))) 
                  :op4 (k / knockout))) 
      :mod (a2 / also))

# ::snt The hallmarks of intermediate MSUD human patients are persistently increased levels of BCAA and BCKDH activity in the range of 3 -- 30 % of normal [ 1 ] .
# ::tok The hallmarks of intermediate MSUD human patients are persistently increased levels of BCAA and BCKDH activity in the range of 3 -- 30 % of normal [ 1 ] .
# ::alignments 27-28|0.0.1.0 25-26|0.0.0.0 23-24|0.0.1.1.0 22-23|0.0.1.1 20-21|0.0.0.0.0 18-19|0.0.0 15-16|0.0.1 13-14|0.0.1.2 12-13|0.0.1.2.0.0.0+0.0.1.2.0.0+0.0.1.2.0 10-11|0.0 9-10|0 8-9|0.2 6-7|0.1.0.0.0+0.1.0.0+0.1.0 5-6|0.1.0.1 3-4|0.1.0.2 1-2|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:55.193
(i / increase-01 
      :ARG1 (l / level 
            :ARG1-of (r / range-01 
                  :ARG2-of (n / normal-02 
                        :ARG1 3)) 
            :mod (a / activity-06 
                  :ARG0 1 
                  :ARG1 (3 / 30 
                        :value-of (p / percentage-entity)) 
                  :op2-of (a2 / and 
                        :op1 (o / organization 
                              :name (n2 / name 
                                    :op1 "BCAA"))))) 
      :ARG2 (h3 / hallmark 
            :poss (p3 / person 
                  :ARG0-of (h / have-rel-role-91 
                        :ARG2 (p4 / patient)) 
                  :mod (h2 / human) 
                  :mod (i2 / intermediate))) 
      :manner (p2 / persistently))

# ::snt Because of the phenotypic similarities of the rescue mice to the human patients , these genetically engineered mice represent a useful small animal model of the intermediate form of MSUD .
# ::tok Because of the phenotypic similarities of the rescue mice to the human patients , these genetically engineered mice represent a useful small animal model of the intermediate form of MSUD .
# ::alignments 27-28|0.1.3 26-27|0.1.3.0 23-24|0.1 22-23|0.1.2 21-22|0.1.1 20-21|0.1.0 18-19|0 17-18|0.0 16-17|0.0.0 15-16|0.0.0.0 14-15|0.1.0.0.0 12-13|0.2.0.0.0.0+0.2.0.0.0+0.2.0.0 11-12|0.2.0.0.1 8-9|0.2.0.1 7-8|0.1.0.0 4-5|0.2.0 3-4|0.2.0.2 0-1|0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:55.701
(r / represent-01 
      :ARG0 (m2 / mouse 
            :ARG1-of (e / engineer-01 
                  :ARG2 (g / genetics))) 
      :ARG1 (m / model 
            :ARG1-of (u / useful-05 
                  :ARG1-of (r2 / rescue-01 
                        :ARG0 (t / this))) 
            :mod (s / small) 
            :mod (a / animal) 
            :poss (f / form 
                  :mod (i / intermediate))) 
      :ARG1-of (c / cause-01 
            :ARG0 (s2 / similar-00 
                  :ARG0 (p / person 
                        :ARG0-of (h / have-rel-role-91 
                              :ARG2 (p2 / patient)) 
                        :mod (h2 / human)) 
                  :ARG1 (m3 / mouse) 
                  :mod (p3 / phenotypic))))

# ::snt The transgenic approach that was used to create the intermediate MSUD model was based on the tetracycline regulated gene switch system that has been used with great success in other studies , for example [ 34 ] .
# ::tok The transgenic approach that was used to create the intermediate MSUD model was based on the tetracycline regulated gene switch system that has been used with great success in other studies , for example [ 34 ] .
# ::alignments 35-36|0.1.1.0.0 33-34|0.1.2.1 30-31|0.1.1.0 29-30|0.1.1.0.2 27-28|0.1.1.0.1 26-27|0.1.1.0.1.0 24-25|0.1.1 20-21|0.1 19-20|0.1.2 18-19|0.1.3 17-18|0.1.0 16-17|0.1.2.0 13-14|0 11-12|0.0.0.0.0 9-10|0.0.0.0.0.0 7-8|0.0.0.0 5-6|0.0.0 2-3|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:55.923
(b / base-02 
      :ARG1 (a / approach-02 
            :ARG1-of (u2 / use-01 
                  :ARG2 (c / create-01 
                        :ARG1 (m / model 
                              :mod (i / intermediate))))) 
      :ARG2 (s3 / system 
            :ARG1-of (r / regulate-01) 
            :ARG1-of (u / use-01 
                  :ARG2 (s / study-01 
                        :ARG1 34 
                        :ARG1-of (s2 / succeed-01 
                              :mod (g / great)) 
                        :mod (o / other))) 
            :mod (s4 / switch-01 
                  :ARG0 (t / tetracycline) 
                  :ARG2 (e / example)) 
            :mod (g2 / gene)))

# ::snt The strategy behind our approach was to create mice with an intermediate MSUD phenotype that could be converted to the classic phenotype at the investigator 's discretion by turning off the rescuing transgene .
# ::tok The strategy behind our approach was to create mice with an intermediate MSUD phenotype that could be converted to the classic phenotype at the investigator 's discretion by turning off the rescuing transgene .
# ::alignments 32-33|0.0.2.1 31-32|0.0.2.1.0 28-29|0.0.2 26-27|0.0.2.0.0 24-25|0.0.2.0 21-22|0 20-21|0.1 17-18|0.0 15-16|0.0.1 13-14|0.0.0 11-12|0.0.0.0 8-9|0.0.1.0.1 7-8|0.0.1.0 4-5|0.0.1.0.0 3-4|0.0.1.0.0.0 2-3|0.0.1.0.0.1 1-2|0.0.1.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:56.175
(p / phenotype 
      :ARG2-of (c2 / convert-01 
            :ARG1 (p3 / phenotype 
                  :mod (i2 / intermediate)) 
            :ARG1-of (p2 / possible-01 
                  :ARG2-of (c3 / create-01 
                        :ARG0 (a / approach-02 
                              :ARG1 (w / we) 
                              :op1-of (b / behind)) 
                        :ARG1 (m / mouse) 
                        :domain-of (s / strategy))) 
            :manner (t2 / turn-02 
                  :ARG0 (i / investigator 
                        :poss-of (d / discretion)) 
                  :ARG1 (t / transgene 
                        :ARG1-of (r / rescue-01)))) 
      :mod (c / classic))

# ::snt However , we were unable to consistently turn off the human E2 expression cassette by the potent tetracycline analogue , doxycycline in either of the two transgenic lines tested ( data not shown ) .
# ::tok However , we were unable to consistently turn off the human E2 expression cassette by the potent tetracycline analogue , doxycycline in either of the two transgenic lines tested ( data not shown ) .
# ::alignments 32-33|0 31-32|0.2 30-31|0.1 28-29|0.0.0.1 27-28|0.0.0.1.1 25-26|0.0.0.1.1.1 22-23|0.0.0.1.1.0 20-21|0.0.0.1.0 18-19|0.0.0.0.0 17-18|0.0.0.0.0.0 16-17|0.0.0.0.0.1 13-14|0.0.1.0 12-13|0.0.1 11-12|0.0.2.0+0.0.2+0.0 10-11|0.0.1.1 7-8|0.0.0 6-7|0.0.0.2 2-3|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:56.884
(s / show-01 
      :ARG0 (t3 / thing 
            :ARG1-of (t4 / turn-02 
                  :ARG0 (w / we 
                        :part (a / analogue 
                              :mod (t2 / tetracycline) 
                              :mod (p / potent))) 
                  :ARG2-of (t / test-01 
                        :ARG0 (d2 / doxycycline) 
                        :ARG1 (l / line 
                              :mod (e / either) 
                              :quant 2)) 
                  :manner (c2 / consistent)) 
            :ARG1-of (e2 / express-01 
                  :ARG0 (c / cassette) 
                  :mod (h / human)) 
            :name (n / name 
                  :op1 "E2")) 
      :ARG1 (d / data) 
      :polarity -)

# ::snt The reason these two lines were unresponsive to doxycycline is unknown .
# ::tok The reason these two lines were unresponsive to doxycycline is unknown .
# ::alignments 10-11|0.3+0 8-9|0.2 6-7|0.0.0.0 4-5|0.0.0 3-4|0.0.0.1 2-3|0.0 1-2|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:56.927
(k / know-01 
      :ARG0 (t / this 
            :mod-of (l / line 
                  :domain-of (u / unresponsive) 
                  :quant 2)) 
      :ARG1 (r / reason) 
      :op1-of (d / doxycycline) 
      :polarity -)

# ::snt It is conceivable that the integration site of the transgenes was not permissive for regulated expression .
# ::tok It is conceivable that the integration site of the transgenes was not permissive for regulated expression .
# ::alignments 15-16|0 14-15|0.0 12-13|0.1 11-12|0.1.1 9-10|0.0.0 6-7|0.1.0 5-6|0.1.0.0 2-3|0.1.0.0.0.0 0-1|0.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:57.025
(e / express-01 
      :ARG1-of (r / regulate-01 
            :ARG0 (t / transgen)) 
      :ARG1-of (p / permissive-02 
            :domain (s / site 
                  :mod (i / integrate-01 
                        :ARG0 (i2 / it 
                              :ARG1-of (c / conceive-01)))) 
            :polarity -))

# ::snt Screening of additional lines may be needed to find lines that allow for survival and can also be regulated .
# ::tok Screening of additional lines may be needed to find lines that allow for survival and can also be regulated .
# ::alignments 18-19|0.1.0 16-17|0.1.0.0 15-16|0.1 14-15|0 13-14|0.0.1 11-12|0.0 9-10|0.0.0 8-9|0.0.0.0 6-7|0.0.0.0.0 4-5|0.0.0.0.0.1 3-4|0.0.0.0.0.0.0 2-3|0.0.0.0.0.0.0.0 0-1|0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:57.233
(a2 / and 
      :op1 (a3 / allow-01 
            :ARG0 (l / line 
                  :ARG1-of (f / find-01 
                        :purpose-of (n / need-01 
                              :ARG1 (s2 / screen-01 
                                    :ARG1 (l2 / line 
                                          :mod (a4 / additional))) 
                              :ARG1-of (p2 / possible-01)))) 
            :ARG1 (s / survive-01)) 
      :op2 (p / possible-01 
            :ARG1 (r / regulate-01 
                  :mod (a / also))))

# ::snt The models described in this communication are important advances over the previously described models .
# ::tok The models described in this communication are important advances over the previously described models .
# ::alignments 13-14|0.0.0.0.0 12-13|0.0.0.0 11-12|0.0.0.0.1 8-9|0.0.0 7-8|0.0.0.1 5-6|0.1 4-5|0.1.0 2-3|0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:57.424
(d2 / describe-01 
      :ARG1 (m2 / model 
            :ARG1-of (a / advance-01 
                  :ARG0 (d / describe-01 
                        :ARG1 (m / model) 
                        :time (p / previous)) 
                  :mod (i / important))) 
      :ARG1-of (c / communicate-01 
            :mod (t / this)))

# ::snt An ENU mouse resembling human MSUD was previously created by disrupting the mitochondrial BCAT gene [ 20 ] .
# ::tok An ENU mouse resembling human MSUD was previously created by disrupting the mitochondrial BCAT gene [ 20 ] .
# ::alignments 16-17|0.0.0.0.0 14-15|0.0.1 10-11|0.0 8-9|0 7-8|0.1 4-5|0.0.0.0.1 3-4|0.0.0.0 2-3|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:57.502
(c / create-01 
      :ARG1 (d / disrupt-01 
            :ARG0 (m / mouse 
                  :ARG1-of (r / resemble-01 
                        :ARG0 20 
                        :ARG2 (h / human))) 
            :ARG1 (g / gene)) 
      :time (p / previous))

# ::snt The BCKDH activity in the liver and muscle of this mouse was normal even though the blood BCAA levels were markedly elevated .
# ::tok The BCKDH activity in the liver and muscle of this mouse was normal even though the blood BCAA levels were markedly elevated .
# ::alignments 21-22|0.0 20-21|0 18-19|0.0.0 17-18|0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 16-17|0.0.0.1 13-14|0.0.1.0 12-13|0.0.1 10-11|0.0.1.1.1.1.0 9-10|0.0.1.1.1.1.0.0 7-8|0.0.1.1.1.1 6-7|0.0.1.1.1 5-6|0.0.1.1.1.0 2-3|0.0.1.1 1-2|0.0.1.1.0.0.0+0.0.1.1.0.0+0.0.1.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:57.655
(m / markedly 
      :degree-of (e / elevate-01 
            :ARG1 (l / level 
                  :mod (o / organization 
                        :name (n / name 
                              :op1 "BCAA")) 
                  :mod (b / blood)) 
            :time-of (n2 / normal-02 
                  :ARG0 (e2 / even) 
                  :ARG1 (a2 / activity-06 
                        :ARG1 (t2 / thing 
                              :name (n3 / name 
                                    :op1 "BCKDH")) 
                        :location (a / and 
                              :op1 (l2 / liver) 
                              :op2 (m3 / muscle-01 
                                    :ARG1 (m2 / mouse 
                                          :mod (t / this))))))))

# ::snt While this is an interesting model , it is not a true model of MSUD because the mutation is not in BCKDH and the levels of BCKDH are normal .
# ::tok While this is an interesting model , it is not a true model of MSUD because the mutation is not in BCKDH and the levels of BCKDH are normal .
# ::alignments 28-29|0.0.2 24-25|0.0.2.1 22-23|0.0 21-22|0.0.1.0.0+0.0.1.0+0.0.1 19-20|0.1.0.0 17-18|0.0.2.0 15-16|0 12-13|0.1 11-12|0.1.1 9-10|0.1.2 5-6|0.0.0.0 4-5|0.0.0 1-2|0.0.0.0.0 0-1|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:58.029
(c2 / cause-01 
      :ARG0 (a / and 
            :ARG0-of (i / interest-01 
                  :ARG1 (m3 / model 
                        :domain (t2 / this))) 
            :op1 (c / country 
                  :name (n2 / name 
                        :op1 "BCKDH")) 
            :op2 (n / normal-02 
                  :ARG0 (m / mutation) 
                  :ARG1 (l / level))) 
      :ARG1 (m2 / model 
            :ARG1-of (w / while-01 
                  :ARG0 -) 
            :mod (t / true) 
            :polarity -))

# ::snt Furthermore , no case of MSUD has been described attributing this disease to BCAT deficiency .
# ::tok Furthermore , no case of MSUD has been described attributing this disease to BCAT deficiency .
# ::alignments 14-15|0.0.1 11-12|0.0.0 10-11|0.0.0.0 9-10|0.0 8-9|0 3-4|0.1 2-3|0.2 0-1|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:58.273
(d3 / describe-01 
      :ARG0 (a / attribute-01 
            :ARG1 (d2 / disease 
                  :mod (t / this)) 
            :ARG2 (d / deficiency)) 
      :ARG1 (c / case-03 
            :ARG0 (f / furthermore)) 
      :polarity -)

# ::snt In addition to this mouse model , a cow model of MSUD has also been previously described [ 17-19 ] .
# ::tok In addition to this mouse model , a cow model of MSUD has also been previously described [ 17-19 ] .
# ::alignments 16-17|0 15-16|0.2 13-14|0.1 9-10|0.0 8-9|0.0.0 5-6|0.0.1.0 4-5|0.0.1 3-4|0.0.1.0.1 1-2|0.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:58.350
(d / describe-01 
      :ARG1 (m / model 
            :mod (c / cow) 
            :mod (m3 / mouse 
                  :mod-of (m2 / model 
                        :beneficiary-of (a2 / addition) 
                        :mod (t / this)))) 
      :mod (a / also) 
      :time (p / previous))

# ::snt However , due to practical constraints imposed by such a large animal model and due to the observation of differences between the MSUD cow model and MSUD humans [ 1 ] , this model is also of limited utility .
# ::tok However , due to practical constraints imposed by such a large animal model and due to the observation of differences between the MSUD cow model and MSUD humans [ 1 ] , this model is also of limited utility .
# ::alignments 38-39|0.0.0.1.0 37-38|0.0.0.1 35-36|0.1.0.0 33-34|0.0.0.0.0.0 32-33|0.0.0.0.0.0.0 29-30|0.0.0.0.0.1 27-28|0.1.0.1 25-26|0 24-25|0.1 23-24|0.1.1 19-20|0.1.0 17-18|0.0 13-14|0.0.0 12-13|0.0.0.2 11-12|0.0.0.2.0 10-11|0.0.0.2.1 8-9|0.0.0.2.2 6-7|0.0.0.0 5-6|0.0.0.0.0 4-5|0.0.0.0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:58.813
(a2 / and 
      :op1 (o / observation 
            :beneficiary-of (a3 / and 
                  :ARG0-of (i / impose-01 
                        :ARG1 (c2 / constrain-01 
                              :ARG0 (m / model 
                                    :mod (t / this)) 
                              :ARG1 1 
                              :mod (p / practical))) 
                  :ARG2-of (l / limit-01 
                        :ARG1 (u / utility)) 
                  :op1 (m3 / model 
                        :mod (a4 / animal) 
                        :mod (l2 / large) 
                        :quant (s / such)))) 
      :op2 (m2 / model 
            :ARG2-of (d / differ-01 
                  :ARG0 (a / also) 
                  :ARG1 (h / human)) 
            :mod (c / cow)))

# ::snt In contrast , the murine models described in this report are more valid and appropriate for modeling human MSUD .
# ::tok In contrast , the murine models described in this report are more valid and appropriate for modeling human MSUD .
# ::alignments 17-18|0.0.0.2.0 16-17|0.0.1 14-15|0.0 13-14|0 12-13|0.0.0.1 11-12|0.0.0.1.0 9-10|0.0.0.2.1 8-9|0.0.1.0 6-7|0.0.0.2 5-6|0.0.0 4-5|0.0.0.3 1-2|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:58.928
(a2 / and 
      :op1 (a / appropriate-02 
            :ARG0 (m3 / model 
                  :ARG0-of (c / contrast-01) 
                  :ARG1-of (v / valid-02 
                        :degree (m2 / more)) 
                  :ARG1-of (d / describe-01 
                        :ARG0 (h / human) 
                        :medium (r / report)) 
                  :mod (m4 / murine)) 
            :ARG1 (m / model-01 
                  :ARG1 (t / this))))

# ::snt The most significant opportunity presented by the MSUD mouse models is to test novel treatments such as gene [ 38-41 ] and cell based therapies ( e.g. , hepatocytes [ 42,43 ] or embryonic stem cells [ 44 ] ) .
# ::tok The most significant opportunity presented by the MSUD mouse models is to test novel treatments such as gene [ 38-41 ] and cell based therapies ( e.g. , hepatocytes [ 42,43 ] or embryonic stem cells [ 44 ] ) .
# ::alignments 37-38|0.0.0.1.0 35-36|0.1 34-35|0.1.0 33-34|0.1.1 32-33|0 28-29|0.0.0.0.1.2 26-27|0.0.0.0.1.1 24-25|0.0.1.0.0 23-24|0.0.1.0 22-23|0.0.1 21-22|0.0 17-18|0.0.0.0.0.0 15-16|0.0.0.1.1 14-15|0.0.0.1 13-14|0.0.0.1.2 12-13|0.0.0 9-10|0.0.0.0.1.0 8-9|0.0.0.0.1.0.0 4-5|0.0.0.0.1 3-4|0.0.0.0 2-3|0.0.0.0.0 1-2|0.0.1.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:13:59.530
(o / or 
      :op1 (a / and 
            :op1 (t3 / test-01 
                  :ARG0 (o2 / opportunity 
                        :ARG1-of (s3 / significant-02 
                              :ARG0 (g / gene)) 
                        :ARG1-of (p / present-01 
                              :ARG0 (m / model 
                                    :mod (m2 / mouse)) 
                              :op1-of (e2 / e.g.) 
                              :op1-of (h / hepatocyt))) 
                  :ARG1 (t2 / treat-03 
                        :ARG0 44 
                        :ARG1 (s2 / such) 
                        :ARG2 (n / novel))) 
            :op2 (c2 / cell 
                  :ARG0-of (b / base-02 
                        :ARG1 (t / therapi) 
                        :ARG2 (m3 / most)))) 
      :op2 (c / cell 
            :mod (s / stem) 
            :mod (e / embryonic)))

# ::snt Relevant to gene therapy , recent problems with gene therapy in humans highlight the importance and critical need of animal models of genetic diseases for preclinical studies .
# ::tok Relevant to gene therapy , recent problems with gene therapy in humans highlight the importance and critical need of animal models of genetic diseases for preclinical studies .
# ::alignments 26-27|0.1.1.0.0 25-26|0.1.1.0.0.1 23-24|0.1.1.0 22-23|0.1.1.1.0 20-21|0.1.1.1 19-20|0.1.1.1.1 17-18|0.1.1 16-17|0.1.1.2 15-16|0.1 14-15|0.1.0 12-13|0 11-12|0.0.1.0 9-10|0.0.1 8-9|0.0.1.1 6-7|0.0 5-6|0.0.0 3-4|0.2 2-3|0.2.0 0-1|0.1.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:14:00.105
(h / highlight-01 
      :ARG0 (p2 / problem 
            :time (r / recent) 
            :topic (t / therapy 
                  :location (h2 / human) 
                  :mod (g2 / gene))) 
      :ARG1 (a2 / and 
            :op1 (i / important) 
            :op2 (n / need-01 
                  :ARG0 (d / disease 
                        :purpose (s / study-01 
                              :ARG0 (r2 / relevant) 
                              :ARG1 (p / preclinical))) 
                  :ARG1 (m / model 
                        :location (g / gene) 
                        :mod (a / animal)) 
                  :ARG1-of (c / critical-02))) 
      :ARG2 (t2 / therapy 
            :mod (g3 / gene)))

# ::snt The testing of gene and cell based therapies on appropriate animal model systems provides a preliminary method of establishing not only the efficacy , but also short - and long-term safety .
# ::tok The testing of gene and cell based therapies on appropriate animal model systems provides a preliminary method of establishing not only the efficacy , but also short - and long-term safety .
# ::alignments 30-31|0.1.1 29-30|0.1.0 28-29|0.1 26-27|0.1.1.1 25-26|0.1.1.0 24-25|0 22-23|0.2.0 20-21|0.0 19-20|0.0.0 18-19|0.2 16-17|0.2.1 15-16|0.2.1.1 13-14|0.2.1.0 12-13|0.2.1.0.0.0.2.0 11-12|0.2.1.0.0.0.2 10-11|0.2.1.0.0.0.2.1 9-10|0.2.1.0.0.0.2.0.0 7-8|0.2.1.0.0.0.1.0.0 6-7|0.2.1.0.0.0.1.0 5-6|0.2.1.0.0.0.1 4-5|0.2.1.0.0.0 3-4|0.2.1.0.0.0.0 1-2|0.2.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:14:01.099
(c / contrast-01 
      :ARG1 (o / only 
            :polarity -) 
      :ARG2 (a / and 
            :op1 (l / long-term) 
            :op2 (s / safe-01 
                  :ARG1 (a2 / also) 
                  :mod (s2 / short))) 
      :ARG2-of (e2 / establish-01 
            :ARG1 (e / efficacy) 
            :instrument (m / method 
                  :ARG1-of (p2 / provide-01 
                        :ARG0 (t2 / test-01 
                              :ARG1 (a5 / and 
                                    :op1 (g / gene) 
                                    :op2 (c2 / cell 
                                          :ARG0-of (b / base-02 
                                                :ARG1 (t / therapi))) 
                                    :op3 (m2 / model 
                                          :mod-of (s3 / system 
                                                :ARG1-of (a4 / appropriate-02)) 
                                          :poss (a3 / animal))))) 
                  :mod (p / preliminary))))

# ::snt Success with animal studies is expected to advance such therapeutic approaches and could pave the way for studies in humans .
# ::tok Success with animal studies is expected to advance such therapeutic approaches and could pave the way for studies in humans .
# ::alignments 19-20|0.1.0.0.0.0.0 17-18|0.1.0.0.0.0 15-16|0.1.0.0.0 13-14|0.1.0.0 12-13|0.1.0 11-12|0.1 10-11|0.0.1 9-10|0.0.1.0.0 8-9|0.0.1.0 7-8|0.0 5-6|0 3-4|0.0.0.0 2-3|0.0.0.0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:14:01.188
(e / expect-01 
      :ARG1 (a3 / advance-01 
            :ARG0 (s4 / succes 
                  :topic (s3 / study-01 
                        :ARG1 (a4 / animal))) 
            :ARG1 (a2 / approach-02 
                  :mod (s2 / such 
                        :degree-of (t / therapeutic)))) 
      :op1-of (a / and 
            :op2 (p2 / possible-01 
                  :ARG1 (p / pave-02 
                        :ARG1 (w / way 
                              :purpose (s / study-01 
                                    :ARG0 (h / human)))))))

# ::snt In addition to testing various treatments , these models should also be very useful for investigating the underlying pathophysiologic consequences of the disease .
# ::tok In addition to testing various treatments , these models should also be very useful for investigating the underlying pathophysiologic consequences of the disease .
# ::alignments 22-23|0.0.1.0.1 19-20|0.0.1.0 17-18|0.0.1.0.0 15-16|0.0.1 13-14|0.0 12-13|0.0.2 10-11|0.0.3 9-10|0 8-9|0.0.0 7-8|0.0.0.1 5-6|0.0.0.0 4-5|0.0.0.0.1 3-4|0.0.0.0.0 1-2|0.0.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:14:01.449
(r / recommend-01 
      :ARG1 (u2 / useful-05 
            :ARG1 (m / model 
                  :ARG1-of (t2 / treat-03 
                        :ARG1-of (t3 / test-01) 
                        :mod (v2 / various)) 
                  :mod (t / this)) 
            :ARG2 (i / investigate-01 
                  :ARG1 (c / consequence 
                        :ARG1-of (u / underlie-01 
                              :ARG0 (a2 / addition)) 
                        :poss (d / disease))) 
            :degree (v / very) 
            :mod (a / also)))

# ::snt Such studies are very difficult/impossible to do in human patients for obvious ethical reasons , and often must rely on autopsy tissue .
# ::tok Such studies are very difficult/impossible to do in human patients for obvious ethical reasons , and often must rely on autopsy tissue .
# ::alignments 21-22|0.0.1 20-21|0.0.1.0 18-19|0.0 16-17|0.0.2 15-16|0 13-14|0.0.0.0.0.0.0 12-13|0.0.0.0.0.0.0.1 11-12|0.0.0.0.0.0.0.0 9-10|0.0.0.0.0.0.1+0.0.0.0.0.0+0.0.0.0.0 8-9|0.0.0.0.0.1 6-7|0.0.0.0 3-4|0.0.1.0.0 1-2|0.0.0 0-1|0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:14:01.821
(a2 / and 
      :op1 (r / rely-01 
            :ARG0 (s / study-01 
                  :ARG1-of (d / do-02 
                        :ARG0 (p / person 
                              :ARG0-of (h / have-rel-role-91 
                                    :ARG1 (r2 / reason 
                                          :ARG1-of (o2 / obvious-01) 
                                          :mod (e / ethics)) 
                                    :ARG2 (p2 / patient)) 
                              :mod (h2 / human))) 
                  :mod (s2 / such)) 
            :ARG1 (t / tissue 
                  :ARG1-of (a / autopsy-01 
                        :ARG0 (v / very))) 
            :frequency (o / often)))

# ::snt Additionally , the intermediate MSUD model may also be useful for studies to test the effect of thiamin .
# ::tok Additionally , the intermediate MSUD model may also be useful for studies to test the effect of thiamin .
# ::alignments 17-18|0.0.1.0.0.0 15-16|0.0.1.0.0 13-14|0.0.1.0 11-12|0.0.1 9-10|0.0 7-8|0.0.2 6-7|0 5-6|0.0.0 3-4|0.0.0.0 0-1|0.0.1.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:14:01.877
(p / possible-01 
      :ARG1 (u / useful-05 
            :ARG1 (m / model 
                  :mod (i / intermediate)) 
            :ARG2 (s / study-01 
                  :ARG1 (t2 / test-01 
                        :ARG1 (e / effect-03 
                              :ARG0 (t / thiamin) 
                              :ARG1 (a2 / additional)))) 
            :mod (a / also)))

# ::snt A thiamin-responsive form of MSUD has been described [ 1 ] .
# ::tok A thiamin-responsive form of MSUD has been described [ 1 ] .
# ::alignments 9-10|0.0.0 7-8|0 2-3|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:14:01.894
(d / describe-01 
      :ARG1 (f / form 
            :op1-of 1))

# ::snt The phenotype of these patients is heterogeneous and treatment with a wide range of thiamin doses has produced limited success [ 1 ] .
# ::tok The phenotype of these patients is heterogeneous and treatment with a wide range of thiamin doses has produced limited success [ 1 ] .
# ::alignments 21-22|0.1.0.0.0.0 19-20|0.0.0 18-19|0.0.0.0 17-18|0.1 15-16|0.1.0.0.0 14-15|0.1.0.0.0.1 12-13|0.1.0.0 11-12|0.1.0.0.1 8-9|0.1.0 7-8|0 6-7|0.1.1.0 4-5|0.0.1.0+0.0.1+0.0 3-4|0.0.2 1-2|0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:14:02.009
(a / and 
      :op1 (p2 / person 
            :ARG0-of (s / succeed-01 
                  :ARG1-of (l / limit-01)) 
            :ARG0-of (h2 / have-rel-role-91 
                  :ARG2 (p3 / patient)) 
            :mod (t3 / this)) 
      :op2 (p / produce-01 
            :ARG0 (t2 / treat-03 
                  :ARG1 (r / range-01 
                        :ARG1 (d / dose-01 
                              :ARG1 1 
                              :mod (t / thiamin)) 
                        :ARG2 (w / wide-02))) 
            :ARG1 (p4 / phenotype 
                  :domain-of (h / heterogeneou))))

# ::snt Recent cell culture studies with MSUD cells have suggested that the thiamin-responsive phenotype is dependent upon the presence of at least one E2 expressing allele [ 45,46 ] .
# ::tok Recent cell culture studies with MSUD cells have suggested that the thiamin-responsive phenotype is dependent upon the presence of at least one E2 expressing allele [ 45,46 ] .
# ::alignments 24-25|0.0.0 23-24|0.1.1.0 22-23|0.1.1.0.0.0.0+0.1.1.0.0.0+0.1.1.0.0 17-18|0.1.1 14-15|0.1 12-13|0.1.0 8-9|0 6-7|0.0.1 3-4|0.0 2-3|0.0.2 1-2|0.0.2.0 0-1|0.0.3 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:14:02.309
(s / suggest-01 
      :ARG0 (s2 / study-01 
            :ARG0 (a / allele) 
            :ARG1 (c / cell) 
            :mod (c2 / culture 
                  :mod (c3 / cell)) 
            :time (r / recent)) 
      :ARG1 (d / depend-01 
            :ARG0 (p2 / phenotype) 
            :ARG1 (p / presence 
                  :ARG1-of (e / express-01 
                        :ARG0 (t / thing 
                              :name (n / name 
                                    :op1 "E2"))))))

# ::snt In light of these newer findings , our intermediate MSUD mouse provides a model to test the effect of thiamin with respect to BCKDH activity and blood amino acid levels at the level of the whole animal .
# ::tok In light of these newer findings , our intermediate MSUD mouse provides a model to test the effect of thiamin with respect to BCKDH activity and blood amino acid levels at the level of the whole animal .
# ::alignments 36-37|0.2.0.0 35-36|0.2.0.0.0 32-33|0.2.0 29-30|0.2 28-29|0.2.1 27-28|0.1 26-27|0.1.0 25-26|0 24-25|0.0 21-22|0.3 19-20|0.3.0.0 17-18|0.3.0 15-16|0.3.0.1 13-14|0.3.0.1.0.0.0 11-12|0.3.0.1.0.0 10-11|0.3.0.1.0 8-9|0.3.0.1.0.1 7-8|0.3.0.1.0.2 5-6|0.3.0.1.0.0.1.0.0+0.3.0.1.0.0.1.0 4-5|0.3.0.1.0.0.1.0.2 3-4|0.3.0.1.0.0.1.0.1 1-2|0.3.0.1.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:14:03.210
(a4 / and 
      :op1 (a5 / activity-06) 
      :op2 (a3 / amino 
            :mod (b / blood)) 
      :op3 (l2 / level 
            :location (l / level 
                  :mod (a / animal 
                        :mod (w / whole))) 
            :mod (a2 / acid)) 
      :purpose-of (r / respect-01 
            :ARG1 (e / effect-03 
                  :ARG0 (t / thiamin) 
                  :ARG1-of (t2 / test-01 
                        :ARG0 (m2 / mouse 
                              :ARG0-of (p / provide-01 
                                    :ARG1 (m / model) 
                                    :ARG2 (l3 / light 
                                          :poss (t3 / thing 
                                                :ARG1-of (f / find-01) 
                                                :mod (t4 / this) 
                                                :mod (n / new)))) 
                              :mod (i / intermediate) 
                              :poss (w2 / we))))))

# ::snt Because of recent interest in structural analysis of multienzyme complexes [ 35,36,45,46 ] , the intermediate MSUD model may provide a valuable resource for studies of structural biology .
# ::tok Because of recent interest in structural analysis of multienzyme complexes [ 35,36,45,46 ] , the intermediate MSUD model may provide a valuable resource for studies of structural biology .
# ::alignments 27-28|0.0.1.1.0 26-27|0.0.1.1.0.0 24-25|0.0.1.1 22-23|0.0.1 21-22|0.0.1.0 19-20|0.0 18-19|0 17-18|0.0.0 15-16|0.0.0.0 9-10|0.0.2.0.0.0 6-7|0.0.2.0.0 5-6|0.0.2.0.0.1 3-4|0.0.2.0 2-3|0.0.2.0.1 0-1|0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:14:03.422
(p2 / possible-01 
      :ARG1 (p / provide-01 
            :ARG0 (m / model 
                  :mod (i / intermediate)) 
            :ARG1 (r / resource 
                  :ARG1-of (v / value-02) 
                  :purpose (s2 / study-01 
                        :ARG1 (b / biology 
                              :mod (s / structure)))) 
            :ARG1-of (c2 / cause-01 
                  :ARG0 (i2 / interest-01 
                        :ARG2 (a / analyze-01 
                              :ARG1 (c / complex) 
                              :manner (s3 / structure)) 
                        :time (r2 / recent)))))

# ::snt Lastly , the information and knowledge gained from studies with the MSUD models described here will also be applicable and transferable to other mitochondrial disorders due to defects in multisubunit enzymes .
# ::tok Lastly , the information and knowledge gained from studies with the MSUD models described here will also be applicable and transferable to other mitochondrial disorders due to defects in multisubunit enzymes .
# ::alignments 30-31|0.2.1.0.1.0 27-28|0.2.1.0.1 24-25|0.2.0.0.0 23-24|0.2.0 22-23|0.2.0.0.0.0 20-21|0.2.0.0 19-20|0 18-19|0.2 16-17|0.0 14-15|0.2.1.0.0.1.0.0 13-14|0.2.1.0.0.1.0 12-13|0.2.1.0.0.1 8-9|0.2.1.0.0 6-7|0.2.1.0 5-6|0.1 4-5|0.2.1 3-4|0.2.1.1 0-1|0.2.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:14:03.841
(a / and 
      :mod (a3 / also) 
      :op1 (k / knowledge) 
      :op2 (a2 / apply-02 
            :ARG0 (m / mitochondrial 
                  :ARG1-of (t / transfer-01 
                        :ARG2 (d2 / disorder 
                              :mod (o / other)))) 
            :ARG1 (a4 / and 
                  :ARG1-of (g / gain-02 
                        :ARG2 (s / study-01 
                              :ARG1 (l / last) 
                              :ARG2 (m2 / model 
                                    :ARG1-of (d3 / describe-01 
                                          :location (h / here)))) 
                        :ARG2-of (d / defect-01 
                              :ARG1 (e / enzym))) 
                  :op1 (i / information))))

# ::snt In summary , this report describes the development and characterization of genetically engineered mouse models of classic as well as intermediate MSUD .
# ::tok In summary , this report describes the development and characterization of genetically engineered mouse models of classic as well as intermediate MSUD .
# ::alignments 20-21|0 16-17|0.0.1.1 14-15|0.0.0 13-14|0.0.0.1 12-13|0.0.0.0 11-12|0.0.0.0.1 9-10|0.0.2.0 8-9|0.0.2 7-8|0.0 5-6|0.0.1 4-5|0.0.1.0 3-4|0.0.1.0.0 1-2|0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:14:04.332
(i / intermediate 
      :ARG2-of (d / develop-02 
            :ARG1 (m / model 
                  :ARG1-of (e / engineer-01 
                        :ARG0 (s / summary) 
                        :ARG2 (g / genetics)) 
                  :mod (m2 / mouse)) 
            :ARG1-of (d2 / describe-01 
                  :ARG0 (r / report 
                        :mod (t / this)) 
                  :op1-of (c / classic)) 
            :op1-of (a / and 
                  :op2 (c2 / characterization))))

# ::snt These animals provide useful models to further characterize the pathogenesis of MSUD , as well as models to test novel therapeutic strategies , such as gene and cellular therapies , to treat this devastating metabolic disease .
# ::tok These animals provide useful models to further characterize the pathogenesis of MSUD , as well as models to test novel therapeutic strategies , such as gene and cellular therapies , to treat this devastating metabolic disease .
# ::alignments 35-36|0.3.0 34-35|0.3.0.1 33-34|0.3.0.0 32-33|0.3.0.2 31-32|0.3 28-29|0.2 27-28|0.2.0 26-27|0 25-26|0.1 23-24|0.0 21-22|0.3.1.1 20-21|0.3.0.0.0 19-20|0.3.1.2.0.0.0 18-19|0.3.1 16-17|0.3.1.0 9-10|0.3.1.2.1 7-8|0.3.1.2 6-7|0.3.1.2.2 4-5|0.3.1.2.0 3-4|0.3.1.2.0.0 2-3|0.3.1.2.0.1 1-2|0.3.1.2.0.1.0 0-1|0.3.1.2.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:14:04.923
(a / and 
      :op1 (s / such) 
      :op2 (g / gene) 
      :op3 (t3 / therapi 
            :mod (c / cell)) 
      :op4 (t2 / treat-01 
            :ARG1 (d / disease 
                  :ARG0-of (d2 / devastate-01 
                        :ARG1 (t4 / therapeutic)) 
                  :mod (m / metabolic) 
                  :mod (t / this)) 
            :ARG2-of (t5 / test-01 
                  :ARG0 (m2 / model) 
                  :ARG1 (s2 / strategy) 
                  :purpose-of (c2 / characterize-01 
                        :ARG0 (m3 / model 
                              :ARG1-of (u / useful-05 
                                    :ARG0 (n / novel)) 
                              :ARG1-of (p2 / provide-01 
                                    :ARG0 (a2 / animal 
                                          :mod (t6 / this)))) 
                        :ARG1 (p / pathogenesi) 
                        :degree (f / further)))))

# ::snt The abbreviations used are : MSUD , Maple Syrup Urine Disease ; BCKDH , branched chain ketoacid dehydrogenase ; BCAA , branched chain amino acids ; ENU , N-ethyl-N-nitrosourea ; BCAT , branched chain aminotransferase ; ES cell , embryonic stem cell ; TRE , tetracycline responsive element ; MEF , mouse embryonic fibroblast .
# ::tok The abbreviations used are : MSUD , Maple Syrup Urine Disease ; BCKDH , branched chain ketoacid dehydrogenase ; BCAA , branched chain amino acids ; ENU , N-ethyl-N-nitrosourea ; BCAT , branched chain aminotransferase ; ES cell , embryonic stem cell ; TRE , tetracycline responsive element ; MEF , mouse embryonic fibroblast .
# ::alignments 53-54|0.0.1.2.3.0 52-53|0.0.1.2.3 51-52|0.0.1.2.3.0.0 47-48|0.0.2.0 46-47|0.0.2 45-46|0 41-42|0.0.1.0.0 40-41|0.0.1.0.0.0 39-40|0.0.1.0 37-38|0.0.1.2.1.0 36-37|0.0.1.2.1 34-35|0.0.1.2.0 33-34|0.0.1.2.0.0 32-33|0.0.1.2 28-29|0.0.1.2.2.1.0.0.0.0+0.0.1.2.2.1.0.0.0+0.0.1.2.2.1.0.0 24-25|0.0.0 23-24|0.0.0.1 22-23|0.0.0.0 21-22|0.0 19-20|0.0.1.2.2.0.0.0+0.0.1.2.2.0.0+0.0.1.2.2.0 17-18|0.0.1.1 16-17|0.0.1.1.0 15-16|0.0.1.1.1 14-15|0.0.1 11-12|0.0.1.2.2.1.0 7-11|0.0.1.2.2.1.1.0.3+0.0.1.2.2.1.1.0.2+0.0.1.2.2.1.1.0.1+0.0.1.2.2.1.1.0.0+0.0.1.2.2.1.1.0+0.0.1.2.2.1.1 2-3|0.0.1.2.2 1-2|0.0.1.2.2.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:14:05.980
(t / tetracycline 
      :op1 (b2 / branch-01 
            :ARG1 (a2 / acid 
                  :mod (c4 / chain) 
                  :mod (a3 / amino)) 
            :ARG2-of (b3 / branch-01 
                  :ARG0 (e3 / embryonic 
                        :mod-of (c / cell 
                              :mod (s / stem))) 
                  :ARG1 (d / dehydrogenase 
                        :mod (k / ketoacid) 
                        :mod (c5 / chain)) 
                  :purpose (b / branch-01 
                        :ARG1 (a / aminotransferase 
                              :mod (c3 / chain)) 
                        :ARG2 (e4 / e 
                              :location-of (c2 / cell)) 
                        :ARG2-of (u / use-01 
                              :ARG0 (o / organization 
                                    :name (n2 / name 
                                          :op1 "BCAA")) 
                              :ARG1 (a5 / abbreviation 
                                    :domain-of (a4 / and 
                                          :op1 (p / person 
                                                :name (n / name 
                                                      :op1 "N-ethyl-N-nitrosourea"))) 
                                    :domain-of (t2 / thing 
                                          :name (n3 / name 
                                                :op1 "Maple" 
                                                :op2 "Syrup" 
                                                :op3 "Urine" 
                                                :op4 "Disease")))) 
                        :op1-of (e / embryonic 
                              :mod-of (f / fibroblast 
                                    :mod (m / mouse))))) 
            :op1-of (r / responsive 
                  :mod-of (e2 / element))))

# ::snt The author ( s ) declare that they have no competing interests .
# ::tok The author ( s ) declare that they have no competing interests .
# ::alignments 11-12|0.0.1.0 10-11|0.0.1 9-10|0.0.0.0 7-8|0.1 5-6|0 1-2|0.0.0+0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:14:06.035
(d / declare-02 
      :ARG0 (p / person 
            :ARG0-of (a / author-01 
                  :ARG1 -) 
            :ARG1-of (c / compete-02 
                  :ARG2 (i / interest))) 
      :ARG1 (t / they))

# ::snt GEH designed and produced the mouse models , coordinated experiments , interpreted data , and helped draft the manuscript .
# ::tok GEH designed and produced the mouse models , coordinated experiments , interpreted data , and helped draft the manuscript .
# ::alignments 18-19|0.0.0.3.0.0 16-17|0.0.0.3.0 15-16|0.0.0.3 14-15|0.0.2 12-13|0.0.0.2.0 11-12|0.0.0.2 9-10|0.0.0.1.0 8-9|0.0.0.1 6-7|0.0.1 5-6|0.0.1.0 3-4|0.0.0.0 2-3|0 1-2|0.0 0-1|0.0.0.4.0+0.0.0.4+0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:14:06.132
(a2 / and 
      :op1 (d3 / design-01 
            :ARG0 (o / organization 
                  :ARG0-of (p / produce-01) 
                  :ARG0-of (c / coordinate-01 
                        :ARG1 (e / experiment-01)) 
                  :ARG0-of (i / interpret-01 
                        :ARG1 (d2 / data)) 
                  :ARG0-of (h / help-01 
                        :ARG1 (d / draft-01 
                              :ARG1 (m / manuscript))) 
                  :name (n / name 
                        :op1 "GEH")) 
            :ARG1 (m2 / model 
                  :mod (m3 / mouse)) 
            :op1-of (a / and)))

# ::snt KS conducted much of the characterization of the intermediate MSUD model .
# ::tok KS conducted much of the characterization of the intermediate MSUD model .
# ::alignments 10-11|0.1.0 8-9|0.1.0.0 5-6|0.1 2-3|0.2 1-2|0 0-1|0.0.0.0+0.0.0+0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:14:06.162
(c2 / conduct-01 
      :ARG0 (c3 / country 
            :name (n / name 
                  :op1 "KS")) 
      :ARG1 (c / characterization 
            :mod (m / model 
                  :mod (i / intermediate))) 
      :degree (m2 / much))

# ::snt CF assisted with production of the mouse models , data collection , analysis , and interpretation .
# ::tok CF assisted with production of the mouse models , data collection , analysis , and interpretation .
# ::alignments 15-16|0.4 14-15|0 12-13|0.3 10-11|0.2 9-10|0.2.0 7-8|0.1 6-7|0.1.0 3-4|0.0 1-2|0.0.0 0-1|0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:14:06.248
(a / and 
      :ARG1-of (p / produce-01 
            :ARG2-of (a3 / assist-01 
                  :ARG0 (o / organization 
                        :name (n / name 
                              :op1 "CF")))) 
      :op1 (m / model 
            :mod (m2 / mouse)) 
      :op2 (c / collect-01 
            :ARG1 (d / data)) 
      :op3 (a2 / analyze-01) 
      :op4 (i / interpret-01))

# ::snt SW directed the immunohistochemistry experiments .
# ::tok SW directed the immunohistochemistry experiments .
# ::alignments 4-5|0.1 3-4|0.1.0 1-2|0 0-1|0.0.0.0+0.0.0+0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:14:06.264
(d / direct-01 
      :ARG0 (o / organization 
            :name (n / name 
                  :op1 "SW")) 
      :ARG1 (e / experiment-01 
            :mod (i / immunohistochemistry)))

# ::snt HSP conceived of the knockout model , interpreted data and drafted the manuscript .
# ::tok HSP conceived of the knockout model , interpreted data and drafted the manuscript .
# ::alignments 12-13|0.0.1 10-11|0.0 9-10|0 8-9|0.0.0.1.0 7-8|0.0.0.1 5-6|0.0.0.0.0 1-2|0.0.0.0 0-1|0.0.0.2.0+0.0.0.2+0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:14:06.307
(a / and 
      :op1 (d / draft-01 
            :ARG0 (o / organization 
                  :ARG0-of (c / conceive-01 
                        :ARG1 (m2 / model)) 
                  :ARG0-of (i / interpret-01 
                        :ARG1 (d2 / data)) 
                  :name (n / name 
                        :op1 "HSP")) 
            :ARG1 (m / manuscript)))

# ::snt All authors contributed to composing and editing the manuscript and have read and approved the final version .
# ::tok All authors contributed to composing and editing the manuscript and have read and approved the final version .
# ::alignments 16-17|0.0.0.0.0.0.0.0 15-16|0.0.0.0.0.0.0.0.0 13-14|0.0.0.0.0.0.0 12-13|0.0.0.0.0.0 11-12|0.0.0.0.0.0.1 9-10|0.0.0.0.0 8-9|0.0.1 6-7|0.1 5-6|0 4-5|0.0 2-3|0.0.0.0 1-2|0.0.0 0-1|0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:14:06.386
(a4 / and 
      :op1 (c / compose-01 
            :ARG0 (a5 / author-01 
                  :ARG0-of (c2 / contribute-01 
                        :op1-of (a3 / and 
                              :op2 (a2 / and 
                                    :ARG0-of (a / approve-01 
                                          :ARG1 (v / version 
                                                :mod (f / final))) 
                                    :op1 (r / read-01)))) 
                  :mod (a6 / all)) 
            :ARG1 (m / manuscript)) 
      :op2 (e / edit-01))

# ::snt The pre-publication history for this paper can be accessed here : .
# ::tok The pre-publication history for this paper can be accessed here : .
# ::alignments 9-10|0.0.1 8-9|0.0 6-7|0 5-6|0.0.0.0 4-5|0.0.0.0.0 2-3|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:14:06.427
(p / possible-01 
      :ARG1 (a / access-01 
            :ARG1 (h2 / history 
                  :topic (p2 / paper 
                        :mod (t / this))) 
            :location (h / here)))

# ::snt The authors would like to thank Frank Kist , Jodi Dagget , Edward Mallick , Brian Sloat , and Judith Rodda for expert technical assistance , and Dr. Susan Hutson for the gift of E2 antiserum .
# ::tok The authors would like to thank Frank Kist , Jodi Dagget , Edward Mallick , Brian Sloat , and Judith Rodda for expert technical assistance , and Dr. Susan Hutson for the gift of E2 antiserum .
# ::alignments 35-36|0.0 34-35|0.1.0+0.1+0 32-33|0.0.0+0.0.0.0 28-30|0.0.0.0.0.0.0.0.0.2.0.0.1+0.0.0.0.0.0.0.0.0.2.0.0.0+0.0.0.0.0.0.0.0.0.2.0.0+0.0.0.0.0.0.0.0.0.2.0 27-28|0.0.0.0.0.0.0.2 26-27|0.0.0.0.0.0.0.0.0.2 24-25|0.0.0.0.0.0.0.0.0 23-24|0.0.0.0.0.0.0.0.0.1 22-23|0.0.0.0.0.0.0.0.0.0.0+0.0.0.0.0.0.0.0.0.0 19-21|0.0.0.0.0.4.0.1+0.0.0.0.0.4.0.0+0.0.0.0.0.4.0+0.0.0.0.0.4 18-19|0.0.0.0.0 15-17|0.0.0.0.0.3.0.1+0.0.0.0.0.3.0.0+0.0.0.0.0.3.0+0.0.0.0.0.3 12-14|0.0.0.0.0.2.0.1+0.0.0.0.0.2.0.0+0.0.0.0.0.2.0+0.0.0.0.0.2 9-11|0.0.0.0.0.1.0.1+0.0.0.0.0.1.0.0+0.0.0.0.0.1.0+0.0.0.0.0.1 6-8|0.0.0.0.0.0.1.1+0.0.0.0.0.0.1.0+0.0.0.0.0.0.1+0.0.0.0.0.0 5-6|0.0.0.0.0.0.0 3-4|0.0.0.0.0.0.0.1 1-2|0.0.0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:14:07.911
(t / thing 
      :mod-of (a / antiserum 
            :ARG0-of (g / gift-01 
                  :ARG1 (t2 / thing 
                        :op6-of (a4 / and 
                              :op1 (p7 / person 
                                    :ARG1-of (t4 / thank-01 
                                          :ARG0 (a5 / author-01 
                                                :ARG1-of (a3 / assist-01 
                                                      :ARG0 (p2 / person 
                                                            :ARG1-of (e / expert-01)) 
                                                      :ARG2 (t3 / technical) 
                                                      :op1-of (a2 / and 
                                                            :op2 (p / person 
                                                                  :name (n2 / name 
                                                                        :op1 "Susan" 
                                                                        :op2 "Hutson"))))) 
                                          :ARG1-of (l / like-02) 
                                          :ARG2 (d / dr.)) 
                                    :name (n7 / name 
                                          :op1 "Frank" 
                                          :op2 "Kist")) 
                              :op2 (p6 / person 
                                    :name (n6 / name 
                                          :op1 "Jodi" 
                                          :op2 "Dagget")) 
                              :op3 (p5 / person 
                                    :name (n5 / name 
                                          :op1 "Edward" 
                                          :op2 "Mallick")) 
                              :op4 (p4 / person 
                                    :name (n4 / name 
                                          :op1 "Brian" 
                                          :op2 "Sloat")) 
                              :op5 (p3 / person 
                                    :name (n3 / name 
                                          :op1 "Judith" 
                                          :op2 "Rodda")))))) 
      :name (n / name 
            :op1 "E2"))

# ::snt This work was supported by National Institutes of Health Grants DK51960 , DK57386 , DK57956 , AA10422 , the Scott C. Foster Metabolic Disease Fund , and the MSUD Family Support Group .
# ::tok This work was supported by National Institutes of Health Grants DK51960 , DK57386 , DK57956 , AA10422 , the Scott C. Foster Metabolic Disease Fund , and the MSUD Family Support Group .
# ::alignments 31-32|0.0.1.2 30-31|0.0.1.2.0 29-30|0.0.1.2.0.0 26-27|0.0.1 23-25|0.0.1.1.1.1+0.0.1.1.1.0+0.0.1.1.1+0.0.1.1 21-23|0.0.1.1.0.0.1+0.0.1.1.0.0.0+0.0.1.1.0.0+0.0.1.1.0 19-21|0.0.1.0.0.1+0.0.1.0.0.0+0.0.1.0.0+0.0.1.0 5-11|0.0.0.5+0.0.0.4+0.0.0.3+0.0.0.2+0.0.0.1+0.0.0.0+0.0.0+0.0 3-4|0 1-2|0.1 0-1|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T04:14:08.088
(s3 / support-01 
      :ARG0 (o2 / organization 
            :name (n4 / name 
                  :op1 "National" 
                  :op2 "Institutes" 
                  :op3 "of" 
                  :op4 "Health" 
                  :op5 "Grants" 
                  :op6 "DK51960") 
            :op1-of (a / and 
                  :op2 (t2 / thing 
                        :name (n3 / name 
                              :op1 (s2 / Scott) 
                              :op2 (c / C.))) 
                  :op3 (o / organization 
                        :mod (t / thing 
                              :name (n2 / name 
                                    :op1 (f2 / Foster) 
                                    :op2 (m / Metabolic))) 
                        :name (n / name 
                              :op1 "Disease" 
                              :op2 "Fund")) 
                  :op4 (g / group 
                        :ARG0-of (s / support-01 
                              :ARG1 (f / family))))) 
      :ARG1 (w / work-01 
            :mod (t3 / this)))

